Methods of treating small cell lung cancer with lubicatine formulations

Rubicatin monotherapy or in combination with irinotecan for small cell lung cancer has addressed the issue of poor efficacy of existing treatments, improved response rates and survival in refractory and drug-resistant patients, and reduced chemotherapy toxicity.

CN118924689APending Publication Date: 2024-11-12PHARMA MAR SA
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411258158.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2020-05-15
Filing Date
2020-05-29
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Current treatments for small cell lung cancer (SCLC) have limited effectiveness, especially for refractory and drug-resistant patients. Relapse is common after chemotherapy, and there is a lack of effective second-line treatment options.

Method used

Rubicatin is administered intravenously as a single agent or in combination with the topoisomerase inhibitor irinotecan, combined with antiemetics to prevent nausea and vomiting, with dose and interval adjustments to manage hematologic adverse events, and is available in a stable lyophilized formulation.

Benefits of technology

It significantly improved the overall response rate, progression-free survival, and overall survival in patients with refractory and drug-resistant SCLC, reduced chemotherapy-related toxicities, and prolonged patient survival.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924689A_ABST
    Figure CN118924689A_ABST
Patent Text Reader

Abstract

Methods are provided for treating SCLC patients by administering a therapeutic amount of lubicatine by intravenous infusion. Also provided are methods of treating cancer by administering lubicatine in combination with other anti-cancer drugs, particularly topoisomerase inhibitors. The present invention also relates to the administration of lubikatine in combination with antiemetic agents to effectively control symptoms associated with nausea and vomiting, to reduce the dosage of lubikatine to achieve safer administration and to increase the number of treatment cycles. Also provided are stable lyophilized formulations of lubicatin.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the patent application with application number 202080090766.7, application date May 29, 2020, and invention name “Method for treating small cell lung cancer with rubicatin preparation”. Application number 202080090766.7 is an application entering the Chinese national phase of international application number PCT / EP2020 / 065093. Technical Field

[0002] Methods for treating SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion are provided. Methods for treating cancer by administering lurbinectedin in combination with other anticancer drugs, particularly topoisomerase inhibitors, are also provided. The present invention also relates to administering lurbinectedin in combination with an antiemetic to effectively control symptoms associated with nausea and vomiting, reduce the dose of lurbinectedin to achieve safer administration, and increase the number of treatment cycles. A stable lyophilized formulation of lurbinectedin is also provided. Background Art

[0003] Lung cancer is the leading cause of cancer death in both men and women in the United States. In 1998, an estimated 171,500 new cases were diagnosed and the disease caused approximately 160,100 deaths. Lung cancer kills more women than breast, ovarian, and uterine cancers combined, and it kills four times as many men as prostate cancer.

[0004] Lung cancer is a disease in which malignant (cancer) cells form in the lung tissue. The two main types of lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC accounts for only about 13-15% of all lung cancers at diagnosis; however, SCLC is a more aggressive form of lung cancer. In the case of SCLC, cancer cells tend to grow rapidly and travel more easily to other parts of the body or metastasize. Its incidence is associated with smoking, almost two-thirds of patients have advanced disease, and although the response rate to chemotherapy is high, the benefit is short-lived. The median survival of patients with untreated SCLC is 2 to 4 months (Clark, 1998; Glisson, 2003; Davies, 2004). The most common regimens include cisplatin or carboplatin and etoposide. Unfortunately, despite a 40-90% response rate to first-line chemotherapy, long-term survival is uncommon because patients develop resistance to chemotherapy and relapse (Sundstrom, 2005; Jackman, 2005). The overall expected mean survival after disease relapse without treatment is 2 to 4 months (Huisman, 1999).

[0005] Treatment and survival have not changed significantly over the past two decades. Even though limited-stage disease is rarely cured by definitive local therapy (surgery or radiation therapy), systemic chemotherapy (platinum plus etoposide) remains the cornerstone of first-line treatment in SCLC.

[0006] Topotecan is the only drug approved for second-line treatment of patients with no chemotherapy interval exceeding 60 days. Topotecan monotherapy improves survival rate and quality of life and cancer-related symptoms in second-line treatment. Alternatively, the administration of adriamycin-based combination therapy can obtain similar results, but the symptom control rate is significantly lower. In refractory patients, there is no standard therapy. Amrubicin is a new anthracycline that shows promising activity in refractory and recurrent patients. Phase III trials are ongoing. Other active agents include paclitaxel, docetaxel, gemcitabine, bendamustine and vinorelbine.

[0007] Over the past few years, several clinical trials have evaluated the role of adding immunotherapy to conventional chemotherapy in patients with extensive SCLC. Checkpoint inhibitors are currently under investigation, especially CTLA-4 and PD-1 / PD-L1 inhibitors. Nivolumab and pembrolizumab are the first immunotherapeutic agents approved by the FDA for the treatment of patients with metastatic SCLC who have disease progression during or after platinum-based chemotherapy and at least one other prior line of chemotherapy.

[0008] Lubicardin (PM01183) is a synthetic tetrahydropyrrolo[4,3,2-de]quinolin-8(1H)-one alkaloid analog with antitumor activity. Lubicardin is a selective inhibitor of oncogenic transcription, induces apoptotic DNA double-strand breaks, and modulates the tumor microenvironment. For example, by inhibiting active transcription in tumor-associated macrophages, Lubicardin downregulates IL-6, IL-8, CCL2, and VEGF.

[0009] Lubicardin has been shown to have potent in vitro activity against solid and non-solid tumor cell lines, and significant in vivo activity in several xenograft human tumor cell lines in mice (such as those of breast, kidney, and ovarian cancers). Preliminary clinical results show that Lubicardin has second-line therapeutic activity in SCLC as a single agent. Treatments for SCLC and other solid tumors are needed. Summary of the invention

[0010] Phase 2 clinical trial results showed that the overall response rate of SCLC patients was at least 30% (35.2%) in the case of second-line agents administered as a single agent with rubicatin. Results from Phase 1b-2 trials in patients with solid tumors demonstrated the activity of the combination of rubicatin and irinotecan, particularly in SCLC, endometrial cancer, soft tissue sarcoma, and glioblastoma. Therefore, provided herein are methods for treating SCLC in patients in need, including metastatic SCLC, particularly those whose SCLC has progressed after prior therapy, such as platinum-containing therapy or immunotherapy, including those who were unable to respond or adequately respond to prior therapy, may have responded to prior therapy but then experienced disease progression, and may have such a response, followed by progression more than once. Also provided are methods for treating solid tumors in patients in need, particularly SCLC, endometrial cancer, soft tissue sarcoma, and glioblastoma, by administering a combination of rubicatin and a topoisomerase inhibitor, particularly irinotecan or SN-38. A stable lyophilized formulation is also provided.

[0011] The methods provided herein involve administering an effective amount of rubicatin by intravenous infusion to patients with SCLC, including metastatic SCLC, including adult patients, particularly SCLC patients who have progressed after prior platinum-based chemotherapy. In certain embodiments, a method of administering an effective amount of rubicatin by intravenous infusion to patients with SCLC, including metastatic SCLC, who have progressed after prior immunotherapy, particularly atezolizumab, including a combination with carboplatin and etoposide, or nivolumab, is provided. Lubicardin is preferably administered at 3.2 mg / m every 21 days (or 3 weeks). 2 The drug is administered at a dose of 100 mg / dL, typically for a period of several months, and in most cases until disease progression and death or the patient experiences unacceptable toxicity, depending on the patient's response to the administration.

[0012] In certain embodiments, the therapeutically effective amount of Lubicatin can be 3.2 mg / m every 21 days or 3 weeks. 2The dosing level is administered to the patient as a 1-hour IV infusion to achieve an average total plasma Cmax of about 85.6 μg / L to 133.75 μg / L, preferably 107 μg / L, and an average AUC∞ of about 440.8 μg*h / L to 688.75 μg*h / L, preferably 551 μg*h / L. The treatment results in an overall response rate of greater than 30%, a progression-free survival period with a median of 3.5 months (range 2.6 months to 4.3 months), including a median of 2.6 months in the resistant patient population (CFTI less than 90 days for previous chemotherapy treatment) and a median of 4.6 months in the sensitive patient population (CFTI greater than or equal to 90 days for previous chemotherapy treatment). According to the methods disclosed herein, an overall survival period with a median of 9.3 months can be achieved (resistant patient population, 5.0 months and sensitive patient population, 11.9 months).

[0013] In one embodiment, a method of managing hematologic adverse events associated with a lurbinectedin treatment regimen is provided by dose reduction and / or administration of G-CSF. The method provided involves administering a lurbinectedin formulation to an SCLC patient at a dose of 3.2 mg / m 2 by IV infusion; after administering lurbinectedin, assessing whether the patient experiences an adverse reaction associated with lurbinectedin administration, namely ≥ grade 3 (severe) non-hematologic toxicity, grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm3), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm 3 ) accompanied by bleeding requiring transfusion, grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ) or any grade of neutropenia (neutrophil count < LLN) associated with infection / sepsis or any other adverse reaction. At the next scheduled dose, preferably 3 weeks after the previous dose, and once the patient's neutrophil count is greater than 1500 cells / mm 3 ; platelet count is greater than about 100,000 / mm 3 ; and hemoglobin level is greater than about 9 g / d, (i) if the adverse reaction consists of isolated grade 4 neutropenia, administer the same dose of G-CSF and lurbinectedin as the previous dose to the patient, e.g., 3.2 mg / m 2 , or (ii) if the adverse reaction is a hematologic abnormality that is not just isolated grade 4 neutropenia, administer a reduced dose compared to the previous dose, e.g., 80% to 85% of the previous dose, e.g., if the previous dose was 3.2 mg / m 2 , then administer 2.6 mg / m 2Optionally, if the adverse reaction is isolated grade 4 neutropenia, the dose may be reduced at the next planned dose, specifically 80% to 85% of the previous dose. For example, if the previous dose was 3.2 mg / m 2 , then 2.6 mg / m 2 is administered.

[0014] In the case of an adverse event in which, after receiving a reduced dose of lurbinectedin, the patient experiences ≥ grade 3 (severe) non-hematological toxicity, grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm3), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm3) accompanied by bleeding requiring transfusion), or any grade of neutropenia (neutrophil count < LLN) associated with infection / sepsis or any other adverse reaction (but in some embodiments, not isolated grade 4 neutropenia), then at the next planned dose, preferably 3 weeks after the previous dose, and once the patient's neutrophil count is greater than 1500 cells / mm 3 ; platelet count greater than approximately 100,000 / mm 3 ; and hemoglobin level greater than approximately 9 g / d, a second reduced dose is administered to the patient, specifically 60% to 65% of the first non-reduced dose, specifically 2.0 mg / m 2 (60 - 65% of the 3.2 mg / m 2 dose). Optionally, if the adverse reaction is isolated grade 4 neutropenia after administration of a reduced dose of lurbinectedin, the dose may be reduced at the next planned dose, specifically 60% to 65% of the first non-reduced dose. For example, if the initial dose was 3.2 mg / m 2 , then 2.6 mg / m 2 is administered.

[0015] In another embodiment, a method is provided for managing hematological toxicity, myelosuppression, and / or hepatotoxicity that may be associated with the administration of lurbinectedin in the treatment of patients, including adult patients, with SCLC, including metastatic SCLC, by dose reduction and / or dose delay. A method is provided for treating SCLC, including metastatic SCLC, by administering a dose of 3.2 mg / m 3 lurbinectedin to a patient in need having an absolute neutrophil count of at least 1500 cells / mm 3 and a platelet count of at least 100,000 / mm 2 , preferably by infusion over 60 minutes. In another embodiment, 21 days after the previous dose, the patient has an absolute neutrophil count of at least 1500 cells / mm 3 and a platelet count of at least 100,000 / mm 3platelet count and administered 3.2 mg / m 2 The dose of Lupicardin is preferably administered by infusion over 60 minutes. In an embodiment, the patient is monitored for hepatotoxicity and is free of hepatotoxicity prior to administration of Lupicardin. 3 Absolute neutrophil count of at least 100,000 / mm 3 Subsequent treatment is administered to patients who have platelet counts below 500 mg / kg and who preferably do not have any grade 2 or higher adverse reactions.

[0016] In certain embodiments, the invention provides for the administration of 3.2 mg / m 2 The method of administering rubicatin at a dose of 3.2 mg / m2 to treat SCLC, including metastatic SCLC, in patients in need thereof by infusion over 60 minutes followed by monitoring of the patient for hematologic or hepatic reactions or other grade 2 or higher adverse reactions. 2 Patients receiving rubicatin who developed grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ) or any febrile neutropenia, do not administer a subsequent dose of rubicatin until 21 days after the previous dose or when the patient exhibits less than Grade 1 neutropenia (at least 1500 cells / mm 3 ), this may be greater than 21 days after the previous dose, and then at 2.6 mg / m every three weeks 2 Lubicatin was administered at a reduced dose or at 3.2 mg / m every 3 weeks with G-CSF prophylaxis. 2 Lubicatin was administered at a dose of 3.2 mg / m 2 Patients receiving rubicatin developed grade 3 thrombocytopenia (25,000-50,000 platelets / mm 3 ) with bleeding or grade 4 thrombocytopenia (less than 25,000 platelets / mm 3 ), then the subsequent rubicatin dose is not administered until 21 days after the previous dose or when the patient demonstrates greater than or equal to 100,000 / mm 3 The platelet count was 1.000, and the subsequent dose was 2.6 mg / m every three weeks (21 days) 2 When 3.2 mg / m 2If a patient who has received a dose of lumikatin exhibits hepatotoxicity or other adverse reactions that are Grade 2, 3, or 4, then the subsequent dose of lumikatin is not administered until 21 days after the previous dose or when the patient exhibits less than or equal to Grade 1 hepatotoxicity (or other adverse reactions of Grade 1 or less), and if the patient exhibits Grade 2 hepatotoxicity (or other adverse reactions), then the subsequent dose is 3.2 mg / m every three weeks (21 days) 2 If the patient exhibits grade 3 or 4 hepatotoxicity or other adverse reactions, the subsequent dose is 2.6 mg / m every three weeks (21 days) 2 If, following a dose reduction, the patient develops Grade 4 neutropenia or any grade of febrile neutropenia, Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia, or Grade 3 or 4 hepatotoxicity or other adverse reactions, then the subsequent dose is not administered until 21 days later or when the patient recovers as detailed above, and then 2 mg / m2 every three weeks is administered. 2 Further dose reductions of lumigatin or, in case of grade 4 neutropenia, administration of the same lumigatin dose as the previous dose while on G-CSF prophylaxis. 2 Treatment was discontinued if lumikatin was discontinued at a dose that was intolerable (i.e., Grade 4 neutropenia or febrile neutropenia of any grade, Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia, or Grade 3 or 4 hepatotoxicity or other adverse reaction after lumikatin administration) or if administration was delayed more than 2 weeks after the scheduled dose (21 days after the previous dose) to allow the patient to recover and meet the criteria for lumikatin administration.

[0017] Provided by administration of 2 to 3.2 mg / m 2 In certain embodiments, a method of treating SCLC or a solid tumor in a patient in need thereof is provided, wherein a moderate CYP3A inhibitor is also administered to the patient, and then a reduced dose of Lupicardin, such as 2.6 mg / m2, is administered to the patient every 3 weeks (21 days). 2 or 2 mg / m 2 dosage.

[0018] Also provided are embodiments in which an antiemetic is administered prophylactically prior to nausea and / or vomiting associated with Lupicardin administration (acute and delayed phase), comprising administering to the patient 2 to 3.2 mg / m 2Antiemetic prophylaxis is administered on the day and before the dose of Lubicardin, particularly when the antiemetic comprises a corticosteroid and a serotonin antagonist. Treatment can be for SCLC, including metastatic SCLC or any other solid tumor in patients in need of such treatment. In certain embodiments, the corticosteroid is dexamethasone, preferably at a dose of 8 mg administered intravenously, or a corticosteroid dose equivalent to 8 mg dexamethasone administered intravenously, and wherein the serotonin antagonist is ondansetron, preferably at a dose of 8 mg administered intravenously, or a serotonin antagonist dose equivalent to 8 mg ondansetron administered intravenously. In certain embodiments, antiemetic therapy is administered on the day of administration of Lubicardin or 2, 3 or 4 days thereafter after infusion, preferably including administration of corticosteroids, serotonin antagonists and metoclopramide. In a specific embodiment, the corticosteroid is dexamethasone administered orally at a dose of 4 mg, or a dose of the corticosteroid equivalent to 4 mg of dexamethasone administered orally; the serotonin antagonist is ondansetron administered orally at a dose of 8 mg, or a serotonin antagonist equivalent to 8 mg of ondansetron administered orally; and metoclopramide is administered intravenously or orally at a dose of 10 mg, or a dose equivalent to 10 mg of metoclopramide administered orally or intravenously, wherein the metoclopramide is administered every 8 hours.

[0019] One aspect of the invention is a method of treating a patient with a solid tumor in need thereof by administering a combination of rubicatin and a topoisomerase inhibitor, particularly irinotecan. In a specific embodiment, the patient with a solid tumor is treated with a regimen wherein on day 1 of the treatment cycle, 1 to 2.5 mg / m 2 Lubicatin was administered at a dose of 75 mg / m on days 1 and 8. 2 The dose of irinotecan is 21 days, and irinotecan is administered together with G-CSF. The treatment cycle is usually 21 days, so that in the second treatment cycle, 1 to 2.5 mg / m 2 The dose of Lubicatin was 75 mg / m 2 dose of irinotecan and 7 days later 75 mg / m was administered on day 29 after the initial treatment. 2 Dosage of irinotecan. Subsequent treatments are usually administered once every three weeks, with 1 to 2.5 mg / m2 administered on day 1 of the cycle. 2 Lubicardin and 75 mg / m 2 Irinotecan combination, and 75 mg / m 2Irinotecan is administered with G-CSF. In certain embodiments, if the patient exhibits hematological toxicity after combined administration on day 1, the dose of irinotecan is not administered on day 8. In some embodiments, the solid cancer is selected from endometrial cancer, SCLC, soft tissue sarcoma (including Ewing sarcoma and synovial sarcoma), glioblastoma, pancreatic cancer, mesothelioma, colorectal cancer, and epithelial ovarian cancer. In a preferred embodiment, the solid tumor is endometrial cancer, SCLC, soft tissue sarcoma (including Ewing sarcoma or synovial sarcoma) or glioblastoma.

[0020] In one aspect, a stable lyophilized formulation of lubicartin is provided, comprising lubicartin, a buffer derived from an organic acid (e.g., an organic carboxylic acid, such as a lactate buffer), and a disaccharide, the formulation having a pH of 3.8 to 4.5 when reconstituted with 8 mL of water. Reference to reconstitution of 4 mg of lubicartin with a concentration of 0.5 mg / mL in 8 mL may be based on a calculated concentration of 0.47 mg / mL in 8.55 mL.

[0021] In some embodiments, the lyophilized composition comprises or consists of 4 mg of Lupicardin, 22.1 mg of lactic acid, 5.1 mg of sodium hydroxide, and 800 mg of sucrose (or comprises or consists of these ingredients in this ratio). The composition is preferably packaged in a 30 ml vial and can be reconstituted in 8 mL of water to produce a solution containing 0.5 mg / ml of Lupicardin.

[0022] In some embodiments, the lyophilized formulation can be stored at 5°C ± 3°C for 24 months or 36 months or longer, during which time Lubicardin maintains its therapeutic effect and exhibits minimal chemical degradation. For example, after 24 months or 36 months of storage, the amount of impurity D (a degradation product of Lubicardin resulting from deacetylation of Lubicardin) present in the composition does not exceed 0.8% wt. / wt. of the total weight of Lubicardin. In certain embodiments, the stored formulation does not contain more than 2.0%, 1.5% or 1.3% (area or wt / wt) of total degradation products.

[0023] Also provided are methods of storing lyophilized formulations of Lubicardin and methods of treating SCLC and solid tumors by administering Lubicardin infusion solutions prepared from the stored stable lyophilized Lubicardin formulations.

[0024] The present invention identifies methods of treatment using lubicartin alone or in combination with other agents. When referring to methods of treatment, the present invention also encompasses lubicartin and / or the additional agent in the manufacture of a medicament for treating cancer, as well as lubicartin and / or the additional agent as disclosed herein for use in treating cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1: X-ray powder diffraction pattern (XRPD) of Rubikatin Form A (Batch R05)

[0026] Figure 2a : X-ray powder diffraction pattern (XRPD) of Rubikatin Form B (Batch 1924128-LT (covered) and 1924129-LT)

[0027] Figure 2b : X-ray powder diffraction pattern (XRPD) of Rubikatin Form B, which was prepared by mixing 15 mg of batch 1711182-2 (Form B partially crystalline) and 15 mg of batch P02 (amorphous) with 1 ml of water. The suspension was stirred at room temperature for 24 hours. The resulting solid was filtered).

[0028] Figure 3 : TG-FTIR of Rubikatin Form B (Batch 1711182-2).

[0029] Figure 4 : DSC of Rubikatin Form B (Batch 1711182-2).

[0030] Figure 5 : DVS of Rubikatin Form B (Batch P05).

[0031] Figure 6 : From top to bottom, superimposed XRPD patterns of Rubikatin Form B in an initial 1:1 mixture of Rubikatin Form A and Form B after 6 h equilibration in water and after 24 h equilibration in water. (The mixture was prepared by mixing Rubikatin Form A (Batch P02) and Rubikatin Form B (Batch 1711182-2)).

[0032] Figure 7a : IR of Rubikatin Form A (Batch P04).

[0033] Figure 7b : IR of Rubikatin Form B (Batch 1711182-2).

[0034] Figure 8 : Scheme of Faraday cage.

[0035] Figure 9a : Electrostatic charge (nC) of different amounts of Rubikatin Form A (Batch P04) and Rubikatin Form B (Batch 1924129-LT).

[0036] Figure 9b : Electrostatic charge (nC) of different amounts of Rubikatin Form A (Batch R05) and Rubikatin Form B (Batch 1924128-LT).

[0037] Fig.10a : Charge density of Rubikatin Form A (Batch P04) and Rubikatin Form B (Batch 1924129-LT).

[0038] Fig.10b : Charge density of Rubikatin Form A (Batch R05) and Rubikatin Form B (Batch 1924128-LT). DETAILED DESCRIPTION

[0039] Provided herein are methods for effectively treating small cell lung cancer (SCLC) based on the administration of rubicatin as a monotherapy. Also provided are methods for treating solid tumors by administering a combination of rubicatin and irinotecan. Such methods can be performed by administering rubicatin prepared from a stable lyophilized formulation disclosed herein.

[0040] Ruby Cardin

[0041] Rubikatin is a synthetic alkaloid and ecteinascidin analog with the following chemical structure:

[0042]

[0043] It is described, for example, in US Pat. No. 7,763,615, which is incorporated herein by reference in its entirety. Rubikatin can be prepared according to methods known in the art, such as those disclosed in International Application Publication No. PCT WO2003 / 014127, which is incorporated herein by reference.

[0044] Any reference to a Lupicardin compound herein is intended to represent hydrates, solvates, amorphous and crystalline or partially crystalline forms and mixtures thereof when these forms are present in a medium. In addition, the Lupicardin compounds referred to herein may exist in an isotopically labeled form. All geometric hydrates, solvates and isotopically labeled forms of the compounds referred to herein and mixtures thereof are considered to be within the scope of the formulations and methods of the present invention.

[0045] As used herein, "cancer" is intended to include tumors, neoplasias, and any other malignant disease caused by malignant tissues or cells.

[0046] As used herein, unless otherwise indicated, the term "treat" means to reverse, alleviate or inhibit the progression of a disease or condition to which such term is applicable, or one or more symptoms of such disease or condition. As used herein, unless otherwise indicated, the term "treat" refers to the act of treating, and treatment is immediately defined above. Specifically, the method of "treatment" or "treating" herein can be used to alleviate one or more symptoms of solid tumors, delay the progression of solid tumors, reduce the tumor size of solid tumor patients, inhibit solid tumor growth, extend overall survival, extend progression-free survival, prevent or delay solid tumor metastasis, reduce (such as eradicate) pre-existing solid tumor metastasis, reduce the incidence or burden of pre-existing solid tumor metastasis, or prevent the recurrence of solid tumors.

[0047] As used herein, the term "immunotherapy" means a therapy that modulates the immune response to cancer cells, including promoting the immune response or blocking the inhibition of the immune response, such as, but not limited to, antibodies, proteins, or other agents that bind to checkpoint inhibitors, such as CTLA-4, PD-1, PD-L1, and other agents with similar activity in promoting the immune response to cancer cells. Examples of immunotherapy include, but are not limited to, atezolizumab, nivolumab, pembrolizumab, ipilimumab, cemiplimab, durvalumab, avelumab, and the like.

[0048] Adverse events, such as neutropenia, thrombocytopenia, hepatotoxicity and other adverse reactions are graded according to the criteria listed in the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 (May 28, 2009). The grades are generally as follows: Grade 1: Mild; no symptoms or mild symptoms; clinical or diagnostic observation only; no intervention indicated; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living, such as food preparation; Grade 3: Severe or medically significant, but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; incapacitating; limiting self-care activities of daily living, such as dressing, toileting, etc., but not bedridden; Grade 4: life-threatening consequences; urgent intervention indicated; Grade 5: death related to the adverse event.

[0049] Treatment of SCLC

[0050] Embodiments of the present invention include methods of treating small cell lung cancer (SCLC), including metastatic SCLC, in patients suffering from the disease by administering to the patient a therapeutically effective amount of Lubicardin using a pharmaceutical formulation of Lubicardin described herein according to a dosing regimen for one or more treatment cycles. In certain embodiments, Lubicardin therapy is a second-line therapy, such that the patient has previously been administered a therapy, such as a platinum-containing therapy or a platinum-based chemotherapy and / or an immuno-oncology therapy, and the disease has progressed in response to the therapy. Such a treatment regimen is preferably administered to SCLC patients by intravenous infusion, preferably over 1 hour, every three weeks (or 21 days) at a dose of 2.0 to 3.2 mg / m 2 The dose of Lubicatin, in a preferred embodiment, is at least 3.2 mg / m for the initial dose. 2 , provided that the dose may be reduced and / or delayed based on the occurrence of adverse events, particularly hematological abnormalities and hepatotoxicity as disclosed herein. In some embodiments, SCLC patients are administered 3.2 mg / m by intravenous infusion over 60 minutes, repeated every 3 weeks. 2 , until disease progression or unacceptable toxicity (e.g., when the patient has not recovered to meet dosing criteria more than 5 weeks after the previous dose or has stopped tolerating 2.0 mg / m 2 In various aspects of the invention, treatment produces an overall response rate of greater than 30%, including greater than 35% or 35.2%; a median progression-free survival of 3.5 months, including 2.6 to 4.6 months, or 2.6 months in the resistant patient population (chemotherapy-free interval (CTFI), less than 90 days)) to 4.6 months in the sensitive patient population (CTFI greater than or equal to 90 days)); and an overall survival of 9.3 months median (resistant patient population (CTFI less than 90 days), 5.0 months and sensitive patient population (CTFI greater than or equal to 90 days), 11.9 months).

[0051] In various embodiments, the present invention provides methods for treating SCLC, including metastatic SCLC, in patients in need thereof, particularly those patients whose SCLC has progressed following prior therapy, such as platinum-containing or platinum-based chemotherapy, immunotherapy, or both, including patients who were unable to respond or responded adequately to prior therapy, who may have responded to prior therapy but then experienced disease progression, and who may have had such a response and then progressed more than once.

[0052] In some embodiments, the present disclosure provides methods for treating metastatic SCLC. In some embodiments, the present disclosure provides methods for treating adult patients with metastatic SCLC with disease progression following platinum-based chemotherapy.

[0053] SCLC patients

[0054] Patients with SCLC, including metastatic SCLC, are considered "refractory" if they fail to respond to or progress through first-line platinum-containing chemotherapy and / or immunotherapy. Patients who initially respond to initial or "first-line" chemotherapy containing a platinum agent, and then relapse / progress within 90 days (3 months) are considered "resistant." Patients who respond to initial treatment but then relapse or whose tumor progresses within approximately 91 to 180 days (3-6 months) after stopping first-line therapy with a platinum agent are considered sensitive and are considered herein to have "91 to 180 day progressive" SCLC. Patients who respond to an initial relapse or whose tumor progresses after 180 days are "sensitive"

[0055] Lubicardin therapy can be a second-line therapy where the SCLC patient has previously been treated with one or more other chemotherapeutic agents such as carboplatin or cisplatin (platinum-based chemotherapy) and etoposide. Specifically, the treatment is suitable for SCLC patients who have relapsed or are refractory to previous chemotherapy. In some embodiments, the SCLC patient has stopped responding to or stopped responding adequately to or has no response to a previous platinum-containing therapy. More specifically, Lubicardin therapy can be used when the SCLC patient is refractory, resistant, or, including in certain embodiments, relapses / progresses within 0 to 90 days, or within 91 to 180 days after stopping first-line platinum-containing chemotherapy and optionally radiation therapy. SCLC patients who progress within 0 to 90 days or within 91 to 180 days after stopping first-line therapy, as well as patients whose SCLC is refractory to treatment and progresses within 90 days, 180 days, or any time, or whose SCLC responds to initial treatment and then progresses within 90 days, 180 days, or any time after stopping initial treatment can be advantageously treated with rubikatin to increase one or more of their progression-free survival, overall survival, or the length of response duration. In some embodiments, the SCLC patient has a chemotherapy-free interval of at least 90 days, at least 120 days, at least 150 days, or at least 180 days after the previous administration of a previous platinum-containing therapy. In specific embodiments, the patient has not received a platinum-containing therapy for at least 30 days, at least 60 days, or at least 90 days before the administration of rubikatin. In some embodiments, the present disclosure provides a method for treating a SCLC patient who has progressed after a previous platinum-containing therapy. In some embodiments, the present disclosure provides a method for treating an adult patient with metastatic SCLC who has disease progression after platinum-based chemotherapy.

[0056] Rubikatin therapy can also be administered after a combination of first-line platinum-based chemotherapy (such as carboplatin or cisplatin and etoposide) with a checkpoint inhibitor (such as atezolizumab, pembrolizumab, ipilimumab, durvalumab, or a combination thereof), or after second-line therapy with nivolumab or other immunotherapy (such as atezolizumab, pembrolizumab, ipilimumab, or durvalumab). Specifically, the treatment is suitable for SCLC patients who have relapsed or are refractory to previous immunotherapy. For example, in some embodiments, rubikatin treatment is suitable for SCLC patients who have relapsed or are refractory to previous first-line carboplatin / etoposide / atezolizumab combination therapy or second-line immunotherapy with nivolumab. In some embodiments, the SCLC patient stops responding to the previous immunotherapy or stops responding sufficiently or does not respond to the previous immunotherapy. More specifically, rubicatin therapy can be used when the SCLC patient is refractory, resistant, sensitive, or relapses / progresses within 91 to 180 days after stopping the combination of first-line platinum-containing chemotherapy and immunotherapy or second-line nivolumab, and in certain embodiments the patient has received radiation therapy. SCLC patients who progress after stopping first-line chemotherapy (including combinations with platinum-containing therapy) or stopping second-line immunotherapy at any time after therapy (including within 90 days or 180 days of treatment in certain embodiments), as well as patients whose SCLC is refractory to treatment (with a chemotherapy-free interval of less than 90 days) and progresses within 180 days, or whose SCLC responds to initial treatment and then progresses within 180 days of stopping initial treatment, can be advantageously treated with rubicatin to increase one or more of their progression-free survival, overall survival, or length of response duration. In some embodiments, the SCLC patient has a chemotherapy-free interval (including immunotherapy) of less than 90 days relative to the previous treatment, and in other embodiments, the SCLC has a chemotherapy-free interval of at least 90 days, at least 120 days, at least 150 days, or at least 180 days, but in certain embodiments, has a chemotherapy-free interval of no more than 120 days, 150 days, or 180 days. In a specific embodiment, the patient has not received first-line immunotherapy (in combination with platinum-containing therapy) or second-line immunotherapy for at least 30 days, at least 60 days, or at least 90 days prior to the administration of Lubicardin.

[0057] It is expected that when the treatment disclosed herein is administered to SCLC patients in need of such treatment, including metastatic SCLC patients, the treatment will produce an effect as measured by the degree of anti-cancer effect, (overall) response rate, time to disease progression or survival rate. In one embodiment, the overall response rate is at least 30%, at least 35%, at least 40%, at least 45%, at least 50% or at least 60%. In some embodiments, for patients with a chemotherapy-free interval of less than 90 days, the overall response rate is at least 11%, or at least 20%, or at least 25%, or at least 30%, or at least 35%, or wherein for patients with a chemotherapy-free interval of at least 90 days, the overall response rate is at least 30% or at least 40% or at least 45%, or at least 50% or at least 55%. In some embodiments, the duration of response is at least 5.3 months (4.1 months to 6.4 months) or at least 4.7 months (2.6 months to 5.6 months) for resistant patients (less than 90 days of chemotherapy-free interval), or wherein, for sensitive patients with at least 90 days of chemotherapy-free interval, the duration of response is at least 6.2 months (3.5 months to 7.3 months).

[0058] In certain embodiments, SCLC patients treated with rubicatin as disclosed herein have a progression-free survival of at least 3.5 months (2.6 months to 4.3 months), and for resistant patients, a progression-free survival of 2.6 months (1.3 months to 3.9 months), and for sensitive patients, a progression-free survival of 4.6 months (2.8 months to 6.5 months). In other embodiments, SCLC patients treated with rubicatin as disclosed herein have an overall survival of 9.3 months (6.3 months to 11.8 months), and for resistant patients, an overall survival of 5.0 months (4.1 months to 6.3 months), and for sensitive patients, an overall survival of 11.9 months (9.7 months to 16.2 months).

[0059] Alternatively, the treatment may be a second-line therapy for SCLC with extensive or localized disease that is refractory to initial chemotherapy or that progresses within less than 90 days (3 months) of completing first-line platinum-containing therapy. SCLC patients who progress after stopping first-line therapy (including within 30 to 90 days of treatment, but can be at any time), as well as patients whose SCLC is refractory to treatment and progresses within 90 days or whose SCLC responds to initial treatment and then progresses within 90 days of stopping initial treatment can be advantageously treated with rubicatin to increase one or more of their progression-free survival, overall survival, or duration of response. In some embodiments, the SCLC patient has a chemotherapy-free interval of less than 90 days, such as less than 30 days, less than 60 days, or less than 90 days, for prior treatment.

[0060] In various embodiments, the SCLC patient is first treated with platinum-based chemotherapy and immunotherapy, wherein the platinum-based chemotherapy and immunotherapy are administered simultaneously or sequentially, and then the patient is administered an effective amount of Lubicardin as disclosed herein or an effective cycle of Lubicardin treatment, comprising 3.2 mg / m every three weeks. 2 (or delayed or reduced in patients who exhibit hematologic toxicity). For example, in some embodiments, the SCLC patient has received prior immunotherapy comprising administration of an antibody targeting PD-L1, CTLA-4, or PD-1, wherein the antibody is selected from atezolizumab, nivolumab, pembrolizumab, ipilimumab, durvalumab, or a combination thereof. In some embodiments, the patient has previously been administered atezolizumab in combination with a platinum-containing therapy and etoposide. In some embodiments, the patient has been administered nivolumab. Thus, a regimen of 3.2 mg / m every three weeks is provided. 2 Methods of treating SCLC patients who have progressed on atezolizumab (including in combination with carboplatin and etoposide) or on nivolumab with rubicatin (or delayed or reduced in patients who exhibit hematologic toxicity).

[0061] In some embodiments, the patient to whom Lupicardin is administered is an adult.

[0062] Treatment cycle

[0063] Administration of the pharmaceutical composition comprising Lubicardin is preferably performed by intravenous infusion. Infusion times of up to 72 hours may be used, but are preferably between 1 and 24 hours, and are typically about 1 hour. Short infusion times that allow treatment without an overnight stay in the hospital are particularly desirable. In a preferred embodiment, Lubicardin is administered by infusion over 1 hour (60 minutes).

[0064] Preferably, the administration of Lubicardin is performed in cycles. In a preferred administration plan, an intravenous infusion of Lubicardin is given to the patient on the first day of each cycle, and the patient is allowed to recover during the remainder of the cycle. The preferred duration of each cycle is 3 weeks or 21 days. However, the treatment cycle can be increased or decreased, for example, by 1 to 6 days, 1 week or 2 weeks, or more than 3 weeks, such as 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 days or more, depending on the patient's response to the treatment. In certain embodiments, if the treatment cycle is delayed for more than 2 weeks because the patient has not recovered from an adverse event and does not meet the hematological criteria for Lubicardin treatment, treatment with Lubicardin can be discontinued. Administration of Lubicardin by intravenous infusion over about 1 hour every 3 weeks is the most preferred administration plan, although other regimens can be designed as variations. Multiple cycles can be given as needed. During the treatment of SCLC, 1 to 24 doses of Lubicardin may be administered at intervals of about 21 days (three weeks), typically 4 to 8 doses are administered. For example, if it is necessary to modify the treatment plan to reduce or manage side effects (as discussed in detail below), an interval of up to six weeks, such as 3 to 4 weeks, may be used. During the treatment of cancer, 1 to 24 Lubicardin treatments may be administered at intervals of about 21 days (three weeks), typically 4 to 8 treatments are administered. In some embodiments, one dose of Lubicardin is administered per treatment cycle, and the patient undergoes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 treatment cycles. In an embodiment, Lubicardin is administered in 3-week treatment cycles, or administration is delayed to allow the patient to recover from adverse events until disease progression or unacceptable toxicity.

[0065] The bioavailability of a drug is defined as the proportion of a drug or other substance that enters the circulation when introduced into the body and is therefore able to produce an active effect. Bioavailability measures well known in the art include the area under the plasma concentration-time curve (AUC) and the maximum concentration (Cmax). Cmax is the maximum plasma concentration achieved after drug administration.

[0066] Provided herein are methods for administering lupicardin by one or more pharmacokinetic parameters, wherein the administration of the dose is effective for treating resistant, refractory, or progressive SCLC. In an exemplary embodiment, the one or more pharmacokinetic parameters are peak concentration (Cmax) or area under the curve (AUC). In one embodiment, 3.2 mg / m is administered to a SCLC patient in need thereof. 2Lubicardin is administered as a 1-hour infusion to achieve an average total plasma Cmax within 80% to 125% of about 107 μg / L and an average AUC∞ within 80% to 125% of about 551 μg*h / L. In some embodiments, Lubicardin is administered to SCLC patients in a cycle of 1 day on and 20 days off (1 / 20 cycle). In one embodiment, the administration cycle is 1 / 20 cycle and the target average AUC∞ is about 551 μg*h / L. In one embodiment, the administration cycle is 1 / 20 cycle and the target average AUC∞ is about 551 μg*h / L±5%, about 551 μg*h / L±10%, about 551 μg*h / L±20%, or about 551 μg*h / L±25%. In a preferred embodiment, the administration cycle is 1 / 20 cycle and the target average AUC∞ is within 80% to 125% of about 551 μg*h / L. In one embodiment, the administration cycle is 1 / 20 cycle and the average target Cmax is about 107 μg / L. In one embodiment, the administration cycle is 1 / 20 cycle and the average target Cmax is about 107 μg / L ± 5%, about 107 μg / L ± 10%, about 107 μg / L ± 20%, or about 107 μg / L ± 25%. In a preferred embodiment, the administration cycle is 1 / 20 cycle and the average target Cmax is within 80% to 125% of about 107 μg / L.

[0067] Before administering rubikatin to patients with SCLC, renal, hepatic, and hematologic impairment must be excluded. In one embodiment, rubikatin is administered to patients with SCLC who have at least 1500 cells / mm 3 Absolute neutrophil count of at least 100,000 / mm 3 About 3.2 mg / m2 is given to patients with SCLC who have a platelet count of at least 1.5 g / dL and optionally a hemoglobin level of at least 9 g / dL (transfusion if necessary). 2 In another embodiment, about 3.2 mg / m is administered to a patient with SCLC determined to have a calculated hepatic clearance greater than 30 mL / min and an AST or ALT less than 3×ULN or a bilirubin less than 1.5×ULN and a calculated creatinine clearance greater than 30 mL / min. 2 The first dose of Lupicatin. Approximately 21 days after the first dose, the patient was given 3.2 mg / m 2 A second dose of rubicatin is administered and further dosing at this level is continued if hematologic, renal, and liver parameters remain stable. In one embodiment, if a patient has at least 1500 cells / mm 3 Absolute neutrophil count of at least 100,000 / mm 3If the platelet count is below 50%, the patient is given a dose of rubicatin, specifically an initial dose of 3.2 mg / m 2 The planned dose or reduced dose 3 weeks after the previous dose. To achieve the preferred dosing, preferably, each dose, e.g., each intravenous infusion, is administered at about 3.2 mg / m 2 Administration of Lubicardin may include each dose, for example, each intravenous infusion of about 3.2 mg / m 2 Lubicardin, or a reduced dose thereof, as discussed below.

[0068] Antiemetic therapy

[0069] Best supportive care and solid tumor treatment for SCLC, including metastatic SCLC and adult patients includes a variety of palliative treatments. For example, in one embodiment of the invention, best supportive care includes one or more and preferably all of analgesic administration to control pain, constipation management, and dyspnea treatment and anemia treatment (e.g., by blood transfusion to maintain hemoglobin levels (i.e., >9 g / dL)).

[0070] In other embodiments, the therapy is administered to specifically prevent and treat or manage nausea and / or vomiting associated with administration of lupicardin, as described below.

[0071] Chemotherapeutic agents vary in their emetogenicity. In the absence of antiemetic prophylaxis, agents associated with a >90% risk of emesis are classified as highly emetogenic chemotherapies, and those associated with a 30%-90% risk of emesis are classified as moderately emetogenic chemotherapies.

[0072] Various aspects include methods for preventing and treating rubicatin-induced (acute and delayed) nausea and / or vomiting, wherein an effective antiemetic amount of a serotonin antagonist or a corticosteroid, or a combination thereof, is administered to a patient prior to administration of rubicatin, particularly immediately prior to administration of rubicatin, so as to reduce the side effects of nausea and vomiting that may accompany administration of rubicatin. A preferred embodiment is treating SCLC, including metastatic SCLC, in a patient in need thereof, or otherwise reducing the side effects of administering rubicatin to a patient, comprising: (1) administering to the patient one or more antiemetics effective in reducing nausea associated with administration of rubicatin on and before the day of administration of rubicatin to the patient; and (2) administering to the patient 2 to 3.2 mg / m by intravenous infusion 2 In certain embodiments, Lubicardin is administered as a single agent chemotherapeutic agent and / or is not administered in combination with doxorubicin. In other embodiments, Lubicardin may be administered at 2 mg / m 2 Lubicardin and 75 mg / m 2The combination of irinotecan on the same day and before and in certain embodiments on day 8 of the treatment cycle with 75 mg / m 2 Antiemetic therapy was administered to patients together with irinotecan.

[0073] In some embodiments, the antiemetic is administered intravenously or orally. If one or more antiemetics are administered intravenously, one or more agents are administered between 30 and 90 minutes before the administration of Lupicard, or about 30 minutes, about 45 minutes, about 60 minutes, about 75 minutes, or about 90 minutes, preferably 30 or 60 minutes before the administration of Lupicard. If one or more antiemetics are administered orally, one or more agents are administered between 30 and 60 minutes before the administration of Lupicardin, between about 3 hours and 9 hours before the administration of Lupicardin, or about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, or about 9 hours before the administration of Lupicardin. In some embodiments, the antiemetic is composed of a corticosteroid and a serotonin antagonist, wherein the corticosteroid is selected from the group consisting of dexamethasone, hydrocortisone, or methylprednisolone, and the serotonin antagonist is selected from the group consisting of ondansetron, granisetron, and palonosetron. The dose of corticosteroid is or is equivalent to about 4 mg to 20 mg of dexamethasone delivered intravenously, preferably 8 mg of dexamethasone delivered intravenously. The dose of serotonin antagonist is or is equivalent to about 8 mg to 16 mg of ondansetron delivered intravenously, preferably 8 mg of ondansetron delivered intravenously. If administered orally, the dose can be increased to a dose equivalent to up to 24 mg of ondansetron. In a preferred embodiment, the prophylactic antiemetic comprises dexamethasone administered intravenously at 8 mg, ondansetron administered intravenously at 8 mg, or a combination thereof.

[0074] In some embodiments, the method further comprises administering one or more antiemetics within 2, 3 or 4 days after administration of Lubicardin to the patient, for example, on the same day of administration of Lubicardin, for example, within 2, 3, 4, 5, 6, 7 or 8 hours of administration of Lubicardin and / or on the 1st, 2, 3 or 4th day after administration of Lubicardin. The one or more antiemetics administered after administration of Lubicardin are selected from the group consisting of corticosteroids, serotonin antagonists and metoclopramide, wherein the corticosteroids are selected from dexamethasone, hydrocortisone and methylprednisolone, and wherein the serotonin antagonists are selected from ondansetron, granisetron and palonosetron. In a preferred embodiment, the post-infusion antiemetic treatment is 4 mg dexamethasone (oral), 8 mg ondansetron (oral) or 10 mg metoclopramide (oral or as an infusion) or a combination thereof. Metoclopramide can be administered at 8 hour intervals. In some embodiments, the post-infusion antiemetic is administered intravenously. In some embodiments, the first dose of the post-infusion antiemetic is given in the evening or 1, 2, 3, 4, 5, 6, 7, or 8 hours after the administration of Lupicardin and continues for up to 1, 2, 3, or 4 days after the infusion. In some embodiments, a corticosteroid, such as dexamethasone, is given in the evening or 1, 2, 3, 4, 5, 6, 7, or 8 hours after chemotherapy at a dose equivalent to 4 mg of dexamethasone, and then twice a day for a length of 1, 2, 3, or 4 days. In some embodiments, metoclopramide is orally administered at a dose of 10 to 20 mg every 8 hours after chemotherapy for up to 1, 2, 3, or 4 days. In other embodiments, a serotonin antagonist, such as ondansetron, is orally administered at a dose equivalent to 8 mg or 16 mg of ondansetron, respectively, every 12 or 24 hours after Lupicardin administration for up to 1, 2, or 3 days.

[0075] In some embodiments, about 2.0 mg / m is administered by intravenous infusion. 2 , about 2.6mg / m 2 or about 3.2 mg / m 2 SCLC patients receiving rubicatin were given antiemetic prophylaxis and optionally post-infusion antiemetic therapy. 2 Patients with solid tumors were administered antiemetic prophylaxis and optionally post-infusion antiemetic therapy in combination with rubicatin and irinotecan.

[0076] Dosing and dose reduction

[0077] Additional embodiments of the present invention include administering 3.2 mg / m 2 Dose modifications were made after the first dose of lumikatin in the event that ≥ Grade 2 adverse events (AEs) were identified (e.g., greater than 2 weeks) in SCLC patients, particularly adult patients with metastatic SCLC, with lumikatin administered on Day 1 and dose delays exceeding a 21-day treatment cycle.

[0078] In some embodiments, a lower amount of lurbinectedin is used compared to the amount typically used in individual therapy. In some embodiments, the same or greater therapeutic benefit is achieved using an amount of lurbinectedin that is less than the amount typically used in individual therapy (e.g., a lower dose or a lower frequency dosing schedule). For example, using a lower amount of lurbinectedin can result in a reduction in the number, severity, frequency, or duration of one or more side effects associated with lurbinectedin infusion. For example, in a preferred embodiment, the first dose modification is a dose reduction of lurbinectedin from about 3.2 mg / m 2 to about 2.6 mg / m 2 (or 80% to 85% of the initial dose), and the second dose modification is a dose reduction of lurbinectedin from about 2.6 mg / m 2 to about 2.0 mg / m 2 (or 60% to 65% of the initial dose). If, after the second dose reduction, the patient experiences an adverse event that requires a further dose reduction, treatment may be discontinued. Adverse events that require frequent or prolonged (>2 weeks) dose delays include, but are not limited to, any grade 3 or 4 hematologic toxicities, or any grade 2, 3, or 4 non-hematologic toxicities or adverse reactions, such as hepatotoxicity. In the case of grade 2, 3, or 4 non-hematologic toxicities, the next cycle is delayed until the non-hematologic parameters improve to grade 1 or 0. Administration of lurbinectedin for two doses is always separated by at least 21 days.

[0079] Do not initiate a treatment cycle until the hematologic parameters (such as neutrophil count, platelet count, and optionally hemoglobin level) improve such that the absolute neutrophil count is greater than or equal to 1500 cells / mm 3 , and the platelet count is greater than 100,000 / mm 3 , and optionally in some embodiments, the hemoglobin level is greater than or equal to 9 g / dL (transfusion if necessary). For example, upon the first occurrence of grade >3 (severe) non-hematologic toxicity, grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm 3 ), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm 3 ) with bleeding requiring transfusion, grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ), or any grade neutropenia (neutrophil count < LLN) associated with infection / sepsis or any adverse reaction that requires frequent or prolonged (>2 weeks) dose delay, the lurbinectedin dose is reduced from about 3.2 mg / m 2 to 2.6 mg / m 2(or 80% to 85% of the initial dose), and the next cycle is delayed until the patient's neutrophil count is greater than 1500 cells / mm 3 ; platelet count is greater than about 100,000 / mm 3 ; and hemoglobin level is greater than about 9 g / dL. In one embodiment, if the identified adverse event consists of isolated grade 4 neutropenia, the method includes administering a dose of G-CSF to the patient ("secondary G-CSF prophylaxis") as prophylaxis to manage the isolated grade 4 neutropenia, and then administering a dose of rubitecan equal to the previous dose, rather than reducing the rubitecan dose. If after the first dose reduction, the patient experiences an adverse event that requires a dose reduction (greater than grade 3 (severe) non-hematological toxicity, grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm 3 ), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm 3 ) accompanied by bleeding requiring transfusion, grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ) or any grade neutropenia (neutrophil count < LLN) associated with infection / sepsis or any adverse reaction that requires frequent or prolonged (greater than 2 weeks) dose delay), then once the patient recovers, with neutrophils greater than or equal to 1500 cells / mm 3 , platelet count greater than or equal to 100,000 / mm 3 and hemoglobin level greater than or equal to 9 g / dL (transfusion if necessary), the subsequent dose is reduced to 2.6 mg / m 2 (or 60% to 65% of the initial dose) 3 weeks later. After the second dose reduction, if the patient again has an adverse reaction that requires a dose reduction, treatment is terminated. If the absolute neutrophil count is greater than or equal to 1500 cells / mm 3 and platelet count is greater than or equal to 100,000 / mm 2 due to the patient not having recovered, resulting in a dose delay greater than 2 weeks, treatment can be terminated.

[0080] If the identified adverse reaction is not just isolated grade 4 neutropenia, the method includes administering a reduced dose of rubitecan to the patient. The administration of two doses of rubitecan must be separated by at least 21 days, regardless of the dose of rubitecan.

[0081] One preferred embodiment is to treat small cell lung cancer (SCLC), including metastatic SCLC, in patients in need, which includes: (1) administering 3.2 mg / m to the patient by intravenous infusion 2The first dose of lurbinectedin; (2) identifying an adverse reaction in the patient, wherein the adverse reaction is selected from the group consisting of: ≥ grade 3 (severe) non-hematological toxicity, grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm 3 ), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm 3 ) accompanied by bleeding requiring transfusion, grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ) or any grade neutropenia (neutrophil count < LLN) associated with infection / sepsis or any other adverse reaction; and (3) after identifying the adverse reaction and when the patient's neutrophil count is greater than 1500 cells / mm 3 ; platelet count greater than about 100,000 / mm 3 ; and hemoglobin level greater than about 9 g / dL: (i) if the identified adverse reaction consists of isolated grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ), then administer one dose of G-CSF and one dose of lurbinectedin equivalent to the previous dose to the patient; or (ii) if the identified adverse reaction is not just isolated grade 4 neutropenia, then administer a reduced dose of lurbinectedin to the patient, wherein the administration interval between two doses of lurbinectedin is 21 days or 20 to 23 days or at least 18, 19, 20, 21, 22, or 23 days.

[0082] In some embodiments, after the first occurrence of an adverse reaction that is not just isolated grade 4 neutropenia, the first dose reduction is 80% to 85% of the first dose, or wherein after the first occurrence of an adverse reaction that is not just isolated grade 4 neutropenia, the first reduced dose is 2.6 mg / m 2 . In some embodiments, after the second occurrence of an adverse reaction that is not just isolated grade 4 neutropenia, the second reduced dose is 60 - 65% of the first dose, or wherein after the second occurrence of an adverse reaction that is not just isolated grade 4 neutropenia, the second reduced dose is 2.0 mg / m 2 , wherein the second reduced dose is administered to the patient. After identifying an adverse reaction after administering the second reduced dose, discontinue the administration of lurbinectedin.

[0083] Before administering the initial dose or subsequent doses of lurbinectedin, patients with SCLC, particularly metastatic SCLC, including adult patients, have an absolute neutrophil count of at least 1500 cells / mm 3 and at least 100,000 / mm 3Therefore, a method of treating with 3.2 mg / m 2 The dose of rubicin was sufficient to treat cells with at least 1500 cells / mm 3 Absolute neutrophil count of at least 100,000 / mm 3 platelet counts in patients with SCLC, including metastatic SCLC, and if patients experienced adverse events, underwent dose delays or dose reductions.

[0084] Methods are provided for managing hematologic toxicity, myelosuppression, and / or hepatotoxicity that may be associated with the administration of rubicatin in the treatment of SCLC, including metastatic SCLC, by dose reductions and / or dose delays. Adverse events that may trigger dose delays or reductions include Grade 4 or any grade of febrile neutropenia (Grade 4 neutropenia is a neutrophil count less than 500 cells / mm 3 ), grade 3 thrombocytopenia with bleeding or grade 4 thrombocytopenia (grade 3 thrombocytopenia is 25,000-50,000 platelets / mm 3 And grade 4 thrombocytopenia is less than 25,000 platelets / mm 3 ), Grade 2 or higher hepatotoxicity, or other adverse reactions. In the case of all these adverse reactions, subsequent doses may be delayed until the patient recovers such that the patient demonstrates less than or equal to Grade 1 neutropenia (greater than 1500 cells / mm 3 ), with 100000 / mm 3 Patients who develop Grade 4 neutropenia or any grade of febrile neutropenia, Grade 3 associated bleeding, or Grade 4 thrombocytopenia or Grade 3 or higher hepatotoxicity or other adverse reactions, after recovery, are administered a reduced dose in subsequent treatment cycles. If the previous dose was 3.2 mg / m 2 , the reduced dose is 2.6 mg / m 2 , and if the previous dose was 2.6 mg / m 2 , the reduced dose is 2.0 mg / m 2 , once every three weeks. 2 If an adverse event indicating a dose reduction is experienced after a dose of 100 mg / dL, treatment may be discontinued. For patients who exhibit grade 4 neutropenia, if G-CSF prophylaxis is administered to the patient, the subsequent dose may not be reduced once the patient recovers, i.e., it may be the same as the previous dose, once every three weeks. For patients who exhibit grade 2 hepatotoxicity or other adverse reactions, after the patient recovers to grade 1 or lower toxicity, the subsequent dose is the same as the previous dose, once every three weeks.

[0085] Thus, providing a method of treating a cell population having at least 1500 cells / mm 3 Absolute neutrophil count of at least 100,000 / mm 3 Patients with platelet counts below 3.2 mg / m 2 A dose of rubicatin, preferably by infusion over 60 minutes, is provided for the treatment of SCLC, including metastatic SCLC. In another embodiment, the patient has at least 1500 cells / mm 21 days after the previous dose. 3 Absolute neutrophil count of at least 100,000 / mm 3 platelet count and administered 3.2 mg / m 2 The dose of Lupicardin is preferably administered by infusion over 60 minutes. In an embodiment, the patient is monitored for hepatotoxicity and is free of hepatotoxicity prior to administration of Lupicardin. 3 Absolute neutrophil count of at least 100,000 / mm 3 Patients with elevated platelet counts were administered subsequent treatment.

[0086] In certain embodiments, the invention provides for the administration of 3.2 mg / m 2 A method of treating SCLC, including metastatic SCLC, in patients in need thereof by administering 3.2 mg / m 2 Patients receiving rubicatin who developed grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ) or any febrile neutropenia, do not administer a subsequent dose of rubicatin until 21 days after the previous dose or when the patient exhibits less than Grade 1 neutropenia (at least 1500 cells / mm 3 ), this may be greater than 21 days after the previous dose, and then at 2.6 mg / m every three weeks 2 Lubicatin was administered at a reduced dose or at 3.2 mg / m every 3 weeks with G-CSF prophylaxis. 2 Lubicatin was administered at a dose of 3.2 mg / m 2 Patients receiving rubicatin developed grade 3 thrombocytopenia (25,000-50,000 platelets / mm 3 ) with bleeding or grade 4 thrombocytopenia (less than 25,000 platelets / mm 3), then the subsequent rubicatin dose is not administered until 21 days after the previous dose or when the patient demonstrates greater than or equal to 100,000 / mm 3 The platelet count was 1.000, and the subsequent dose was 2.6 mg / m every three weeks (21 days) 2 When 3.2 mg / m 2 If a patient who has received a dose of 3.2 mg / m2 of lumikatin exhibits hepatotoxicity or other adverse reactions that are Grade 2, 3, or 4, then the subsequent dose of lumikatin is not administered until 21 days after the previous dose or when the patient exhibits less than or equal to Grade 1 hepatotoxicity (or other adverse reactions), and if the patient exhibits Grade 2 hepatotoxicity (or Grade 2 or other adverse reactions), then the subsequent dose is 3.2 mg / m2 every three weeks. 2 If the patient exhibits grade 3 or 4 hepatotoxicity or other adverse reactions, the subsequent dose is 2.6 mg / m every three weeks (21 days) 2 If, following a dose reduction, the patient develops Grade 4 neutropenia or any grade of febrile neutropenia, Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia, or Grade 3 or 4 hepatotoxicity or other adverse reactions, then the subsequent dose is not administered until 21 days later or when the patient recovers as detailed above, and then 2 mg / m2 every three weeks is administered. 2 Further dose reductions of lumigatin or, in case of grade 4 neutropenia, administration of the same lumigatin dose as the previous dose while on G-CSF prophylaxis. 2 Treatment was discontinued if lumikatin was discontinued at a dose that was intolerable (i.e., Grade 4 neutropenia or febrile neutropenia of any grade, Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia, or Grade 3 or 4 hepatotoxicity or other adverse reactions occurred after lumikatin administration) or if administration was delayed more than 2 weeks after the scheduled dose (21 days after the previous dose).

[0087] Co-administration with strong or moderate CYP3A inhibitors increases systemic exposure of lupicardin and therefore patients taking CYP3A inhibitors should be advised to remove the CYP3A inhibitor or discontinue the CYP3A inhibitor, or alternatively, the lupicardin dose should be increased from, for example, 3.2 mg / m 2 The dose was reduced to 2.6 mg / m 2 or 2.0 mg / m 2Examples of CYP3A inhibitors include clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, verapamil, goldenseal and grapefruit. Thus, a method of treating SCLC, particularly metastatic SCLC or solid tumors in a patient is provided, which is performed by administering a dose of rubicatin every 3 weeks, including 3.2 mg / m 2 Lupicardin, where the patient is not taking a CYP3A inhibitor (and the CYP3A inhibitor may have been removed prior to Lupicardin administration to avoid drug interactions), or if the patient is also taking a CYP3A inhibitor, administer less than 3.2 mg / m 2 Doses include 2.6 mg / m 2 or 2.0 mg / m 2 ).

[0088] Co-administration with strong CYP3A inducers reduces systemic exposure of Lupicardin, which may reduce efficacy. Examples of CYP3A inducers include phenobarbital, phenytoin, rifampicin, St. John's wort, and glucocorticoids. Thus, a method of treating SCLC, particularly metastatic SCLC or solid tumors in a patient is provided by administering a dose of Lupicardin every 3 weeks, including 3.2 mg / m 2 Rubikatin was used in patients not taking strong or moderate CYP3A inducers.

[0089] Combination therapy for solid tumors

[0090] In other embodiments, the present invention relates to the treatment of cancer, and more specifically solid tumors, particularly endometrial cancer, SCLC, soft tissue sarcomas (including Ewing sarcoma or synovial sarcoma), glioblastoma (including supratentorial or intratentorial tumors), pancreatic cancer, mesothelioma, colorectal cancer and epithelial ovarian cancer in combination with a topoisomerase I and / or II inhibitor. In a preferred embodiment, the solid tumor is endometrial cancer, SCLC, soft tissue sarcoma (including Ewing sarcoma and synovial sarcoma) or glioblastoma. In some embodiments, the method of treating a patient with a solid tumor comprises administering 1 to 2.5 mg / m 2 A combination of 1 to 2.5 mg / m2 of rubicatin with other anticancer agents, such as a topoisomerase inhibitor selected from SN-38 or irinotecan. 2 Doses, especially 2.0 mg / m 2 administration, and wherein the topoisomerase inhibitor is administered at a dose equivalent to 50 to 75 mg irinotecan / m 2The chemotherapeutic group of topoisomerase I and / or II inhibitors includes, but is not limited to, topotecan, SN-38, irinotecan, camptothecin, rubicin, etoposide, amsacrine and teniposide. Particularly preferred is the combination of rubicin and irinotecan in the treatment of cancer, in particular solid tumors, and more specifically endometrial cancer, SCLC, soft tissue sarcomas (including Ewing sarcoma and synovial sarcoma), glioblastoma, pancreatic cancer, mesothelioma, colorectal cancer and epithelial ovarian cancer.

[0091] In some embodiments, rubicatin is administered at 1, 1.5, 2, or 2.4 mg / m 2 The topoisomerase inhibitor was administered at a dose equivalent to 50 to 75 mg / m 2 In a preferred embodiment, irinotecan is administered at a dose of 2 mg / m 2 irinotecan was administered at 75 mg / m 2 G-CSF is administered to the patient together with the combination.

[0092] In some embodiments, rubikatin and the topoisomerase inhibitor are administered on day 1 of a treatment cycle. In some embodiments, the method further comprises administering G-CSF to the patient to manage the myelosuppressive effects of therapy. In another embodiment, the topoisomerase inhibitor is also administered to the patient on day 7, 8, 9, or 10 of the treatment cycle. In some embodiments, the treatment cycle is an 18, 19, 20, 21, 22, 23, 24, or 25 day cycle.

[0093] In a specific embodiment, a method of treating a solid tumor in a patient in need thereof is provided by administering a dose of lupicatin, particularly 2.0 mg / m 2 and irinotecan at a dose of 75 mg / m2, and then 75 mg / m2 on day 8 of the treatment cycle. 2 The dosage of irinotecan is administered together with G-CSF to manage the myelosuppressive effect of therapy. The treatment cycle can be a 3-week (21 day) cycle, so that the subsequent treatment cycle starts on the 22nd day. In certain embodiments, patients who exhibit hematological toxicity (including grade 3-4 adverse events) after administering the combined dose on the 1st day of the treatment cycle can not administer the irinotecan dose on the 8th day (or any other time in this treatment cycle), or can administer a reduced dose of irinotecan on the 8th day of the treatment cycle or at any other time in the treatment cycle. Treatment can include multiple treatment cycles until disease progression or unacceptable toxicity occurs. Specifically, 1, 2, 3, 4, 5 or more, including 8, 10, 12, 15, 20 or 30 or more cycles of combined therapy can be administered to the patient.

[0094] In a specific embodiment, the combination treatment method results in a reduction in tumor size resulting in a median progression-free survival of at least 4.3 months (particularly for SCLC), at least 7.1 months (particularly for endometrial cancer), at least 2.6 months (particularly for soft tissue sarcomas), or at least 1.4 months (particularly for glioblastoma).

[0095] In one embodiment, the method further comprises administering one or more antiemetics (as described in detail above for treatment of SCLC with rubicatin) on the first day of the treatment cycle and post-infusion antiemetic therapy as described herein for treatment of SCLC.

[0096] Pharmaceutical composition and preparation method

[0097] Pharmaceutical compositions of Lupicatin that may be used include solutions, lyophilized compositions, and the like, and suitable excipients for intravenous administration.

[0098] In one aspect, Lupicardin is provided and stored as a stable and sterile lyophilized product comprising Lupicardin, a buffer derived from an organic acid (e.g., an organic carboxylic acid buffer), a disaccharide, and sufficient base to provide the appropriate pH for injection when the composition is reconstituted in an appropriate solvent.

[0099] In some embodiments, the organic carboxylic acid buffer is derived from an organic acid selected from the group consisting of lactic acid, butyric acid, propionic acid, acetic acid, succinic acid, citric acid, ascorbic acid, tartaric acid, malic acid, maleic acid, fumaric acid, glutamic acid, aspartic acid, gluconic acid and alpha-ketoglutaric acid. In some embodiments, the organic carboxylic acid buffer is derived from an organic acid selected from lactic acid or succinic acid. In some embodiments, the organic carboxylic acid buffer is derived from lactic acid. In certain embodiments, the buffer is not a phosphate buffer.

[0100] In some embodiments, the disaccharide is selected from the group consisting of sucrose, trehalose or lactose or a combination thereof. In some embodiments, the disaccharide is sucrose.

[0101] In some embodiments, the base is selected from the group consisting of carbonates, hydroxides, bicarbonates and ammonium salts. Particularly preferred bases are sodium carbonate, potassium carbonate, calcium carbonate, NH4OH, sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium bicarbonate, potassium bicarbonate and calcium bicarbonate. In some embodiments, the base is sodium hydroxide.

[0102] In some embodiments, the pH of the reconstituted lyophilized composition is about 4. In some embodiments, the pH of the reconstituted lyophilized composition is about 3 to about 5. In some embodiments, the pH of the reconstituted lyophilized composition is about 3.5 to about 4.5. In some embodiments, the pH of the reconstituted lyophilized composition is 3.8 to 4.1.

[0103] In some embodiments, the stable lyophilized product comprises lupicardin; lactic acid; sodium hydroxide and sucrose, and the pH of the reconstituted lyophilized composition is 3.8 to 4.1. In some embodiments, the stable lyophilized product comprises 4 mg lupicardin; 22.1 mg lactic acid; 5.1 mg sodium hydroxide (or comprises about 0.25 mmol lactate); and 800 mg sucrose. In some embodiments, the stable lyophilized product consists essentially of: 4 mg lupicardin; 22.1 mg lactic acid; 5.1 mg sodium hydroxide (or comprises about 0.25 mmol lactate); and 800 mg sucrose.

[0104] The formulation containing lupicadin of the present invention can be prepared by freeze drying a composition of the present invention in the form of a buffered bulk solution, the composition comprising lupicadin, a buffer derived from an organic acid (such as a lactate buffer or a succinate buffer) and a disaccharide. The disaccharide is preferably sucrose. The bulk solution is usually buffered to a pH of, for example, about 3 to 5, preferably about 3.5 to 4.5, more preferably pH 3.8 to 4.1. The preferred buffer is a sodium lactate buffer. In a preferred embodiment, the lactate buffer comprises lactic acid and a base, preferably a pharmaceutically acceptable inorganic base, such as sodium hydroxide.

[0105] Thus, in an embodiment of the present invention, a buffered lyophilized composition is provided, comprising lupicardin, a buffer derived from an organic acid (such as a lactate buffer or a succinate buffer) and a disaccharide; wherein the buffer is configured such that upon reconstitution, the pH of the reconstituted lyophilized composition is from about 3 to about 5, from about 3.5 to about 4.5, or from 3.8 to 4.1.

[0106] The present invention has identified a method that allows complete dissolution of Lubicardin in a desired buffer while minimizing the generation of impurities. In an embodiment, the use of an organic acid buffer allows Lubicardin to be dissolved directly in an organic acid buffer (preferably at a pH of about 1 to 5, about 2 to 4.5, about 3 to 4.5, or about 4), followed by the addition of a bulking agent (such as a disaccharide, preferably sucrose). This formulation strategy enables direct dissolution into a bulk formulation and avoids the need for a pre-dissolution step. In one embodiment, direct dissolution of Lubicardin is provided, comprising dissolving Lubicardin in an organic acid buffer (preferably at a pH of about 1 to 5, about 2 to 4.5, about 3 to 4.5, or about 4), followed by the addition of a bulking agent (such as a disaccharide, preferably sucrose) to form a bulk solution. The bulk solution may be sterile filtered. The bulk solution may then be filled in vials according to the desired dose. The bulk solution in the vial may then be lyophilized to form a lyophilized buffered Lubicardin formulation. The lyophilized formulation may then be reconstituted to form a reconstituted solution. The reconstituted solution may be diluted to form an injection solution. Preferably, in the case of direct dissolution, Lupicadin is amorphous or substantially amorphous.

[0107] As explained herein, Lubicartin has limited water solubility. It has been found that the solubility of Lubicartin in the bulk solution is improved by first forming a concentrated Lubicartin pre-solution in a buffer derived from an organic acid (e.g., lactic acid, succinic acid, citric acid or acetic acid), which is further diluted with water for injection. The disaccharide is then dissolved in an aqueous solution containing an alkaline component, such as an aqueous sodium hydroxide solution, and the Lubicartin pre-solution and the buffer solution containing the disaccharide are mixed to obtain a Lubicartin bulk solution in a pH=4 organic buffer containing a disaccharide (e.g., sucrose) when the pH is adjusted to a set value. After this process, the Lubicartin concentration in the bulk solution can be increased, thereby enabling a reduction in the vial fill volume. In these embodiments of the invention, the fill volume is typically reduced by about 80% relative to the conventional fill volume. By way of illustration and not limitation, embodiments of the invention provide a fill volume of 1 mg of Lubicartin in a 2 ml solution in a 10 ml vial; or a fill volume of 4 mg of Lubicartin in an 8 ml solution in a 30 ml vial. In other embodiments of the invention, the fill volume may optionally be further reduced by increasing the lupicardin concentration.

[0108] A method is provided for increasing the solubility of lubicartin in a bulk solution, comprising dissolving lubicartin in lactic acid, e.g., 0.31 M lactic acid (25 mg / mL), and subsequently diluting the solution with water for injection to produce a concentrated solution of lubicartin in 0.1 M lactic acid, mixing the solution containing the pre-dissolved lubicartin with a buffered saline solution comprising a sodium lactate buffer and a disaccharide, and optionally adjusting the pH. In some illustrative but non-limiting embodiments of the invention, the pH adjustment is achieved with a lactate buffer.

[0109] An illustrative embodiment of a bulk solution for freeze drying according to the present invention is provided by a lupicadine solution buffered at pH 4 with sodium hydroxide and lactic acid and sucrose as a bulking agent.

[0110] An illustrative embodiment of a method according to the present invention is provided as follows: Lupicardin is dissolved in 0.31 M lactic acid, pH ~3, and subsequently diluted with water for injection to produce a concentrated solution of 8.3 mg / mL Lupicardin in 0.1 M lactic acid, pH ~3. A sodium lactate buffered saline solution is prepared by mixing a 0.31 M lactic acid solution with a 0.01 M sodium hydroxide solution to form a 0.05 M lactic acid buffered saline solution. Sucrose is then added to the sodium lactate buffered saline solution. The 0.05 M lactic acid buffered saline solution containing sucrose is diluted with water for injection to produce a 0.04 M sodium lactate buffer containing 17% sucrose, pH ~4.2. The two solutions are then mixed, 8.3 mg / mL Lupicardin in 0.1 M lactic acid, pH ~3, and 0.04 M sodium lactate buffer containing 17% sucrose, pH ~4.2. Dissolution is visually inspected at all steps before continuing, and dissolution is considered complete when visually assessed as such. The pH of the solution is checked and adjusted to a value in the range of about 1 to about 5, more preferably in the range of about 2 to about 4.5, even more preferably in the range of about 3 to about 4.5, and most preferably to a pH of about 4.0 by slowly adding a suitable acid or base. A preferred embodiment of such an acid is lactic acid, in which case the preferred concentration is about 0.1 M. A suitable base is optionally added to control the pH. A preferred embodiment of such a base is sodium hydroxide, preferably in solution, in which case the preferred concentration is about 0.1 M. The volume is finally adjusted by adding a suitable biocompatible fluid, preferably water for injection. The resulting bulk solution preferably contains 0.5 mg of lupicardin in 0.03 M sodium lactate buffer, pH = 4, with 10% (w / v) sucrose. The bulk solution is then filled in vials according to the required dose.

[0111] In an embodiment, the rubikatin to be dissolved is at least partially crystalline. The rubikatin to be dissolved may be in one or more solid forms as described herein. Crystalline rubikatin (including partially crystalline) rubikatin has been found to have a lower solubility than amorphous rubikatin. By way of example, while direct dissolution of 0.5 mg / mL amorphous rubikatin in 0.03 M sodium lactate buffer pH 4 is complete in about 30 minutes, partially crystalline rubikatin only reaches 60%-70% of the target concentration in 2 hours, meaning that it has much slower dissolution kinetics.

[0112] It has been found that lowering the pH accelerates the dissolution kinetics of partially crystallized Lupicadin. Thus, in an embodiment, a concentrated Lupicadin solution is prepared in an organic acid before adding other excipients. In a preferred embodiment, the organic acid has a pH of less than 4, preferably less than 3.5, more preferably less than 3 or about 3. The maximum solubility of Lupicadin in different molar concentrations of the organic acid lactic acid was studied. The solubility is high and increases linearly in the range of 7.2 mg / ml for 0.05M lactic acid to 90.4 mg / ml for 0.5M lactic acid. In a preferred embodiment, Lupicadin is dissolved in an organic acid at a molar concentration of about 0.1M to 0.5M, preferably about 0.2M to 0.4M, more preferably about 0.3M. An exemplary molar concentration is 0.31M organic acid.

[0113] Lupicadin can be first dissolved in a high concentration of organic acid. In a preferred embodiment, the pre-dissolution step is at least 30 minutes, at least 60 minutes, or at least 90 minutes, between 30-90 minutes, between 60-90 minutes, between 60-70 minutes, or about 60 minutes. After dissolution, the pre-dissolved solution can be diluted to form a desired concentration, such as 8.3 mg / ml. The dilution can involve x1, x2, x3 or more dilutions with WFI to obtain a target concentration. In an embodiment, dilution is performed to achieve a desired concentration of an appropriate molar concentration. By way of example, a x3 dilution of an organic acid with 2x initial volume can achieve 8.3 mg / mL in a 0.1M organic acid (e.g., lactic acid).

[0114] During the manufacturing process, the volume capacity of the dissolution step may be limited, and therefore Lupicadin dissolution is advantageously achieved with limited organic acid. Thus, the use of high molar concentrations of organic acid can achieve high Lupicadin concentrations in limited organic acid volumes.

[0115] In an embodiment, a multi-step compounding strategy is used to prepare Lubicardin. Step 1 is the pre-dissolution step described above, for example: partially crystallized Lubicardin is pre-dissolved in 0.31M lactic acid at 25 mg / mL and diluted 3x with WFI to obtain a concentrated solution of 8.3 mg / mL in 0.1M lactic acid. To avoid precipitation of Lubicardin, the remaining excipients should have an acidic pH when added to the compounded formulation. It has been found that high concentration Lubicardin solutions can be mixed with buffer solutions at a pH of 5.6 or lower, such as between 4 and 5.6 or 4.2 and 5.6, without precipitation of Lubicardin. Thus, in step 2, an organic buffer solution containing a bulking agent (e.g., a disaccharide) can be prepared at a suitable pH. By way of example, this can include preparing a 0.04M sodium lactate buffer containing sucrose at a pH of about 4.2. In step 3, the solutions from step 1 and step 2 are combined to form the final bulk solution. The final bulk solution can be adjusted with WFI to achieve the final target weight. By way of example, in step 3, a concentrated solution of 8.3 mg / mL Lupicardin in 0.1 M lactic acid at pH≈3 is diluted with 0.04 M sodium lactate buffer pH≈4.2 containing sucrose. By way of example, the final bulk solution composition after adjustment to the final weight with WFI can be 0.5 mg / mL Lupicardin in 0.03 M sodium lactate buffer pH=4+10% (w / v) sucrose. Thus, the present invention identifies a compounding strategy for formulating partially crystallized Lupicardin.

[0116] In one embodiment, the lyophilized composition comprises or consists of: 4 mg of Lupicardin, 800 mg of sucrose, 22.1 mg of lactic acid, and 5.1 mg of sodium hydroxide. In some embodiments, the weight ratio in the lyophilized composition is between 0.4% and 0.6% (w / w) of active compound, 96% to 98% (w / w) of sucrose, 2% to 3% (w / w) of lactic acid, and 0.5% to 0.7% (w / w) of sodium hydroxide. In a preferred embodiment, the weight ratio in the lyophilized composition is 0.5% (w / w) of active compound, 96.2% (w / w) of sucrose, 2.7% (w / w) of lactic acid, and 0.6% (w / w) of sodium hydroxide. For 4 mg of Lupicardin, the lyophilized formulation contains about 0.25 mmol of lactate ions. When reconstituted to 8 ml in a vial, the resulting solution is 0.5 mg / ml Lupicadin, 0.03 M sodium lactate buffer, 10% w / v sucrose, pH about 4.0 (pH range 3.5 to 4.5, preferably 3.8 to 4.5).

[0117] The lyophilized material is typically present in vials containing a specified amount of Lubicardin. Preferably, the lyophilized composition of Lubicardin is provided in a 30 mL vial. The specified amount of Lubicardin in the lyophilized composition may be between 0.2 and 5 mg, or about 1 mg, about 2 mg, about 3 mg, or about 4 mg. The specified amount of Lubicardin in the lyophilized composition is preferably 4 mg. In a lyophilized embodiment, the composition contains between 0.4% and 0.6% Lubicardin by weight, preferably 0.5%.

[0118] It is necessary to ensure that Lupicardin is sterile and aseptically filled into vials. This is critical for parenteral drugs. According to embodiments of the present invention, terminal sterilization by heat or gamma radiation is not used to avoid degradation of Lupicardin. Instead, according to embodiments of the present invention, the bulk Lupicardin solution is sterile filtered before sterile vial filling. In embodiments, the filter can be a filter such as PVDF or PES. In embodiments, the filter can be a 0.2 μm filter.

[0119] Storage of Lupicardin Drug Preparations

[0120] Embodiments of the present invention also provide a method for storing a lyophilized Lubicardin composition. It is necessary to ensure that Lubicardin is stable for at least 24 months. The Lubicardin lyophilized formulation is storage stable such that after extended storage at 5°C ± 3°C, Lubicardin retains its therapeutic effectiveness and exhibits minimal chemical degradation (e.g., degradation is minimized and within acceptable tolerances; for example, the impurity and degradation product distribution of Lubicardin, the amount of each impurity and degradation product, and the Lubicardin content are substantially the same before and after extended storage as determined by HPLC analysis).

[0121] In one aspect, when the lyophilized lupicadin compositions of the present disclosure are stored for an extended period of time (e.g., at least 24 months), the compositions minimize the amount of lupicadin degradation products ("impurity D") resulting from the deacetylation of lupicadin (having a relative retention time of 0.87 to 0.88 as determined by commercial HPLC). In some embodiments, after extended storage at 5°C ± 3°C, the amount of impurity D present is less than 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, or 0.8% wt / wt of the total weight of lupicadin in the formulation. Impurities B, D, and G have the following structures:

[0122]

[0123] In a preferred embodiment, the method of storing a lyophilized Lubicartin composition comprises storing a lyophilized composition comprising 4 mg Lubicartin; a lactate buffer; and a disaccharide at a temperature of 5°C ± 3°C for at least 24 months, wherein the lyophilized composition is formulated such that reconstitution with 8 mL of water will produce a solution having a pH of 3.5 to 4.5 and a concentration of 0.5 mg / ml Lubicartin, and wherein after at least 24 months of storage, the amount of impurity D present in the composition does not exceed 0.8% wt. / wt. of the total weight of Lubicartin. In some embodiments, the lyophilized Lubicartin composition is stored at a temperature of 5°C ± 3°C for 24 months, 30 months, 36 months, 42 months, 48 ​​months, or 60 months, wherein after 24 months, 30 months, 36 months, 42 months, 48 ​​months, or 60 months of storage, the amount of Lubicartin degradation product impurity D present in the composition does not exceed 0.8% wt. / wt. of the total weight of Lubicartin. In some embodiments, the amount of impurity D present in the composition after storage for 60 months at about 5°C ± 3°C does not exceed 0.8% wt. / wt, or less than 0.7% wt. / wt., less than 0.6% wt. / wt., less than 0.5% wt. / wt., or less than 0.4% wt. / wt. of the total weight of Lupicardin. In one embodiment, the amount of impurity D, a degradation product of Lupicardin, present in the composition does not exceed 0.8% wt. / wt. of the total weight of Lupicardin after storage for at least 36 months. In some embodiments, the total % (by % area) of impurities and degradation products does not exceed 0.6%, 0.7%, 0.8%, 0.9% or 1.0% (by % area) after storage for 24 months, 30 months or 36 months at about 5°C ± 3°C. In some embodiments, the initial amount of impurity D present in the composition (i.e., one day of lyophilization) is less than 0.4% wt. / wt. of the total weight of Lupicardin. In some embodiments, the initial amount of impurity D present in the composition is at least 0.05% wt. / wt. or at least 0.1% wt. / wt. of the total weight of Lubicardin. In some embodiments, the initial amount of impurity D present in the composition is no more than 0.8% wt. / wt., no more than 0.5% wt. / wt., or no more than 0.1% wt. / wt. of the total weight of Lubicardin. In some embodiments, after storage at about 5°C ± 3°C for 24 months, 30 months, 36 months, 48 ​​months, or 60 months, the stable lyophilized Lubicardin formulation shows negligible degradation of the Lubicardin assay content compared to the bulk solution from which the formulation is prepared, such as a decrease in the amount of Lubicardin within 1.0%, 0.5%, or 0.2% of the total amount of Lubicardin compared to the amount of Lubicardin.

[0124] Thus, a stable lyophilized Lubicardin formulation is provided, comprising a buffer derived from an organic acid (e.g., an organic carboxylic acid buffer, such as a succinate, citrate, acetate or lactate buffer) at a molar ratio of buffer to Lubicardin of about 48 (including a molar ratio of 52 to 46, 54 to 44, 50 to 48, 52 to 58, or a molar ratio of 51 to 48), and sucrose as a bulking agent, the formulation having a pH of about 4.0, including pH 3.5-4.5 or pH 5.0 when reconstituted in 8 mL of water. 3.8-4.1, which contains no more than 0.8% wt / wt of impurity D, or less than 0.7% wt. / wt., less than 0.6% wt. / wt., less than 0.5% wt. / wt., or less than 0.4% wt. / wt, based on the total weight of Lubicardin, and preferably, impurity D does not increase to more than 0.8% wt / wt of the total weight of Lubicardin after storage at 5°C±3°C for 12 months, 24 months, 30 months, 36 months, 48 ​​months, or 60 months; or after storage at 25°C / 60% RH for 3 months, 6 months, 9 months, 12 months, or 18 months; or after storage at 40°C / 60% RH for 1 month, 3 months, 6 months, or 12 months. In these embodiments, Lubicardin is 95% to 105% or 97% to 103% of the amount of Lubicardin measured by the assay on day 1 or 4 mg Lubicardin.

[0125] Also provided is a method for reducing the degradation of rubicatin in a lyophilized formulation by incorporating a buffer derived from an organic acid, preferably a lactate or succinate buffer, into a lyophilized formulation having rubicatin, such that impurity D in the formulation does not exceed 0.5% wt / wt, 0.6% wt / wt, 0.7% wt / wt or 0.8% wt / wt of the total weight of rubicatin after storage at 5°C±3°C for 12 months, 24 months, 30 months, 36 months, 48 ​​months or 60 months; or after storage at 25°C / 60% RH for 3 months, 6 months, 9 months, 12 months or 18 months; or after storage at 40°C / 60% RH for 1 month, 3 months, 6 months or 12 months, particularly when the amount of rubicatin is 4 mg rubicatin or 95% to 105% or 97% to 103% of the amount of rubicatin measured by the assay on day 1.

[0126] Other impurities or degradation products that may be minimized in the storage of the stable lyophilized lupicardin formulation may be degradation products having the following relative retention times on the commercial HPLC method: rrt 0.68, rrt 0.80, rrt 1.11 (impurity G), and 1.12.

[0127] In other embodiments, the total residual water content of the lyophilized Lupicadin formulation does not exceed 3% (w / w), preferably does not exceed 1.5% (w / w), preferably does not exceed 1% (w / w), preferably between 0.5-0.7% (w / w).

[0128] Embodiments of the present invention also provide a pharmaceutical product comprising a vial containing a lyophilized Lupicadin composition. In a preferred embodiment, the pharmaceutical product comprises a vial containing a lyophilized composition consisting of: 4 mg Lupicadin; 22.1 mg lactic acid; 5.1 mg sodium hydroxide (or containing about 0.25 mmol lactate); and 800 mg sucrose; and a label attached to the vial, which includes an expiration date of at least 48 months from the date of production. In some embodiments, the label attached to the vial includes an expiration date of at least 24 months, at least 30 months, at least 36 months, at least 42 months, or at least 48 months from the date of production. In some embodiments, the vial has a size of 30 mL to 50 mL, such as 30 mL, 35 mL, 40 mL, 45 mL, or 50 mL. In a preferred embodiment, the vial is a 30 mL vial. The 30 mL vial size is optimized to overcome the limitations of larger vial sizes, which result in reduced production capacity due to reduced freeze dryer capacity, and also result in sufficient extractable volume due to size. The 30 mL vial size overcomes both of these limitations.

[0129] Rubicartin solid form and its use

[0130] In an embodiment according to the invention, the pre-lyophilized Rubikatin contains at least some crystalline material. The pre-lyophilized Rubikatin may be partially crystalline. The use of partially crystalline pre-lyophilized Rubikatin has advantages, including better control of impurities and / or degradation products.

[0131] The present invention has identified a novel solid-state form of Lupicardin which is easier to handle under typical pharmaceutical processing conditions than the known amorphous form (hereinafter referred to as Form A). The amorphous Form A can be obtained by the process described in WO 03 / 014127. Form A becomes electrostatically charged during its handling, which leads to production problems. Therefore, it is desirable to obtain a form of Lupicardin which is easier to handle under typical pharmaceutical processing conditions.

[0132] In an embodiment according to the present invention, a novel solid state form of rubikatin is provided, hereinafter designated as rubikatin in form B. Form B exhibits advantageous physical properties compared to the known form A. For example, form B exhibits better triboelectric properties than the prior known forms of rubikatin. Triboelectric charging is the process by which certain materials become charged after contact with a different material through friction. In many pharmaceutical operations, uncontrolled static electricity can cause serious production problems. These problems may include product contamination, product loss, cleanliness and safety, and the problems may be exacerbated in nanomolar cytotoxic drugs such as rubikatin. Even in the most stringent clean rooms, static charge attracts particulates from personnel, processes and equipment, so it is important to take appropriate measures to ensure that it is kept to a minimum.

[0133] Compared to known forms of Lubicardin, Form B exhibits a lower average charge density. Compared to known forms of Lubicardin, Form B also exhibits a narrower charge density dispersion. Compared to known forms of Lubicardin, Form B has lower residual solvents. Compared to known forms of Lubicardin, Form B also has a simplified impurity profile. These properties make it particularly suitable for the preparation of drugs. Pre-lyophilized Lubicardin can contain Form B. The amount of Form B can vary and can be considered a crystalline mixture (partially crystalline). In other embodiments, the crystalline mixture can contain other crystalline Lubicardin (e.g., crystalline Lubicardin other than Form B).

[0134] In another embodiment, the present invention relates to a method for preparing Form B of Lubicardin, comprising: a) preparing an acidic aqueous solution containing Lubicardin or a protonated form thereof; and b) alkalizing the resulting acidic aqueous solution with a base or an alkaline buffer to precipitate Form B of Lubicardin. Form B of Lubicardin can then be converted into a different physical form, preferably an amorphous form. Form B can be used in the manufacturing process of preparing a lyophilized bulk product.

[0135] In another embodiment, the present invention relates to a pharmaceutical composition comprising lupicardin Form B and a pharmaceutically acceptable carrier. Such a composition may be a pre-lyophilized composition.

[0136] In a further embodiment, the invention relates to a pharmaceutical composition comprising Lubicardin manufactured using Lubicardin Form B and a pharmaceutically acceptable carrier. The pharmaceutical composition may no longer contain any Lubicardin Form B, but the composition manufacturing process uses at least some of the Form B in one or more steps. In a further embodiment, the invention relates to Lubicardin Form B for use in the manufacture of a pharmaceutical composition comprising Lubicardin. In yet a further embodiment, the invention relates to the use of Lubicardin Form B in the manufacture of a pharmaceutical composition comprising Lubicardin. In yet a further embodiment, the invention relates to Lubicardin Form B for use as a medicament. Again, the Form B may no longer be present in the final composition, but may be used in the manufacturing process.

[0137] In a further embodiment, the present invention relates to a composition for use as a medicament comprising Lubicardin Form B and a pharmaceutically acceptable carrier. In a further embodiment, the present invention relates to Lubicardin Form B for use as a medicament for the treatment of cancer. In a further embodiment, the present invention relates to a composition for use as a medicament for the treatment of cancer comprising Lubicardin Form B and a pharmaceutically acceptable carrier.

[0138] In a further embodiment, the present invention relates to a process for the manufacture of a pharmaceutical composition comprising lubicartin using lubicartin Form B, preferably as a starting material.

[0139] In another embodiment, the present invention also relates to the use of rubikatin in form B, or the use of a pharmaceutical composition comprising rubikatin in form B and a pharmaceutically acceptable carrier in the treatment of cancer. In another embodiment, the present invention also relates to the use of rubikatin in form B, or the use of a pharmaceutical composition comprising rubikatin in form B and a pharmaceutically acceptable carrier in the preparation of a medicament for the treatment of cancer. Other embodiments of the present invention are methods of treatment, and rubikatin in form B for use in these methods. Therefore, the present invention also provides a method of treating any mammal, especially a human, affected by cancer, comprising administering to the affected individual a therapeutically effective amount of rubikatin in form B or a pharmaceutical composition comprising rubikatin in form B and a pharmaceutically acceptable carrier; or a pharmaceutical composition made by a method utilizing rubikatin in form B.

[0140] The present invention also provides a method for treating any mammal, especially a human, affected by cancer, comprising administering to the affected individual a therapeutically effective amount of rubicatin produced by rubicatin form B. The present invention also provides a method for treating any mammal, especially a human, affected by cancer, comprising administering to the affected individual a therapeutically effective amount of a pharmaceutical composition comprising rubicatin produced by rubicatin form B and a pharmaceutically acceptable carrier.

[0141] In another embodiment, the present invention relates to Lubicardin having no more than 1%, 0.5%, 0.1% or substantially no detectable residual solvent. In another embodiment, the present invention relates to Lubicardin having a water content greater than 1.6% w / w or 1.7-5% w / w. In another embodiment, the present invention relates to Lubicardin having a water content of no more than 5%, 4% or 3% w / w.

[0142] In the case of Lupicadin in solid form, the alkanes in the present invention can be branched or unbranched and have from about 5 to about 10 carbon atoms. A more preferred class of alkanes has 5 to 9 carbon atoms. Even more preferred are alkanes having 5, 6 or 7 carbon atoms. Particularly preferred alkanes of the present invention are n-pentane, n-hexane, n-heptane, cyclohexane and methylcyclohexane. As used herein, unless otherwise indicated, the term alkane refers to both cyclic and non-cyclic alkanes.

[0143] In the case of lupicardin in solid form, pharmaceutically acceptable solvents are those classified under Class 2 and Class 3 of the guideline "Impurities: Guideline for residual solvents Q3C (R6)" of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.

[0144] In one embodiment, the present invention relates to the B form of rubikatin.

[0145] Form B of Rubikatin may be characterized by exhibiting an X-ray powder diffraction pattern comprising four or more characteristic peaks at 2-θ angles selected from the group consisting of 6.2±0.2°, 7.6±0.2°, 9.0±0.2°, 10.9±0.2°, 14.9±0.2°, and 15.3±0.2°. Alternatively, Form B may be characterized by exhibiting an X-ray powder diffraction pattern comprising five or more of the characteristic peaks. Alternatively, Form B may be characterized by exhibiting an X-ray powder diffraction pattern comprising all six of the characteristic peaks.

[0146] Specifically, Rubikatin Form B may be characterized by an X-ray powder diffraction pattern comprising peaks and intensities as shown in the following table:

[0147] Angle [2-θ] Relative strength [%] 6.2±0.2° 79±6 7.6±0.2° 100±3 9.0±0.2° 63±3 10.9±0.2° 100±3 14.9±0.2° 76±3 15.3±0.2° 75±3

[0148] In a preferred embodiment, additional peaks may be present at 2-θ angles of 12.4±0.2°, 19.2±0.2° and 26.5±0.2°. Specifically, Form B of Lupicadin may be characterized by an X-ray powder diffraction pattern comprising characteristic peaks and intensities as shown in the following table:

[0149] Angle [2-θ] Relative strength [%] Angle [2-θ] Relative strength [%] 6.2±0.2° 79±6 14.9±0.2° 76±3 7.6±0.2° 100±3 15.3±0.2° 75±3 9.0±0.2° 63±3 19.2±0.2° 34±3 10.9±0.2° 100±3 26.5±0.2° 33±3 12.4±0.2° 40±3

[0150] In a more preferred embodiment, additional peaks may be present at 2-θ angles of 18.4±0.2°, 20.7±0.2° and 24.9±0.2°. Specifically, Form B of Lupicadin may be characterized by an X-ray powder diffraction pattern comprising characteristic peaks and intensities as shown in the following table:

[0151]

[0152]

[0153] In a most preferred embodiment, the present invention relates to the B form of rubikatin, which exhibits Figure 2a An X-ray powder diffraction pattern substantially the same as any of the X-ray powder diffraction patterns shown in or 2b.

[0154] Additionally, Form B of Rubikatin may be characterized by exhibiting an IR spectrum including peaks at wavelengths of 2928, 1755, 1626, 1485, 1456, 1370, 1197, 1150, 1088, 1003, 959, 916, and 587. An illustrative IR spectrum is shown at Figure 7b Displayed in.

[0155] Additionally, Rubikatin Form B may be characterized by TG-FTIR degradation above 150°C. Alternatively or additionally, Rubikatin Form B may be characterized by a TG-FTIR mass change relative to 150°C due to water loss. The loss due to water may be less than about 5%, less than about 4%, or less than about 3%. Alternatively or additionally, Rubikatin Form B may be characterized by a TG-FTIR indicating a water loss of preferably about 2-3% by weight water, more preferably 2.6% by weight water. An illustrative TG-FTIR mass change relative to 150°C due to water loss may be less than about 5%, less than about 4%, or less than about 3%. Alternatively or additionally, Rubikatin Form B may be characterized by a TG-FTIR mass change relative to 150°C due to water loss. The loss due to water may be less than about 5%, less than about 4%, or less than about 3%. Figure 3 Displayed in.

[0156] Additionally, Form B of Lubicardin can be characterized by a DSC in which degradation begins above 130°C. An illustrative DSC thermogram is Figure 4 Displayed in.

[0157] In one embodiment, Form B of Rubikatin has an average charge density of no more than about 30 nC / g, no more than about 20 nC / g, no more than about 10 nC / g, no more than about 6 nC / g, no more than about 5 nC / g, about 5±2 nC / g, about 4±2 nC / g, about 4-5 nC / g, about 5 nC / g, or about 4 nC / g. In one embodiment, Form B of Rubikatin has a charge density dispersion of less than 4.8 nC / g, between about 0.7 nC / g and less than 4.8 nC / g, or 2.4±2 nC / g. In another embodiment, Form B of Rubikatin has a water content greater than 1.6% w / w or 1.7-5% w / w. In one embodiment, Form B of Rubikatin has no more than 1%, 0.5%, 0.1%, or substantially no detectable residual solvent.

[0158] The present invention encompasses lubicatin comprising at least a detectable amount of Form B, up to 1% w / w Form B, up to 5% w / w Form B, up to 10% w / w Form B, up to 20% w / w Form B, up to 30% w / w Form B, up to 40% w / w Form B, up to 50% w / w Form B, up to 60% w / w Form B, up to 70% w / w Form B, up to 80% w / w Form B, up to 90% w / w Form B, up to 95% w / w Form B, up to 98% w / w Form B, or substantially pure Form B. In one embodiment, partially crystallized Lubicardin as described herein may contain at least a detectable amount of Form B, up to 1% w / w Form B, up to 5% w / w Form B, up to 10% w / w Form B, up to 20% w / w Form B, up to 30% w / w Form B, up to 40% w / w Form B, up to 50% w / w Form B, up to 60% w / w Form B, up to 70% w / w Form B, up to 80% w / w Form B, up to 90% w / w Form B, up to 95% w / w Form B, up to 98% w / w Form B, or substantially pure Form B. W / w is intended to mean the amount of Lubicardin that is in the Form B state. Thus, by way of example only, 50% w / w means that the Lubicardin API contains 50% by weight Form B and 50% by weight of another form, such as the amorphous A Form.

[0159] In one embodiment, the present invention relates to a method for preparing Form B of Lubicardin comprising:

[0160] a) preparing an acidic aqueous solution comprising lupicardin or a protonated form thereof; and

[0161] b) alkalizing the resulting acidic aqueous solution with a base or a buffer to precipitate the B-form of rubikatin.

[0162] In step a), a solution of rubikatin in acidic water is provided. Examples of methods for preparing such a solution include, but are not limited to: dissolving rubikatin in any solid form in acidic water; or extracting rubikatin from a solution containing rubikatin in an organic phase immiscible with water into acidic water. In a preferred embodiment, an acidic aqueous solution of rubikatin is obtained by dissolving rubikatin in acidic water.

[0163] Any form of Rubikatin, such as amorphous Rubikatin, can be used to form crystalline Rubikatin. The concentration of Rubikatin in the acidic water can range from about 10 to about 50 g / L. A concentration of about 15 to about 40 g / L is particularly preferred, and a concentration of about 20 to about 30 g / L is more preferred. The most preferred concentration of Rubikatin in the acidic water is about 26 g / L.

[0164] The preferred pH of the acidic water can range from about 1 to about 4, more preferably from about 1 to about 3, even more preferably from about 1 to about 2, and most preferably about 1. Acidic conditions can be provided by an acid or by a buffer. Suitable pharmaceutically acceptable acids include hydrochloric acid, phosphoric acid, sulfuric acid, carboxylic acids such as aliphatic and aromatic carboxylic acids. More preferred acids include hydrochloric acid, phosphoric acid, sulfuric acid, trifluoroacetic acid, nitrobenzoic acid and citric acid. Suitable acidic buffers provide a pH between about 1 and about 4. Examples of suitable acidic buffers include, but are not limited to, phosphate buffers, citrate buffers, lactate buffers, ascorbic acid buffers, tartaric acid / citrate buffers, bicarbonate / hydrochloric acid buffers, acetate buffers, succinate buffers and glycine / hydrochloric acid buffers. More preferably, acidic conditions are provided by an acid, and most preferably the acid is hydrochloric acid. The preferred pH of a solution of rubicin in acidic water can range from about 1 to about 4, from about 1 to about 3, or from about 2 to about 3.

[0165] In step b), the resulting acidic aqueous solution is treated with an excess of a base or a buffer to alkalize it and precipitate the B-form of rubikatin. Alkalization can be performed with a base or with a buffer. The preferred pH range of the resulting acidic solution can be from about 8 to about 11, most preferably from about 9 to about 11. Suitable pharmaceutically acceptable bases include carbonates, hydroxides, bicarbonates and ammonium salts. Particularly preferred bases are sodium carbonate, potassium carbonate, NH4OH, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium bicarbonate and potassium bicarbonate. Suitable acidic buffers provide a pH between about 8 and about 11. Examples of suitable alkaline buffers include ammonium and phosphate buffers, such as KH2PO4 buffer, Na2HPO4 / citric acid and NH4Cl-NH4OH. In a preferred embodiment, the alkalization is performed with a buffer, and in a most preferred embodiment, the alkalization is performed with an NH4Cl-NH4OH buffer.

[0166] The obtained form of Lupicadin B can be separated by a separation operation such as filtration or centrifugation, preferably by filtration. In addition, after filtration, the separated solid can be subjected to a drying treatment by any known method. The precipitate can be dried preferably under vacuum at a temperature ranging from preferably about 15° C. to 35° C., more preferably from about 20° C. to 30° C., and most preferably at about 25° C. for a time ranging from preferably about 10 to 24 hours, more preferably from about 16 to 20 hours, and most preferably about 18 hours.

[0167] In a preferred embodiment, the acidic aqueous solution obtained after step a) is washed one or more times with a pharmaceutically acceptable water-immiscible polar solvent and one or more times with a pharmaceutically acceptable water-immiscible non-polar solvent, and then treated with an excess of base or buffer in step b).

[0168] Examples of pharmaceutically acceptable water-immiscible polar solvents suitable for this washing include chloroform, 1-butanol, 2-butanol, butyl acetate, ethyl acetate, methyl acetate, 1-pentanol, propyl acetate and dichloromethane. More preferred pharmaceutically acceptable water-immiscible polar solvents for this washing are chloroform, ethyl acetate and dichloromethane, with dichloromethane being most preferred.

[0169] Preferred pharmaceutically acceptable water-immiscible nonpolar solvents suitable for use in this wash include C5-C7 alkanes such as n-heptane, n-hexane, n-pentane, cyclohexane and methylcyclohexane; n-pentane is most preferred.

[0170] In one embodiment, the present invention is directed to a pharmaceutical composition comprising or manufactured from lubicartin Form B and a pharmaceutically acceptable carrier. Lubicartin used in the composition or used in the manufacture of the composition may include lubicartin comprising at least a detectable amount of Form B, up to 1% w / w Form B, up to 5% w / w Form B, up to 10% w / w Form B, up to 20% w / w Form B, up to 30% w / w Form B, up to 40% w / w Form B, up to 50% w / w Form B, up to 60% w / w Form B, up to 70% w / w Form B, up to 80% w / w Form B, up to 90% w / w Form B, up to 95% w / w Form B, up to 98% w / w Form B, or substantially pure Form B.

[0171] In embodiments, partially crystallized rubikatin as disclosed herein may comprise at least a detectable amount of Form B, up to 1% w / w Form B, up to 5% w / w Form B, up to 10% w / w Form B, up to 20% w / w Form B, up to 30% w / w Form B, up to 40% w / w Form B, up to 50% w / w Form B, up to 60% w / w Form B, up to 70% w / w Form B, up to 80% w / w Form B, up to 90% w / w Form B, up to 95% w / w Form B, up to 98% w / w Form B, or substantially pure Form B. In alternative embodiments, other non-Form B crystalline rubikatin may form partially crystallized rubikatin in the same w / w amount.

[0172] Partially crystallized Lubicardin as disclosed herein may be used to form a pharmaceutical composition according to the present invention. Thus, in an embodiment, partially crystallized Lubicardin is used to make a bulk Lubicardin solution, which is then lyophilized to form a lyophilized Lubicardin formulation. Partially crystallized Lubicardin may comprise Form B as disclosed herein.

[0173] Although partially crystalline Lubicardin may not be present in the final dosage form (due to the dissolution and subsequent lyophilization steps), it may still affect the properties of the final dosage form. By way of example, the use of partially crystalline Lubicardin may reduce and / or simplify the total impurities including degradation products. A characteristic impurity profile may demonstrate the use of partially crystalline Lubicardin during the manufacturing process. According to one embodiment, the total degradation products in the final lyophilized product may not exceed (NMT) 1.9%, 1.8%, 1.7%, 1.6%, 1.5%, 1.4% or 1.3%. In a preferred embodiment, the total degradation products do not exceed 1.3%. According to another embodiment, the final lyophilized product contains no more than 0.8% of impurity D. According to another embodiment, the final lyophilized product contains no more than 0.3% of any unspecified impurity.

[0174] The use of partially crystalline Lubicardin may also advantageously control residual solvents. In one embodiment, Lubicardin contains no more than 0.2% residual solvent, preferably no more than 0.1% residual solvent, preferably substantially no residual solvent is detected.

[0175] In one embodiment, the partially crystallized rubikatin used to make the compositions disclosed herein may have an assay (%) in the range of 94.0%-102.0% and an impurity level below 1.0%. The specified impurities and their limits may be impurity B (≤0.20%), impurity D (≤0.50%), and / or impurity G (≤0.50%). Any other individual non-specified impurities may have a limit of ≤0.20%.

[0176] Uses of Lupicadine Pharmaceutical Preparations

[0177] The present invention identifies various methods of treatment using lubicartin alone or in combination with other agents. When referring to methods of treatment, the present invention also encompasses lubicartin and / or the additional agent in the manufacture of a medicament for treating cancer, as well as lubicartin and / or the additional agent for use in treating cancer. The following methods may utilize the compositions of the present invention as defined herein.

[0178] In some embodiments, the method of treating SCLC in a patient in need thereof comprises: (1) administering via intravenous infusion of Lupicardin infusion solution at 3.2 mg / m 2 The dose (or 2.6 mg / m 2 or 2.0 mg / m 2 Lubicartin is administered to a patient at a reduced dose of 100 mg / mL (about 200 mg / mL) wherein the Lubicartin infusion solution administered to the patient is prepared from a lyophilized composition comprising 4 mg Lubicartin, a lactate buffer and a disaccharide, reconstituted to form a reconstituted solution having a pH of 3.8 to 4.5. In a preferred embodiment, the disaccharide is sucrose. In a preferred embodiment, the lyophilized composition comprises 4 mg Lubicartin, a lactate buffer (preferably produced from a solution comprising 22.1 mg lactic acid and 5.1 mg sodium hydroxide, comprising about 0.25 mmol lactate) and a disaccharide (preferably sucrose, in particular 800 mg sucrose), wherein reconstitution of the lyophilized composition in about 8 mL of aqueous solution provides a Lubicartin solution of 0.5 mg / mL Lubicartin having a pH of about 3.8 to about 4.5. In some embodiments, the Lubicartin infusion solution is prepared by diluting the reconstituted solution with an isotonic solution, wherein the isotonic solution is a 0.9% sodium chloride solution or a 5% glucose solution. In some embodiments, the reconstituted solution is diluted with at least 100 mL or at least 250 mL of an isotonic solution to prepare a lupicadin infusion solution. In some embodiments, after reconstitution or dilution, the solution can be stored at room temperature (ie, about 23°C) / light or under refrigeration (5°C ± 3°C) for up to 24 hours after reconstitution, including the infusion time. In specific embodiments, after storing the reconstituted or diluted solution at room temperature (ie, about 23°C) / light or under refrigeration (5°C ± 3°C) for 24, 48, or 72 hours, the % wt / wt of impurity D relative to lupicadin increases by no more than 0.1%, 0.2%, or 0.3% wt / wt.

[0179] Some embodiments provide a method of administering a pharmaceutical composition to a patient in need thereof, e.g., a patient with SCLC that is refractory to first-line therapy, comprising (1) reconstituting a lyophilized pharmaceutical composition in a vial after the composition has been stored for 30 to 36 or 48 months, wherein the lyophilized pharmaceutical composition is prepared by lyophilizing a stock solution comprising lupicardin, lactic acid, sodium hydroxide, and sucrose at a ratio of 4 mg lupicardin: 22.1 mg lactic acid: 5.1 mg sodium hydroxide: 800 mg sucrose: 8 mL water; and (2) administering the reconstituted solution to the patient, wherein the reconstituted solution can be diluted with an isotonic solution, such as a 0.9% sodium chloride solution or a 5% glucose solution, from a volume of 100 ml to 250 ml for administration to the patient as an infusion solution.

[0180] In another aspect, there is provided a use of rubicatin in the manufacture of a medicament for treating small cell lung cancer (SCLC), wherein the treatment comprises:

[0181] (1) administering a prophylactic dose of a corticosteroid and a serotonin antagonist effective to reduce nausea associated with administration of lupicardin to said patient on and before the day of administration of lupicardin to said patient; and

[0182] (2) Administer 2 to 3.2 mg / m 2 Dose of Rubicartin.

[0183] In another aspect, there is provided a use of a corticosteroid in the manufacture of a medicament for treating small cell lung cancer (SCLC), wherein the treatment comprises:

[0184] (1) administering a prophylactic dose of said corticosteroid and serotonin antagonist effective to reduce nausea associated with administration of lupicardin to said patient on and before the day of administration of lupicardin to said patient; and

[0185] (2) Administer 2 to 3.2 mg / m 2 Dose of Rubicartin.

[0186] In another aspect, there is provided a use of a serotonin antagonist in the manufacture of a medicament for treating small cell lung cancer (SCLC), wherein the treatment comprises:

[0187] (1) administering a prophylactic dose of a corticosteroid and said serotonin antagonist effective to reduce nausea associated with administration of lupicardin to said patient on and before the day of administration of lupicardin to said patient; and

[0188] (2) Administer 2 to 3.2 mg / m 2 Dose of Rubicartin.

[0189] In another aspect, there is provided a use of rubicatin in the manufacture of a medicament for treating small cell lung cancer (SCLC), wherein the method comprises:

[0190] (1) Administer 3.2 mg / m 2 first dose of Lubicardin; and

[0191] (2) Identify adverse reactions in the patient, wherein the adverse reactions are selected from the group consisting of: ≥ Grade 3 (severe) non-hematological toxicity, Grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm 3 ), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm 3 ) with bleeding requiring transfusion, grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ) or any grade of neutropenia (neutrophil count <LLN);

[0192] (3) After the adverse reaction is identified and the patient's neutrophil count is greater than 1500 cells / mm 3 ; Platelet count greater than about 100,000 mm 3 ; and after the hemoglobin level is greater than about 9 g / dL:

[0193] (i) If the identified adverse reaction consists of Grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ), then administer to the patient a dose of G-CSF and a dose of lupicardin equivalent to the first dose; or

[0194] (ii) if the identified adverse reaction is more than Grade 4 neutropenia, administer to the patient a dose of Lupicardin that is reduced compared to the first dose,

[0195] The two doses of Lubicartin were administered at least 21 days apart.

[0196] In another aspect, there is provided use of G-CSF in the manufacture of a medicament for treating small cell lung cancer (SCLC), wherein the method comprises:

[0197] (1) Administer 3.2 mg / m 2 first dose of Lubicardin; and

[0198] (2) Identify adverse reactions in the patient, wherein the adverse reactions are selected from the group consisting of: ≥ Grade 3 (severe) non-hematological toxicity, Grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm 3 ), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm 3 ) with bleeding requiring transfusion, grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ) or any grade of neutropenia (neutrophil count <LLN);

[0199] (3) After the adverse reaction is identified and the patient's neutrophil count is greater than 1500 cells / mm 3 ; Platelet count greater than about 100,000 mm 3 ; and after the hemoglobin level is greater than about 9 g / dL:

[0200] (i) if the identified adverse reaction consists of Grade 4 neutropenia (neutrophil count less than 500 cells / mm3), administer to the patient one dose of G-CSF and one dose of rubicatin equivalent to the first dose; or

[0201] (ii) if the identified adverse reaction is more than Grade 4 neutropenia, administer to the patient a dose of Lupicardin that is reduced compared to the first dose,

[0202] The two doses of Lubicartin were administered at least 21 days apart.

[0203] In another aspect, there is provided a use of rubicatin in the manufacture of a medicament for treating small cell lung cancer (SCLC), wherein the method comprises:

[0204] Lupicardin infusion solution was administered by intravenous infusion at 3.2 mg / m 2 Lubicartin is administered to a patient at a dose of , wherein the Lubicartin infusion solution administered to the patient is prepared from a lyophilized composition comprising 4 mg of Lubicartin, a buffer derived from an organic carboxylic acid, and a disaccharide, which is reconstituted to form a reconstituted solution with a pH of 3.5 to 4.5.

[0205] In another aspect, there is provided a use of rubicatin in the manufacture of a medicament for treating endometrial cancer, SCLC, soft tissue sarcoma, glioblastoma, pancreatic cancer, mesothelioma, colorectal cancer, or epithelial ovarian cancer, wherein the treatment comprises:

[0206] administering to the patient lubicatin and a topoisomerase inhibitor selected from SN-38 and irinotecan on day one of the treatment cycle;

[0207] Lubicardin is administered at 1 to 2.5 mg / m 2 The dosage is administered, and

[0208] The topoisomerase inhibitor was given at a dose equivalent to 50 to 75 mg irinotecan / m 2 dosage administration.

[0209] In another aspect, provided is a use of a topoisomerase inhibitor selected from SN-38 and irinotecan in the manufacture of a medicament for treating endometrial cancer, SCLC, soft tissue sarcoma, glioblastoma, pancreatic cancer, mesothelioma, colorectal cancer, or epithelial ovarian cancer, wherein the treatment comprises:

[0210] administering lupicardin and the topoisomerase inhibitor selected from SN-38 and irinotecan to the patient on day one of the treatment cycle;

[0211] Lubicardin is administered at 1 to 2.5 mg / m 2 The dosage is administered, and

[0212] The topoisomerase inhibitor was given at a dose equivalent to 50 to 75 mg irinotecan / m 2 dosage administration.

[0213] In another aspect, there is provided a use of rubikatin in the manufacture of a medicament for treating cancer, the treatment comprising:

[0214] reconstitute the lyophilized pharmaceutical composition in a vial after storage of the composition for 30 to 60 months,

[0215] The lyophilized pharmaceutical composition is prepared by lyophilizing a stock solution containing 4 mg of lupicardin, a buffer derived from an organic carboxylic acid and sucrose,

[0216] wherein the composition comprises lupicardin and a disaccharide in a ratio of 1 mol lupicardin: 455 to 465 mol sucrose,

[0217] wherein the lyophilized composition is formulated such that reconstitution with 8 mL of water will produce a solution having a pH of 3.5 to 4.5; and

[0218] The reconstituted solution is administered to the patient.

[0219] In another aspect, there is provided a use of rubicatin in the manufacture of a medicament for treating small cell lung cancer (SCLC), wherein the treatment comprises:

[0220] The patient was administered 2 to 3.2 mg / m by intravenous infusion. 2 dose of Rubicartin;

[0221] wherein an immunotherapeutic antibody for treating SCLC is administered to the patient prior to starting a treatment cycle, and

[0222] wherein the duration of response is at least 2 months, 3 months, 4 months, 5 months or 6 months, or wherein the overall response rate is at least 40%.

[0223] In another aspect, there is provided a use of rubicatin in the manufacture of a medicament for treating small cell lung cancer (SCLC), wherein the treatment comprises:

[0224] Patients are administered 2 to 3.2 mg / m2 of rubikatin by intravenous infusion every 3 weeks, wherein the rubikatin is provided as a lyophilized formulation comprising rubikatin, a buffer derived from lactic acid, and sucrose, wherein the ratio of rubikatin: lactic acid: sucrose is between 1 mol:46 mol:455 mol and 1 mol:50 mol:465 mol, wherein the formulation is stable at 5°C ± 3°C for at least 24 months, or at least 36 months, or at least 48 months, or at least 60 months, such that rubikatin degradation products from deacetylation do not exceed 0.8% wt. / wt. of the total weight of rubikatin.

[0225] In another aspect, there is provided a use of rubicatin in the manufacture of a medicament for treating small cell lung cancer (SCLC), wherein the treatment comprises:

[0226] 1) dissolving a packaged lyophilized composition comprising 4 mg of Lupicardin, a buffer derived from an organic acid, and a disaccharide in about 8 mL of water to provide a Lupicardin solution having a pH of about 3.5 to about 4.1, and

[0227] 2) About 2 to 3.2 mg / m2 by intravenous infusion every 3 weeks to patients whose SCLC has progressed after prior platinum-containing therapy 2 Ruby Cardin, and

[0228] wherein the lyophilized composition comprises less than about 0.3% of impurity D (w / w, based on rubikatin) when the composition is packaged, and wherein after storage at about 5°C for about 24, 36 or 48 months, the composition comprises less than about 0.8% of impurity D (w / w, based on rubikatin).

[0229] In another aspect, rubicatin is provided for use in treating small cell lung cancer (SCLC), wherein the treatment comprises:

[0230] (1) administering a prophylactic dose of a corticosteroid and a serotonin antagonist effective to reduce nausea associated with administration of lupicardin to said patient on and before the day of administration of lupicardin to said patient; and

[0231] (2) Administer 2 to 3.2 mg / m 2 Dose of Rubicartin.

[0232] In another aspect, a corticosteroid for use in treating small cell lung cancer (SCLC) is provided, wherein the treatment comprises:

[0233] (1) administering a prophylactic dose of said corticosteroid and serotonin antagonist effective to reduce nausea associated with administration of lupicardin to said patient on and before the day of administration of lupicardin to said patient; and

[0234] (2) Administer 2 to 3.2 mg / m 2 Dose of Rubicartin.

[0235] In another aspect, a serotonin antagonist is provided for use in treating small cell lung cancer (SCLC), wherein the treatment comprises:

[0236] (1) administering a prophylactic dose of a corticosteroid and said serotonin antagonist effective to reduce nausea associated with administration of lupicardin to said patient on and before the day of administration of lupicardin to said patient; and

[0237] (2) Administer 2 to 3.2 mg / m 2 Dose of Rubicartin.

[0238] In another aspect, rubicatin is provided for use in treating small cell lung cancer (SCLC), wherein the method comprises:

[0239] (1) Administer 3.2 mg / m 2 first dose of Lubicardin; and

[0240] (2) Identify adverse reactions in the patient, wherein the adverse reactions are selected from the group consisting of: ≥ Grade 3 (severe) non-hematological toxicity, Grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm 3 ), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm 3 ) with bleeding requiring transfusion, grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ) or any grade of neutropenia (neutrophil count <LLN);

[0241] (3) After the adverse reaction is identified and the patient's neutrophil count is greater than 1500 cells / mm 3 ; Platelet count greater than about 100,000 mm3 ; and after the hemoglobin level is greater than about 9 g / dL:

[0242] (i) If the identified adverse reaction consists of Grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ), then administer to the patient a dose of G-CSF and a dose of lupicardin equivalent to the first dose; or

[0243] (ii) if the identified adverse reaction is more than Grade 4 neutropenia, administer to the patient a dose of Lupicardin that is reduced compared to the first dose,

[0244] The two doses of Lubicartin were administered at least 21 days apart.

[0245] In another aspect, G-CSF is provided for use in treating small cell lung cancer (SCLC), wherein the method comprises:

[0246] (1) Administer 3.2 mg / m 2 first dose of Lubicardin; and

[0247] (2) Identify adverse reactions in the patient, wherein the adverse reactions are selected from the group consisting of: ≥ Grade 3 (severe) non-hematological toxicity, Grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm 3 ), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm 3 ) with bleeding requiring transfusion, grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ) or any grade of neutropenia (neutrophil count <LLN);

[0248] (3) After the adverse reaction is identified and the patient's neutrophil count is greater than 1500 cells / mm 3 ; Platelet count greater than about 100,000 mm 3 ; and after the hemoglobin level is greater than about 9 g / dL:

[0249] (i) If the identified adverse reaction consists of Grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ), then administer to the patient a dose of G-CSF and a dose of lupicardin equivalent to the first dose; or

[0250] (ii) if the identified adverse reaction is more than Grade 4 neutropenia, administer to the patient a dose of Lupicardin that is reduced compared to the first dose,

[0251] The two doses of Lubicartin were administered at least 21 days apart.

[0252] In another aspect, rubicatin is provided for use in treating small cell lung cancer (SCLC), wherein the method comprises:

[0253] Lupicardin infusion solution was administered by intravenous infusion at 3.2 mg / m 2 Lubicartin is administered to a patient at a dose of , wherein the Lubicartin infusion solution administered to the patient is prepared from a lyophilized composition comprising 4 mg of Lubicartin, a buffer derived from an organic carboxylic acid, and a disaccharide, which is reconstituted to form a reconstituted solution with a pH of 3.5 to 4.5.

[0254] In another aspect, rubicin is provided for use in treating endometrial cancer, SCLC, soft tissue sarcoma, glioblastoma, pancreatic cancer, mesothelioma, colorectal cancer, or epithelial ovarian cancer, wherein the treatment comprises:

[0255] administering to the patient lubicatin and a topoisomerase inhibitor selected from SN-38 and irinotecan on day one of the treatment cycle;

[0256] Lubicardin is administered at 1 to 2.5 mg / m 2 The dosage is administered, and

[0257] The topoisomerase inhibitor was given at a dose equivalent to 50 to 75 mg irinotecan / m 2 dosage administration.

[0258] In another aspect, a topoisomerase inhibitor selected from SN-38 and irinotecan for use in treating endometrial cancer, SCLC, soft tissue sarcoma, glioblastoma, pancreatic cancer, mesothelioma, colorectal cancer, or epithelial ovarian cancer is provided, wherein the treatment comprises:

[0259] administering lupicardin and the topoisomerase inhibitor selected from SN-38 and irinotecan to the patient on day one of the treatment cycle;

[0260] Lubicardin is administered at 1 to 2.5 mg / m 2 The dosage is administered, and

[0261] The topoisomerase inhibitor was given at a dose equivalent to 50 to 75 mg irinotecan / m 2 dosage administration.

[0262] In another aspect, there is provided rubicatin for use in treating cancer, the treatment comprising:

[0263] reconstitute the lyophilized pharmaceutical composition in a vial after storage of the composition for 30 to 60 months,

[0264] The lyophilized pharmaceutical composition is prepared by lyophilizing a stock solution containing 4 mg of lupicardin, a buffer derived from an organic carboxylic acid and sucrose,

[0265] wherein the composition comprises lupicardin and a disaccharide in a ratio of 1 mol lupicardin: 455 to 465 mol sucrose,

[0266] wherein the lyophilized composition is formulated such that reconstitution with 8 mL of water will produce a solution having a pH of 3.5 to 4.5; and

[0267] The reconstituted solution is administered to the patient.

[0268] In another aspect, rubicatin is provided for use in treating small cell lung cancer (SCLC), wherein the treatment comprises:

[0269] The patient was administered 2 to 3.2 mg / m by intravenous infusion. 2 dose of Rubicartin;

[0270] wherein an immunotherapeutic antibody for treating SCLC is administered to the patient prior to starting a treatment cycle, and

[0271] wherein the duration of response is at least 2 months, 3 months, 4 months, 5 months or 6 months, or wherein the overall response rate is at least 40%.

[0272] In another aspect, rubicatin is provided for use in treating small cell lung cancer (SCLC), wherein the treatment comprises:

[0273] Patients are administered 2 to 3.2 mg / m2 of lumikatin by intravenous infusion every 3 weeks, wherein the lumikatin is provided as a lyophilized formulation comprising lumikatin, lactic acid and sucrose, wherein the ratio of lumikatin: lactic acid: sucrose is between 1 mol:46 mol:455 mol and 1 mol:50 mol:465 mol, wherein the formulation is stable at 5°C±3°C for at least 24 months, or at least 36 months, or at least 48 months, or at least 60 months, such that lumikatin degradation products from deacetylation do not exceed 0.8% wt. / wt. of the total weight of lumikatin.

[0274] In another aspect, rubicatin is provided for use in treating small cell lung cancer (SCLC), wherein the treatment comprises:

[0275] 1) dissolving a packaged lyophilized composition comprising 4 mg of Lupicardin, a buffer derived from an organic acid, and a disaccharide in about 8 mL of water to provide a Lupicardin solution having a pH of about 3.5 to about 4.1, and

[0276] 2) About 2 to 3.2 mg / m2 by intravenous infusion every 3 weeks to patients whose SCLC has progressed after prior platinum-containing therapy 2 Ruby Cardin, and

[0277] wherein the lyophilized composition comprises less than about 0.3% of impurity D (w / w, based on rubikatin) when the composition is packaged, and wherein after storage at about 5°C for about 24, 36 or 48 months, the composition comprises less than about 0.8% of impurity D (w / w, based on rubikatin).

[0278] In another aspect, there is provided a use of rubicatin in the manufacture of a medicament for treating a solid tumor, including SCLC, endometrial cancer, soft tissue sarcoma, or glioblastoma, wherein the treatment comprises:

[0279] (1) administering a prophylactic dose of a corticosteroid and a serotonin antagonist effective to reduce nausea associated with administration of lupicardin to said patient on and before the day of administration of lupicardin to said patient; and

[0280] (2) Administer 2 mg / m 2 Lubicatin at a dose of 75 mg / m 2 of irinotecan.

[0281] In another aspect, there is provided a use of a corticosteroid in the manufacture of a medicament for treating a solid tumor, wherein the treatment comprises:

[0282] (1) administering a prophylactic dose of said corticosteroid and serotonin antagonist effective to reduce nausea associated with administration of lupicardin to said patient on and before the day of administration of lupicardin to said patient; and

[0283] (2) Administer 2 mg / m 2 Lubicatin at a dose of 75 mg / m 2 dose of irinotecan.

[0284] In another aspect, there is provided a use of a serotonin antagonist in the manufacture of a medicament for treating a solid tumor, including SCLC, endometrial cancer, soft tissue sarcoma, or glioblastoma, wherein the treatment comprises:

[0285] (1) administering a prophylactic dose of a corticosteroid and said serotonin antagonist effective to reduce nausea associated with administration of lupicardin to said patient on and before the day of administration of lupicardin to said patient; and

[0286] (2) Administer 2 mg / m 2 Lubicatin at a dose of 75 mg / m 2 dose of irinotecan.

[0287] In another aspect, there is provided a use of rubicatin in the manufacture of a medicament for treating a solid tumor, including SCLC, endometrial cancer, soft tissue sarcoma, or glioblastoma, wherein the treatment comprises:

[0288] (1) Administer 2 mg / m 2 Lubicatin at a dose of 75 mg / m 2 dose of irinotecan;

[0289] (2) After 7 days, the patient was given 75 mg / m 2 dose of irinotecan; and

[0290] (3) administering G-CSF to said patient to manage the myelosuppressive effects of said administration.

[0291] In another aspect, there is provided a use of rubicatin in the manufacture of a medicament for treating a solid tumor, including SCLC, endometrial cancer, soft tissue sarcoma or glioblastoma, wherein the method comprises:

[0292] (1) Administer 2 mg / m 2 Lubicatin at a dose of 75 mg / m 2 dose of irinotecan; and

[0293] (2) identifying whether the patient exhibits grade 3 or 4 hematologic toxicity following said administration;

[0294] (3) If the patient does not have grade 3 or 4 hematologic toxicity, administer 75 mg / m by intravenous infusion to the patient 7 days after step 1. 2 dose of irinotecan.

[0295] In another aspect, there is provided a use of rubicatin in the manufacture of a medicament for treating a solid tumor, wherein the method comprises:

[0296] Lupicardin infusion solution was administered by intravenous infusion at a dose of 2.0 mg / m 2 Lupicardin was administered to patients at a dose of 10 mg / m and 75 mg / m was administered to patients by intravenous infusion. 2dose of irinotecan, wherein the rubicatin infusion solution administered to the patient is prepared from a lyophilized composition comprising 4 mg of rubicatin, a buffer derived from an organic carboxylic acid, and a disaccharide, reconstituted to form a reconstituted solution having a pH of 3.5 to 4.5.

[0297] Example

[0298] Example 1: Preparation of Rubikatin in different buffers

[0299] Bulk lupicadin solutions containing 0.5 mg / mL (calculated reconstitution concentration of 0.47 mg / mL based on a final volume of 8.55 mL) were prepared in acetic, citric, lactic, and succinic acid buffer solutions at buffer concentrations ranging from 0.02 to 0.05 M, buffered with sodium hydroxide to pH 3, 4, and 5. Examples of lupicadin formulations with lactic acid buffered to pH = 4 are provided in Table 1 below.

[0300] Table 1: Composition of Lubicatin 4 mg reconstituted solution

[0301]

[0302] Example 2: Solubility of Rubikatin in different buffers

[0303] Bulk solutions of phosphate, acetate, citrate, lactate and succinate buffers were prepared to determine the maximum solubility of Lupicadin. Table 2 shows the maximum solubility of Lupicadin in 0.02M-0.05M or 0.06-0.1M buffer at pH=4. The results show that Lupicadin is poorly soluble in phosphate buffer. The results also show that the molarity of the buffer has no significant effect on the solubility.

[0304] Table 2: Maximum solubility of rubikatin in various buffers at pH 4. Effect of buffer molarity

[0305]

[0306]

[0307] Example 3: Stability of Lupicadine Formulations with Different Organic Carboxylic Acid Buffers at Different pH Values

[0308] Stability and solubility studies were performed to determine the pH at which Lubicardin exhibited good stability. Table 3 shows the solubility of Lubicardin in alternative 0.02M-0.05M buffers at pH 3, pH 4, and pH 5, as well as the impurity and degradation product profiles. The solubility at pH 3 and pH 4 was similar, and the solubility decreased dramatically at pH 5. This decrease in solubility was accompanied by an increase in degradation products as the buffer pH increased.

[0309] Table 3: Solubility and degradation product distribution of rubikatin in different organic carboxylic acid buffers in the pH range of 3 to 5

[0310]

[0311] rrt: relative retention time

[0312] 1 HPLC development method: IANA-072Ed02.

[0313] 2 Major degradation product. Area ≥ 0.10%

[0314] 3 Total % degradation products, calculated as 100% - % area of ​​main Rubikatin peak

[0315] The stability of Lupicadin in different buffers was further evaluated at 25°C / 60% RH at 14 days.While Lupicadin was relatively stable at pH 3 and 4, a significant decrease in assay and purity was observed at pH = 5 (Table 4).

[0316] Table 4: Effect of pH on the solubility and stability of Lupicadin in different 0.02M-0.05M organic carboxylic acid buffers in the pH range of 3 to 5 (25°C / 60% RH, 14 days)

[0317]

[0318] 1 HPLC development method: IANA-072Ed02.

[0319] These results show that organic carboxylic acid buffers with a pH not exceeding pH 4.5 are most suitable for increasing the concentration of rubikatin in solution and maintaining adequate stability. Sodium lactate and sodium citrate buffers were found to be most suitable.

[0320] Example 4: Stability of lyophilized vials formulated in sodium lactate and sodium citrate buffer with pH = 4.0 under stress conditions (50°C)

[0321] To determine which of the two buffers was optimal for Lubicardin, a batch of lyophilized vials containing 1 mg Lubicardin / vial was manufactured at laboratory scale, where Lubicardin was formulated at 0.5 mg / mL in 0.03 M sodium lactate pH=4 and 0.05 M sodium citrate pH=4. pH 4 was chosen because it has greater physiological compatibility compared to pH 3. 10% (w / v) sucrose was included as a bulking agent. The stability of the active ingredient in the lyophilized product under stress conditions of temperature (50°C) was evaluated. Lyophilized vials formulated in 0.05 M potassium dihydrogen phosphate buffer pH=4 were also included in these studies for comparison. The stability results of the lyophilized vials after 1 month at 50°C are shown in Table 5. Due to the large number of degradation products that appeared under these conditions, only those degradation products with an area ≥ 0.20% are reported.

[0322] The three formulations showed comparable characteristics at t = 0. After storage at 50°C for 1 month, quality attributes such as appearance of the lyophilized solid, color and pH and water content of the reconstituted solution did not change.

[0323] The Lupicadin assay was significantly reduced (between 11% and 17%) relative to the initial content of the three compositions, with the % degradation products being the main differences observed. The vials formulated in sodium lactate buffer or potassium dihydrogen phosphate buffer showed very similar behavior, however, sodium citrate buffer promoted greater degradation after storage at 50°C for 1 month. In all cases, the main degradation product was an impurity eluting at rrt 0.49-0.50 (HPLC development method), which was significantly higher in the lyophilized vials formulated in sodium citrate buffer. Other degradation products that appeared in very significant percentages were impurity D (rrt 0.73-0.74) and impurities with rrt 0.25, rrt 0.28 and rrt 1.09-1.10.

[0324] Based on the solubility and stability results, it was concluded that the most suitable dissolution medium for the optimized lupicardin formulation was 0.03 M sodium lactate buffer pH 4.

[0325] Table 5. Stability of freeze-dried vials of Rubikatin containing 10% (w / v) sucrose as bulking agent formulated with 0.05M potassium dihydrogen phosphate buffer pH=4, 0.05M sodium citrate buffer pH=4 or 0.03M sodium lactate buffer pH=4 under stress conditions (1 month, 50°C)

[0326]

[0327]

[0328] 1HPLC development method: IANA-090Ed05

[0329] 2 % total impurities and degradation products, calculated as 100% - % area of ​​main peak of Rubikatin

[0330] 3 Reported impurities and degradation products. Area ≥ 0.20%

[0331] NA: Not applicable

[0332] Example 5: Effect of bulk solution pH on the stability of freeze-dried products

[0333] The stability of 4 mg lyophilized products produced from various 0.03 M sodium lactate buffered rubikatin bulk solutions was studied. The bulk solutions had a concentration of 0.5 mg rubikatin / mL at pH 3.6, pH 4.0, and pH 4.5, using 10% sucrose (w / v) as a bulking agent (8 mL, filled in 30 mL glass vials). The stability of these batches was evaluated at 25°C / 60% RH to determine whether small changes in pH could have a significant effect on the stability of the product.

[0334] The stability results of the lyophilized vials after 6 months at 25°C are shown in Table 6. All batches showed similar behavior. Quality attributes such as appearance of the lyophilisate, appearance of the reconstituted solution, color and pH, water content (%) remained constant. The total degradation products did not undergo significant changes,

[0335] As a conclusion and based on the solubility and stability data, Lupicardin solution and freeze-dried presentation, 0.03 M sodium lactate buffer pH 4.0 was selected as the most suitable dissolution medium for Lupicardin presentation.

[0336] Table 6. Stability of Lupicadin 4 mg vial 30 mL at different pH at 25°C / 60% RH

[0337]

[0338]

[0339] rrt: relative retention time

[0340] 1 HPLC commercial method: MPI-00769 6.0

[26]

[0341] 2 Total impurities and degradation products, calculated as the sum of individual impurities ≥ 0.05 (% w / w)

[0342] 3 Impurities and degradation products. %w / w ≥ 0.20%

[0343] Example 6: Expansion Agent Concentration

[0344] The stability of 4 mg lyophilized products produced from various 0.03 M sodium lactate buffered rubikatin bulk solutions was studied. The bulk solutions had a concentration of 0.5 mg rubikatin / mL at pH 3.6, pH 4.0, and pH 4.5, using 10% sucrose (w / v) as a bulking agent (8 mL, filled in 30 mL glass vials). The stability of these batches was evaluated at 25°C / 60% RH to determine whether small changes in pH could have a significant effect on the stability of the product.

[0345] Once the dissolution medium was selected, different bulking agents were screened at different concentrations: sucrose (5%, 7.5% and 10%), mannitol (5%) and a combination of sucrose and mannitol (5% sucrose + 2.5% mannitol).

[0346] For the purpose, several batches of freeze-dried Lupicardin were manufactured with a strength of 4 mg / vial incorporating different bulking agents at different concentrations. Lupicardin was dissolved at 0.5 mg / mL in 0.03 M sodium lactate buffer pH 4. The batch composition is detailed in Table 7. The batches were characterized and their stability under stress conditions (40°C / 75% RH) was evaluated.

[0347] Table 7. Composition of 4 mg vial 30 mL batches of Lupicardin manufactured with different levels of sucrose and mannitol

[0348]

[0349] 1 Evaporation during freeze drying

[0350] NA: Not applicable

[0351] Table 8 below shows the stability results of lyophilized batches with different bulking agents after storage at 40°C / 75% RH for 3 months.

[0352] The batch formulated with 5% sucrose was stable as it showed no changes in the appearance of the freeze dried cake nor in the reconstituted solution, maintained the Rubikatin assay, and showed only a slight increase in degradation products, with Impurity D being the major degradation product observed (rrt 0.88 HPLC commercial method).

[0353] However, batches formulated with a mixture of sucrose and mannitol or with mannitol alone degraded significantly during storage at 40°C. In both cases, the appearance of the freeze-dried cake was different from the batches containing only sucrose (5% or 10%). The formulation containing 5% mannitol had a very significant reduction in the rubicatin assay (43% of the nominal target). In addition, the % degradation products increased in both formulations (up to 57% in the formulation containing 5% mannitol). The two major degradation products in the formulation containing mannitol were those eluting at rrt 0.67-0.68 and rrt 1.06).

[0354] Table 8. Stress stability of Rubicartin batches containing different expanders

[0355]

[0356]

[0357] 1 HPLC commercial method: MPI-00769 6.0

[26]

[0358] 2 Total impurities and degradation products were calculated as the sum of all individual impurities with % w / w ≥ 0.05%.

[0359] 3 Individual impurities and degradation products reported: 5% sucrose: (% w / w) ≥ 0.10%; 5% sucrose + 2.5% mannitol and 5% mannitol: t = 0 (% w / w) ≥ 0.10% and t = 3 months (% w / w) ≥ 1.0%

[0360] Table 9 shows the stability results of lyophilized vials with different concentrations of sucrose ranging from 5% to 10% formulated in 0.03M sodium lactate buffer pH=4 under stress conditions (40°C / 75% RH)

[0361] Table 9. Stress stability of freeze-dried vials of Rubikatin formulated in 0.03 M lactate buffer pH 4 with varying concentrations of sucrose as bulking agent

[0362]

[0363] 1 HPLC commercial method: MPI-00769 6.0

[26]

[0364] 2 Total impurities and degradation products were calculated as the sum of all individual impurities with % w / w ≥ 0.05%. 3 Reported individual impurities and degradation products: 5% Sucrose: % w / w ≥ 0.10%

[0365] Batches containing 3 different concentrations of sucrose showed similar behavior and remained stable. They did not undergo significant changes in the appearance of the freeze-dried cake and the Rubikatin assay (%). A slight increase in the % degradation products was observed. Specifically, impurity D (rrt 0.88, HPLC commercial method) was the main degradation product. The percentage of sucrose did not significantly affect the stability of the product, although 10% sucrose showed the lowest degradation.

[0366] In conclusion, sucrose showed a protective effect against the degradation of rubikatin during storage at high temperature. Based on these results, sucrose was selected as the most suitable bulking agent, with a concentration of 10% (w / v) being the optimal amount for a suitable and stable presentation of rubikatin.

[0367] Example 7: Stability of Rubikatin under long-term storage conditions

[0368] The stability of the lyophilized Lupicadin composition (4 mg) at the conditions proposed for long-term storage (5°C ± 3°C) was evaluated during 36 months. The batch with a high residual water content was selected as it was considered the worst case scenario.

[0369] The product remained stable over the course of the 36-month study (Table 10). None of the quality attributes changed significantly. Minor changes in the content of Lupicadin occurred due to analytical variability during the first 24 months. Total degradation products did not change during the entire storage time. The only related substance observed at reportable levels was Impurity D, which remained constant and maintained at the level present in the active ingredient used to manufacture the batch.

[0370] Table 10. Stability study of 4 mg of Lubicardin at 5°C ± 3°C

[0371]

[0372]

[0373] NA: Not applicable

[0374] Example 8: Clinical Study - Treatment of SCLC Patients with Lubicardin

[0375] Lupicardin monotherapy was studied clinically in patients with SCLC who had refractory or resistant disease as defined herein. In this clinical single-arm, multicenter, open-label, Phase 2 trial, 3.2 mg / m 2 was administered intravenously over a 1-hour period every 21 days. 2A cohort of 105 patients with measurable disease were treated with 105 doses of rubicatin, including patients whose SCLC did not respond to first-line platinum-containing chemotherapy (cisplatin, carboplatin, or oxaliplatin) (refractory) and patients whose SCLC relapsed within 90 days or equal to 90 days after cessation of first-line therapy (resistant). Lubicatin is provided as a sterile isotonic aqueous solution for IV infusion, as described below.

[0376] Study Group

[0377] Adult patients who were at least 18 years old and had a pathologically confirmed diagnosis of SCLC were included if they had the following: pretreatment with only one previous chemotherapy-containing line of treatment (immunotherapy in combination with chemotherapy or alone was allowed); measurable response according to solid tumor response criteria (RECIST version 1.1) and progression recorded before the start of the study; and Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower. Patients were required to have adequate bone marrow function (assessed by laboratory tests for absolute neutrophil count, platelet count and hemoglobin), renal function (assessed by serum creatinine and creatinine kinase), and liver function (assessed by total bilirubin, albumin and aminotransferase). The minimum interval between any previous treatment and the start of the study must be 3 weeks for chemotherapy, 4 weeks for immunotherapy or radiotherapy, and 2 weeks for any investigational or palliative therapy. Only patients with grade 1 or lower toxicity from any previous therapy were included, except for cases of alopecia and peripheral sensory neuropathy (both grade 2), which were also allowed. Women of childbearing age must use adequate contraceptive measures during the study and for at least 3 months after the end of the study.

[0378] Patients were excluded if they had: prior receipt of rubicatin or trabectedin; prior or concurrent malignancy, unless in complete remission for more than 5 years; known CNS involvement (screening for CNS metastases at baseline is mandatory); concomitant unstable or severe medical conditions within the past year (history or presence of unstable angina, myocardial infarction, congestive heart failure, valvular heart disease, arrhythmia, severe dyspnea, or active infection (such as hepatitis or HIV)); impending need for radiotherapy; or inability to comply with the study protocol or limited ability. More details on inclusion and exclusion criteria can be found in Table 11.

[0379]

[0380]

[0381] Study Drug Formulations—Preparation and Administration

[0382] Lupicardin is provided as a lyophilized powder for infusion of a concentrated infusion solution in a 4 mg vial. Prior to use, the 4 mg vial is reconstituted with 8 mL of water for injection to obtain a solution containing 0.5 mg / mL Lupicardin. For administration to a patient as an iv infusion, dilute with glucose 50 mg / mL (5%) infusion solution or reconstitute with sodium chloride 9 mg / mL (0.9%) infusion solution. The complete composition and reconstituted solution per mL are shown in Table 12.

[0383] Table 12. Composition of 4 mg Rubikatin vial

[0384]

[0385] Dosage and Administration

[0386] Lupicatin is administered via a central catheter in a minimum total volume of 100 mL of infusion solution (5% dextrose or 0.9% sodium chloride) or, if administered via a peripheral line, in a minimum total volume of 250 mL, always at a fixed infusion rate over one hour.

[0387] The starting dose is 3.2 mg / m 2 The upper limit of the dose is 2.0 mg / m 2 Patients received rubicatin as a one-hour infusion IV on Day 1 every three weeks until disease progression or unacceptable toxicity. Three weeks was defined as one treatment cycle.

[0388] Preoperative medication

[0389] All patients received antiemetic prophylaxis prior to each treatment infusion. The iv formulations of these agents were used in this setting: corticosteroids (dexamethasone 8 mg or equivalent), serotonin antagonists (ondansetron 8 mg or equivalent), extended therapy with oral serotonin antagonists, and oral dexamethasone for two consecutive days. If necessary and in addition to the above, 10 mg of oral or iv metoclopramide (or equivalent) was administered every 8 hours. Aprepitant and equivalent agents were contraindicated in patients treated with lupicatin.

[0390] Criteria for continuing treatment

[0391] If the patient meets all treatment criteria described in Table 13, additional treatment cycles are administered q3wk (±48 hours).

[0392] Table 13

[0393]

[0394] AE, adverse event; ANC, absolute neutrophil count; AP, alkaline phosphatase; AST / ALT, aspartate aminotransferase / alanine aminotransferase; CPK, creatinine phosphokinase; ECOG, Eastern Cooperative Oncology Group; GGT, gamma-glutamyl transferase; PS, performance status; ULN, upper limit of normal.

[0395] Patients received concentrated red blood cell transfusions and / or erythropoietin therapy to increase / maintain adequate hemoglobin levels, if clinically indicated. If a patient did not meet retreatment requirements on Day 1 of any subsequent cycle, regardless of the reason, reassessment was performed at least every 48-72 hours. Treatment was then withheld for a maximum of three weeks beyond the due date until appropriate resumption. Patients who did not meet retreatment criteria after a maximum delay of 3 weeks had to be withdrawn from the trial. For any delay due to treatment-related adverse events persisting for more than one week, dose reductions were implemented after resumption according to the rules explained in the next section.

[0396] Dose Modifications for Adverse Reactions

[0397] Treatment was continued if the patient presented with any of the following: (1) ≥ Grade 3 treatment-related non-hematologic toxicity. The following were excluded: ≥ Grade 3 nausea and / or vomiting not optimally treated, Grade 3 asthenia persisting ≤ 3 days, Grade 3 diarrhea persisting ≤ 2 days or not optimally treated, Grade 3 transient ALT / AST elevations that were rapidly reversible and did not result in subsequent delays, and non-clinically relevant biochemical abnormalities. (2) Grade 4 thrombocytopenia or Grade 3 thrombocytopenia associated with ≥ Grade 3 bleeding. (3) Grade 4 neutropenia, febrile neutropenia of any grade, or neutropenia associated with infection / sepsis. (4) Prolonged (>1 week) dose delays were frequent due to treatment-related adverse events. Patients who experienced Grade 3 or 4 hypersensitivity reactions discontinued study treatment.

[0398] Previous analyses with rubicatin following body surface area-based dosing showed a rate of febrile neutropenia of less than 10% with rubicatin. Therefore, according to the American Society of Clinical Oncology and European Society of Medical Oncology guidelines, primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is not permitted (secondary prophylaxis against neutropenia with G-CSF is permitted).

[0399] The dose reduction levels are shown in Table 14 below:

[0400] Table 14. Dose Modifications

[0401]

[0402] **The upper limit of dose is 2.0 m2 of BSA (i.e., dose does not exceed 6.4 mg) BSA, body surface area.

[0403] A maximum of 2 dose reductions were allowed per patient. Patients who continued to experience treatment-related toxicity and / or frequent dose delays after the allowed dose reductions were withdrawn from the study. They could continue to receive study drug if objective clinical benefit was adequately demonstrated. Once the dose of an individual patient was reduced, the dose was not re-increased under any circumstances.

[0404] Efficacy evaluation

[0405] The primary objective of this study is to evaluate the antitumor activity of rubicatin in terms of overall response rate (ORR) as the primary endpoint and duration of response (DOR) as a secondary endpoint. ORR was assessed using RECIST v1.1 on a set of measurable lesions identified at baseline as target lesions or non-target lesions (if any) and followed by appropriate methods until the occurrence of disease progression (PD).

[0406] Radiation oncology assessments (CT scans or MRI) were performed at baseline and every 6 weeks from the start of study treatment until cycle 6 or evidence of PD, and every 9 weeks thereafter. If an objective response was observed according to RECIST v1.1., it had to be confirmed by the same method at least four weeks after the date of the first documented response.

[0407] ORR was defined as the percentage of evaluable patients with a confirmed response (complete response (CR) or partial response (PR)) from the start of treatment to the date of progression or the start of subsequent therapy or the end of patient follow-up according to RECIST v1.1. DOR was calculated from the date of the first documented PD, relapse, or death due to any cause in responder patients. The date of response, date of radiological or clinical PD, and date of death were registered and recorded where appropriate based on the investigator's assessment and independent review by the Independent Review Committee (IRC). The IRC determined the patient's best response and assigned the date of the first documented response and progression / review according to RECIST v1.1.

[0408] Counts and percentages and their corresponding exact 95% confidence intervals were calculated for binomial endpoints (ie, ORR, clinical benefit). Time-to-event variables (OS, PFS, and DOR) and their set time estimates (ie, PFS4 / 6 and OS6 / 12) were analyzed according to the Kaplan-Meier method. The evaluation of efficacy endpoints evaluated by IA and IRC was analyzed and compared.

[0409] Pharmacokinetic evaluation

[0410] The plasma PK of lupicardin was evaluated in all treated patients during Cycle 1 and Cycle 2. The sampling schedule is shown in Tables 15 and 16, respectively.

[0411] PK analysis of rubikatin plasma concentration-time data was performed using nonlinear mixed-effects modeling and / or non-compartmental analysis.

[0412] Table 15. Blood samples from PK assessment - Cycle 1

[0413] Sample No. Number of days Sample loading time Loading window #1 D1 Before starting the infusion -- #2* D1 5 minutes before EOI + / -4min #3 D1 30 minutes before EOI + / -4min #4 D1 1 hour before EOI + / -10min #5 D1 3 hours before EOI + / -10min #6 D2 24 hours before EOI + / -2h #7 D4 72 hours before EOI + / -24h #8 D8 168 hours before EOI + / -24h

[0414] Sample #2 must be collected prior to EOI.

[0415] D, day; EOI, end of infusion.

[0416] Table 16. Blood Samples from PK Assessment - Cycle 2

[0417] Sample No. Number of days Sample loading time Loading window #9 D1 Before starting the infusion -- #10* D1 5 minutes before EOI + / -4min #11 D1 30 minutes before EOI + / -4min #12 D1 1 hour before EOI + / -10min #13 D1 3 hours before EOI + / -10min #14 D8 168 hours before EOI + / -24h

[0418] Sample #2 must be collected prior to EOI.

[0419] D, day; EOI, end of infusion.

[0420] Safety evaluation

[0421] Patients were evaluated for safety if they received any partial or complete infusion of rubicatin. All adverse events were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE, v4). Patients' safety profiles were monitored throughout the treatment period and up to 30 days after the last rubicatin infusion (end of treatment), or until the patient started a new anti-tumor therapy or until the date of death, whichever occurred first. Reasons for treatment delays, dose reduction requirements, transfusions, and treatment discontinuations were monitored throughout the study. Any treatment-related adverse event was followed until recovery to at least Grade 1 or symptomatic stabilization or until new anti-tumor therapy was started, whichever occurred first.

[0422]

[0423] Statistical methods

[0424] This Phase II trial was designed to evaluate the antitumor activity of rubicatin in terms of ORR assessed by IA according to RECIST v.1.1, and tumor assessments were also performed by IRC.

[0425] Up to 100 evaluable patients were recruited to test the null hypothesis that 15% or less patients responded (p<0.15) relative to the alternative hypothesis that 30% or more patients responded (p≥0.30). The variance of the standardized test was based on the null hypothesis. The type I error (α) associated with this one-sided test was 0.025, and the type II error (β) was 0.051 (normal approximation; if it was an exact binomial distribution, it was ~0.05); therefore, the statistical power was 95% (normal approximation; if it was an exact binomial distribution, it was ~95%). Under these assumptions, if the number of patients who achieved a confirmed response was ≥23, this would allow the null hypothesis to be rejected. The judgment of the replacement of patients who are evaluable and non-evaluable in each group in the interim analysis was guided by the investigator's assessment.

[0426] Duration of the study period

[0427] Patients were evaluated at scheduled visits during three study periods: (1) Pretreatment: from IC signature to first infusion of study treatment; (2) Treatment: from first infusion of study treatment to end of treatment; and (3) Follow-up: after end of treatment. Patients were followed every 4 weeks until all drug-related adverse events (if any) resolved or stabilized, or until new anti-tumor therapy was initiated. Patients were followed for at least 1 year after the first infusion of rubicatin. Patients who completed treatment without PD were followed every 2 months during the first 6 months and every 3 months thereafter until PD, initiation of new anti-tumor therapy, death, or until end of study date.

[0428] result

[0429] 105 SCLC patients participated in the study. All 105 patients were treated and included in the primary endpoint analysis. Among the 105 treated patients, 60% were male, 75% were white, 92% had ECOGPS 0 or 1, and the median age was 60 years old (range 40-83 years; 35.2% ≥ 65 years old). 2 (1.9%) of the 105 treated patients had previously undergone surgery (one patient underwent radical resection). 75 patients (71.4%) had been administered radiotherapy. The patient received the median value (range, 1-2 lines) of a previous chemotherapy line for advanced disease. The chemotherapy-free interval of 21 (21%) patients was less than 30 days, 45 (43%) patients were less than 90 days, and 60 (57%) patients were 90 days or longer. One patient with CNS metastases at baseline was included, and another patient was re-stimulated with carboplatin plus etoposide and atezolizumab as prior line of therapy; both cases were considered protocol deviations, but they were minor and were included in the primary analysis.

[0430] A total of 618 treatment cycles were administered, with a median of 4 cycles per patient, and 46 (44%) patients received 6 or more cycles. The median relative dose intensity of the study drug was 97.4% of the planned maximum dose. Due to treatment-related adverse events, dose administration was delayed in 23 (22%) patients, and dose reduction was achieved in 28 (26%) patients (neutropenia was the most common reason for dose delays in 13 (12%) patients and dose reductions in 17 (16%) patients).

[0431] Efficacy of rubicatin in patients with SCLC

[0432] At the data cutoff, the median follow-up was 17.1 months. Based on the investigator's assessment of all treated patients, 37 (35.2%) patients had an overall response, as shown in Table 17.

[0433]

[0434] In a preplanned analysis of overall response by chemotherapy-free interval (≥90 days vs. <90 days) in 60 patients with a chemotherapy-free interval of 90 days or longer (i.e., those with chemotherapy-sensitive disease), 27 (45.0%) patients had an overall response with a median duration of response of 6.2 months, whereas among 45 patients with a chemotherapy-free interval of less than 90 days (i.e., chemotherapy-resistant disease), 10 (22.2%) patients had an overall response with a median duration of response of 4.7 months.

[0435] Progression-free survival

[0436] In the entire group, the median progression-free survival assessed by the investigators was 3.5 months (95% CI 2.6-4.3): 4.6 months in patients with a chemotherapy-free interval of 90 days or longer, and 2.6 months in patients with a chemotherapy-free interval of less than 90 days. Of the 94 patients who discontinued rubicatin, 8 (9%) had disease progression with new lesions in the CNS. Thus, no increased incidence of CNS metastases was observed.

[0437] Overall survival

[0438] With 37.1% (39 of 105 patients alive at the data cutoff) censored, the median overall survival for the entire population was 9.3 months (95% CI 6.3-11.8), 11.9 months (9.7-16.2) in patients with a chemotherapy-free interval of 90 days or longer, and 5.0 months (4.1-6.3) in patients with a chemotherapy-free interval of less than 90 days. Notably, 29 of 60 patients (48%) with a chemotherapy-free interval of 90 days or longer and 7 of 45 patients (16%) with a chemotherapy-free interval of less than 90 days were alive 1 year after the first dose.

[0439] In a post hoc analysis, among the 37 patients with an initial objective response, median overall survival was more than 1 year in the entire population (12.6 months, 95% CI 10.8-15.8) and in patients with sensitive disease (15.8 months, 10.2-not reached), and was 10.9 months in patients with resistant disease (10.9 months, 95% CI 6.3-14.0).

[0440] Security

[0441] All 105 treated patients were evaluable for safety (Table 18). The most common grade 3-4 adverse events and laboratory abnormalities (in ≥2% of patients) were hematologic disorders, including anemia (nine [9%] patients), leukopenia (30 [29%]), neutropenia (48 [46%]), thrombocytopenia (seven [7%]), and febrile neutropenia (five [5%]); of these, only febrile neutropenia was considered treatment-related (Table 18). Notably, no cases of drug-induced liver injury were reported. Twenty-three of the 105 patients (22%) received G-CSF secondary prophylaxis or therapy for neutropenia. Serious treatment-related adverse events occurred in 11 of the 105 patients (10%); neutropenia and febrile neutropenia were the most common (five [5%] patients each). Grade 3 pneumonia was reported in two (2%) patients; these episodes were associated with grade 3 febrile neutropenia and grade 4 neutropenia, lasting 3 days in one patient and 13 days in another, and resolved without clinical consequences. One patient developed a grade 3 skin ulcer due to extravasation, without clinical consequences. Only two (2%) patients discontinued rubicatin therapy due to treatment-related adverse events. No treatment-related deaths occurred, but 66 of 105 patients (63%) died from disease progression.

[0442] Table 18.

[0443]

[0444] Previous immunotherapy

[0445] An exploratory post hoc analysis of responses in patients who had previously received immunotherapy was performed (n=8). Data from this group of patients showed a trend toward better responses to single-agent lumikatinib after first-line platinum-containing chemotherapy in combination with a checkpoint inhibitor or second-line with nivolumab (Table 19). This is an important finding given the recent approval of atezolizumab in combination with carboplatin / etoposide for first-line SCLC; thus, lumikatinib may provide a viable option for patients who have progressed on immunotherapy.

[0446] Table 19.

[0447]

[0448] Overview and Conclusion

[0449] Results: One hundred and five patients with SCLC were enrolled and treated with rubicatinib. The median follow-up was 17.1 months (IQR 6.5-25.3). An investigator-assessed overall response was observed in 37 patients (35.2%; 95% CI 26.2-45.2). The most common grade 3–4 adverse events (irrespective of causality) were hematologic abnormalities, namely anemia (in nine [9%] patients), leukopenia (30 [29%]), neutropenia (48 [46%]), and thrombocytopenia (seven [7%]). Serious treatment-related adverse events occurred in 11 (10%) patients, with neutropenia and febrile neutropenia being the most common (five [5%] patients each). No treatment-related deaths were reported.

[0450] Lubicardin as a second-line therapy for SCLC was active in terms of overall response and had an acceptable and manageable safety profile. Lubicardin may represent a potential new treatment for SCLC patients who have few options, especially in the setting of relapse.

[0451] Example 8: Clinical Study - Treatment of Patients with Solid Cancers with Lubicardin and Irinotecan

[0452] A Phase 1 trial was conducted in patients with advanced solid tumors to evaluate escalating doses of rubicatin on day 1 every 3 weeks (q3w) plus a fixed dose of irinotecan 75 mg / m2 on D1 and D8. 2Patients were enrolled following a standard 3+3 dose escalation design. A Phase Ib / II extension portion was conducted at the recommended dose (RD) to explore efficacy in indications where anti-tumor activity signals were observed.

[0453] Study Group

[0454] Details on the inclusion and exclusion criteria can be found in Table 20.

[0455]

[0456]

[0457] Study Drug Formulations—Preparation and Administration

[0458] Lupicardin is provided as a lyophilized powder for concentrated solution for infusion in 4 mg vials. Prior to use, the 4 mg vial is reconstituted with 8 mL of water for injection to obtain a solution containing 0.5 mg / mL Lupicardin. For administration to patients as an iv infusion, dilute with glucose 50 mg / mL (5%) infusion solution or reconstitute the vial with sodium chloride 9 mg / mL (0.9%) infusion solution. The complete composition and reconstituted solution per mL are shown in Table 12 above.

[0459] Irinotecan is supplied as a lyophilized powder for concentrated solution for infusion in 40 mg, 100 mg, or 300 mg vials.

[0460] Dosage and Administration

[0461] Lupicatin is administered via a central catheter in a minimum total volume of 100 mL of infusion solution (5% dextrose or 0.9% sodium chloride) or, if administered via a peripheral line, in a minimum total volume of 250 mL, always at a fixed infusion rate over one hour.

[0462] The dose levels for patients in the escalation phase (n=39) are shown in Table 21. Patients received rubicatin iv as a one-hour infusion on day 1 and irinotecan iv as a 90-minute infusion on days 1 and 8 every three weeks. Three weeks was defined as one treatment cycle.

[0463] Table 21.

[0464]

[0465]

[0466] Outcome Metrics

[0467] The primary outcome measures were (1) maximum tolerated dose (MTD) and (2) recommended dose (RD). MTD was defined as the lowest dose explored during dose escalation at which one-third or more of the evaluable patients experienced a DLT during cycle 1. RD was defined as the highest dose level explored during dose escalation at which less than one-third of the evaluable patients experienced a DLT during cycle 1.

[0468] Secondary outcome measures included safety evaluations, peak plasma concentration (Cmax), area under the plasma concentration versus time curve (AUC), volume of distribution based on terminal half-life (Vz), volume of distribution at steady state (Vss), clearance (CL), half-life (t1 / 2), antitumor response evaluation (RECIST v1.1, treatment start until PD, other antitumor therapy, death, or until 12 months after the last evaluable patient was enrolled in the study (end of study), whichever occurred first), progression-free survival (from the date of the first infusion of study treatment to the date of progression or death or until 12 months after the end of study, whichever occurred first), and overall survival (from the date of the first infusion of study treatment to the date of death or until 12 months after the end of study, whichever occurred first).

[0469] Pharmacokinetic evaluation

[0470] Patients underwent PK studies for the evaluation of rubicatin, irinotecan, and SN38 (the active metabolite of irinotecan) with the goal of ruling out major drug-drug interactions.

[0471] Safety evaluation

[0472] If patients received any partial or complete infusion of rubicatin and irinotecan, their safety was evaluated. All adverse events were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE, v4). The safety profile of patients was monitored throughout the treatment period and up to 30 days after the last administration of the study (end of treatment), or until the patient started a new anti-tumor therapy or until the date of death, whichever occurred first. The reasons for treatment delays, dose reduction requirements, transfusions, and treatment discontinuations were monitored throughout the study. Any treatment-related adverse events were followed until recovery to at least Grade 1 or symptomatic stabilization or until new anti-tumor therapy was started, whichever occurred first.

[0473] result

[0474] Thirty-nine patients were initially treated at 5 dose levels (DL, see Table 21 above); 13 patients were treated at the recommended dose (RD). 56% were female, 69% had ECOGPS = 1; median age was 58 years; median number of prior chemotherapy lines per patient for advanced disease was 2 (range, 0-4). RD was defined as 2.0 mg / m2 of rubicatin at D1. 2 + Irinotecan 75 mg / m on D1 and D8 2 q3w+G-CSF. Dose-limiting toxicity in cycle 1 was observed in 2 / 3 evaluable patients at the maximum tolerated dose (MTD) and in 3 / 13 evaluable patients at the RD. At the MTD and RD, the irinotecan D8 dose was skipped by DLT due to grade 3-4 (G) neutropenia (n=3 patients) or grade G2-4 thrombocytopenia (n=2). At the RD, common G1 / 2 toxicities were nausea, vomiting, fatigue, diarrhea, anorexia, and neuropathy; G3 / 4 hematologic abnormalities included neutropenia (33%), but no thrombocytopenia.

[0475] Pharmacokinetic data

[0476] Concentration-time data for rubicatin, irinotecan, and SN-38 were available from 39 patients. Mean values ​​(±SD) for the main PK parameters are provided in the table below along with those reported elsewhere for single agent rubicatin, irinotecan, and SN-38 (Camptosar label).

[0477] Based on comparability with the reference PK data, these PK results for the three analytes evaluated did not indicate any type of major drug-drug interaction, indicating that the drug combination of rubicatin and irinotecan can be safely administered from a PK perspective.

[0478] Table 22.

[0479]

[0480] Efficacy data

[0481] Encouraging activity was observed in SCLC patients, including some cases as third-line treatment. Active signals were also observed in endometrial carcinoma and soft tissue sarcoma (STS) and glioblastoma (GBM). Therefore, Phase II expansion was performed under RD to further explore the efficacy and safety in SCLC, GBM, STS and endometrial carcinoma. A total of 59 patients were treated under RD, including n=15 SCLC patients, n=11 endometrial carcinoma patients, n=10 STS patients and n=20 GBM patients. The efficacy data of each tumor type at all doses are shown in the table below.

[0482] Table 23.

[0483]

[0484] Security

[0485] Two patients (3.4%) discontinued treatment due to treatment-related adverse events (bilirubin G2, weakness G3). 17 patients (28.8%) had a dose reduction (76% of the reduction was due to the omission of irinotecan related to adverse events on the 8th day). 19.8% of the irinotecan infusions on the 8th day were omitted under RD (mainly due to hematological toxicity). No treatment-related deaths occurred. A detailed description of adverse events and laboratory abnormalities observed in patients under RD is shown in Table 24.

[0486] Table 24.

[0487]

[0488]

[0489] Overview and Conclusion

[0490] In solid tumors, the RD is 2.0 mg / m2 of rubicatinib on day 1. 2 and irinotecan 75 mg / m on days 1 and 8 2 q3wk as well as GCS-F. DLTs were mostly due to omission of irinotecan on day 8 in cycle 1 due to hematologic toxicity. The main toxicities observed were myelosuppression, GI, and fatigue. GI and myelosuppression were predictable and manageable. Promising activity was observed in SCLC. Significant activity was observed in endometrial cancer, and signs of activity were found in STS (particularly Ewing sarcoma and synovial sarcoma). Modest activity was observed in patients with glioblastoma 。 Expansion cohorts for SCLC, endometrial cancer, and STS patients are ongoing to enroll a total of 20 patients in each indication.

[0491] Rubicartin solid form example

[0492] abbreviation:

[0493] DSC Differential Scanning Calorimetry DVS Dynamic moisture adsorption XRPD X-ray powder diffraction pattern TG-FTIR Thermogravimetry combined with Fourier transform infrared spectroscopy r.h. Relative humidity

[0494] X-ray powder diffraction patterns (XRPD) were obtained with a Stadi P diffractometer (Stoe & Cie GmbH) in transmission geometry equipped with a Ge bent crystal monochromator, a Cu-Kα1 radiation source and a Mythen 1K detector in step-scan detector mode. The pattern was recorded at a tube voltage of 40 kV, a tube current of 40 mA, a step size of 0.02° 2-θ was applied over an angular range of 1.5° to 50.5° 2-θ, 12 seconds per step. The detector step size was 1° 2-θ. The typical accuracy of the 2-θ values ​​is in the range of about ±0.2° 2-θ. Therefore, under standard conditions, on most X-ray diffractometers, a diffraction peak appearing at 5.0° 2-θ may appear between 4.8 and 5.2 2-θ.

[0495] TG-FTIR experiments were performed with a Thermo-Microbalance TG-209 (Netzsch) equipped with a FT-IR spectrometer Vector 22 (Bruker) under N2 atmosphere using Al crucibles (open or with micropores), with a heating range between 25°C and 250°C and a heating rate of 10°C / min.

[0496] DSC experiments were performed with a Perkin Elmer DSC 7 using closed Au crucibles in the heating range between -50°C and 250°C at a heating rate of 10 or 20°C / min.

[0497] DVS experiments were performed with a Projekt Messtechnik SPS11-100n multi-sample water vapor sorption analyzer. The samples were equilibrated at 50% rh before starting a predefined humidity program. The program was:

[0498] -2h at 50% RH

[0499] -50% to 0% rh (5% / h)

[0500] -5h at 0% rh

[0501] -0% to 95% rh (5% / h)

[0502] -5h at 95% RH

[0503] -95% to 50% (5% / h)

[0504] -2h at 50% RH

[0505] Example 9. Preparation of Amorphous Form A of Rubikatin

[0506]

[0507] Rubikatin Form A was obtained following the procedure described in WO 03 / 014127. The XRPD pattern of Rubikatin Form A confirmed that this form is amorphous. Figure 1 Several batches of Rubikatin Form A were produced by this method. The analytical results of five of them are shown in Table 25.

[0508] Table 25

[0509]

[0510] ND: Not Detected

[0511] LOQ: Limit of Quantitation

[0512] Table 26 shows the impurity profiles of several batches of Form A Lupicadin.

[0513] Table 26

[0514]

[0515] RRT - relative retention time

[0516] Example 10. Production of Rubikatin Form B

[0517] Crude lupicadin (10 g) obtained as described in Example 1 was dissolved in aqueous HCl (0.1 M, 390 mL). The aqueous solution was washed with CH2Cl2 (2 x 335 mL) and n-pentane (1 x 335 mL), and treated with an aqueous solution of NH4Cl / NH4OH (prepared by dissolving 17.5 g of NH4Cl and 20 mL of NH4OH in 250 mL of water, 68 mL) to precipitate lupicadin Form B, which was filtered, washed with water and dried in vacuo to give 7.5 g, 9.45 mmol, 81% yield of lupicadin Form B.

[0518] Several batches of Rubikatin Form B were produced by this method. The analytical results of ten of them are shown in Table 27.

[0519] Table 27

[0520]

[0521] LOQ: Limit of Quantitation

[0522] NA: Not analyzed

[0523] Another advantage of Form B of Rubikatin over Form A of Rubikatin is the absence of residual solvents.

[0524] Table 28 shows the impurity profiles (% area) of several batches of Form B Lupicardin

[0525] Table 28

[0526]

[0527]

[0528] RRT - relative retention time

[0529] Comparison between the impurity profiles of Rubikatin Form A and Rubikatin Form B clearly shows that Rubikatin Form B presents consistently fewer impurities than Rubikatin Form A.

[0530] Solid State Characterization - Rubikatin Form B was characterized by XRPD, IR, TG-FTIR, DSC and DVS.

[0531] XRPD patterns of several batches of Rubikatin Form B confirmed that this form is partially crystalline (broad peaks, amorphous background) and that its manufacturing process is reproducible. Figure 2a and 2b The XRPD 2-θ angles and their relative intensities of two batches of Rubikatin Form B are shown in Table 29.

[0532] Table 29 XRPD angle 2-θ, relative intensity of two batches of Rubikatin Form B

[0533]

[0534]

[0535] TG-FTIR indicated that Form B of Rubikatin degraded above 150°C. Release of 2.6% of water was detected. Figure 3 .

[0536] Estimation of amorphous content by DSC is not possible. Degradation was observed to start above 130 °C, see Figure 4 . No glass transition temperature or melting point was detected.

[0537] DVS indicated continuous water uptake and release, without steps and with almost no hysteresis. This is due to the partially amorphous character of Form B. The sample is not deliquescent. A mass change of Δm (50% to 96% rh) ≈ 4% was observed, indicating that Form B Rubicon is hygroscopic. After lowering the relative humidity again, the water content dropped and almost returned to the original mass, see Figure 5 .

[0538] Relative stability of Form B rubikatin - Three 1:1 mixtures of Form A and Form B rubikatin (15 mg each) were prepared and suspended in water (1 mL). Samples were collected after 6 hours and 24 hours. The powder patterns after 6 hours and 24 hours were consistent with those of the Form B starting material. See Figure 6 Both patterns after phase equilibrium show sharper peaks and higher peak resolution. These are indicative of improved crystallinity. The available data do not allow for quantification of the amorphous content.

[0539] Obtained Rubycardin Form A (in Figure 7a ) and the B form of Rubicartin (shown in Figure 7b The correlation coefficients between the IR of the three batches of Form B Rubikatin and the IR of Form A Rubikatin varied between 0.81 and 0.86. On the other hand, the correlation factors of several IR spectra of Form A Rubikatin varied between 0.97 and 0.99.

[0540] Example 11. Electrostatic Charge Measurement in Air

[0541] Faraday cages constructed from stainless steel have been used (see Figure 8 ) measured the electrostatic charge of two batches of Rubicartin Form A (Batch P04 and R05) and Rubicartin Form B (Batch 1924129-LT and 1924128-LT) of stainless steel with concentric spheres of 10, 15 and 20 cm ratios. This technique consists of placing the sample to be measured (q) inside an inner sphere (a) and measuring the potential difference induced between the sphere (a) and another reference conductor sphere (b). The outer sphere (c) is grounded to shield the system. The measurement of the potential difference is performed with a precision electrometer (Keithley 617, resolution 10 fC).

[0542] The measurements are carried out under a controlled atmosphere of dry nitrogen to avoid the influence of ambient humidity on the electrostatic charge of the sample. The sample is introduced into the glass capsule using a non-conductor instrument to avoid electrostatic charge losses. The capsule loaded with the sample is introduced into the Faraday cage through a grounded conductor tube to avoid parasitic electrostatic charges in the glass capsule. The entry and removal of the capsule is carried out using a computer-controlled servo engine in order to ensure a constant rate of introduction and removal of the capsule in each measurement to minimize the electrostatic charge generated due to friction of the insulator elements.

[0543] Results: Several measurements with different amounts of material were performed for each batch of each form of Rubikatin. Before loading the capsules, they were cleaned and their residual electrostatic charge was measured to correct the level. Each sample was introduced and removed five times and after each introduction, several consecutive measurements were performed to average out any possible drift effects. Figure 9a and9b The results of this measurement are summarized for each batch pair of Rubiconazole in form A and form B.

[0544] The measured charge Q increases with the amount of material analyzed. Both forms of Rubikatin have a positive electrostatic charge. The total electrostatic charge of Rubikatin form A is significantly higher than that of Rubikatin form B. The data were fitted by linear regression ( Figure 9a and 9b The dashed line in the figure (in the figure) was used to obtain the charge density (Q / m) as the slope of the line. The linear regression was extrapolated to a mass of 0 mg, which represents the residual electrostatic charge of the glass capsule and does not affect the value of Q / m. The results of this regression and the charge density dispersion are summarized in Table 30. All ranges are given at a 95% confidence level.

[0545] Table 30

[0546]

[0547] Fig.10a and 10b The charge density dispersion of Rubikatin Form A and Form B for each batch pair is shown.

[0548] Rubikatin Form B was shown to have an average charge density one order of magnitude lower than Rubikatin Form A. This difference in tribocharging has been demonstrated using two different batches of each form.

[0549] Example 12. Exemplary method for preparing pharmaceutical compositions using Form B as a starting material

[0550] Lupicatin Form B was dissolved in a concentrated lactic acid solution (0.31 M) at a concentration of 25 mg / ml. This solution was then diluted with water for injection (WFI) to a lactic acid solution (0.1 M) containing PM01183 at a concentration of 8.33 mg / ml.

[0551] This solution was then added to the previously prepared sucrose / buffer solution (pH = 4.2) under stirring, which consisted of lactic acid (3.7 mg / ml), sodium hydroxide (1.1 mg / ml) and bulking agent sucrose (167.7 mg / ml). If necessary, the mixed solution could be adjusted to pH = 4.0 with lactic acid solution or sodium hydroxide solution.

[0552] The bulk solution was then brought to a final volume or weight (considering a density value of 1.04 g / cc) to yield a final bulk solution (0.5 mg / ml Lupicadin, 2.76 mg / ml lactic acid, 0.64 mg / ml NaOH, 100 mg / ml sucrose).

[0553] The bulk solution was then filtered through a sterile PVDF filter (0.22 μm) and filled into 30 ml glass vials at 8 ml / vial.

[0554] The vials were lyophilized according to the cycles detailed in Table 31. After lyophilization, the vials were sealed with flip-top closures and stored at +5°C.

[0555] Table 31

[0556] Step(condition) time Frozen, -5°C 1.5h Frozen, -40°C 5.5h Primary drying (-25℃, 0.1-0.2mb) 60h Secondary drying (+25°C, maximum vacuum) 30h Plug NA

[0557] NA: Not applicable

[0558] Although the present invention has been described in detail with reference to its specific embodiments, it will be appreciated that functionally equivalent variations are within the scope of the present invention. In fact, various modifications of the present invention will become apparent to those skilled in the art from the aforementioned description and accompanying drawings, except those shown and described herein. Such modifications are intended to fall within the scope of the appended claims (and clauses). Those skilled in the art will recognize or will be able to determine many equivalents of the specific embodiments of the invention described herein without using excessive routine experiments. Such equivalents are intended to be covered by the following claims (and clauses).

[0559] All publications, patents and patent applications mentioned in this specification are incorporated by reference into the specification herein to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

[0560] The present invention will now be described with reference to the following clauses:

[0561] 1. A method of treating small cell lung cancer (SCLC) in a patient in need thereof, comprising:

[0562] (1) administering a prophylactic dose of a corticosteroid and a serotonin antagonist effective to reduce nausea associated with administration of lupicardin to said patient on and before the day of administration of lupicardin to said patient; and

[0563] (2) Administer 2 to 3.2 mg / m 2 Dose of Rubicartin.

[0564] 2. The method of clause 1, wherein the corticosteroid is dexamethasone administered intravenously at a dose of 8 mg dexamethasone or at a dose of corticosteroid equivalent to 8 mg dexamethasone administered intravenously.

[0565] 3. The method of clause 1 or 2, wherein the serotonin antagonist is ondansetron administered intravenously at a dose of 8 mg or at a dose of the serotonin antagonist equivalent to 8 mg ondansetron administered intravenously.

[0566] 4. The method of any one of clauses 1 to 3, further comprising administering one or more antiemetics within 2, 3 or 4 days after administering lupicardin to the patient.

[0567] 5. The method of clause 4, wherein the one or more antiemetics administered after administration of lupicardin are selected from the group consisting of corticosteroids, serotonin antagonists, and metoclopramide.

[0568] 6. The method of clause 5, wherein the one or more antiemetics are administered at a dose of 4 mg dexamethasone, 8 mg ondansetron or 10 mg metoclopramide, or a combination thereof.

[0569] 7. The method of any one of clauses 1-6, wherein the patient is not treated with doxorubicin in combination with the rubicatin.

[0570] 8. The method of any one of clauses 1-7, wherein the patient has progressed following prior platinum-containing therapy or prior immunotherapy.

[0571] 9. A method of treating small cell lung cancer (SCLC), including metastatic SCLC, in a patient in need thereof, comprising:

[0572] (1) If the patient has at least 1500 cells / mm 3 Absolute neutrophil count of at least 100,000 / mm 3 If the platelet count is below 50%, the patient is given 3.2 mg / m by intravenous infusion. 2 first dose of Lubicardin; and

[0573] (2) identifying adverse reactions in the patient after the administration, wherein the adverse reactions are grade 2 hepatotoxicity or other adverse reactions, grade 3 (severe) hepatotoxicity or other adverse reactions, grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm 3 ), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm 3 ) with bleeding, grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ) or any grade of febrile neutropenia (neutrophil count <LLN);

[0574] (3) After the adverse reaction is identified and 21 days after the first dose or when the patient's neutrophil count is greater than 1500 cells / mm 3 ; Platelet count greater than about 100,000 mm 3 and optionally after the hemoglobin level is greater than about 9 g / dL and the hepatotoxicity or other adverse reaction is Grade 1 or less:

[0575] (i) If the identified adverse reaction consists of isolated Grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ), then administering to the patient a dose of Lupicardin equivalent to the first dose and G-CSF prevention every three weeks;

[0576] (ii) if the identified adverse reaction consists of Grade 2 hepatotoxicity or other adverse reaction, administering to the patient every three weeks a dose of rubicatin equivalent to the first dose; or

[0577] (ii) If the identified adverse reaction is ≥ Grade 3 (severe) hepatotoxicity or other adverse reaction, Grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm 3 ), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm 3 ) is accompanied by bleeding or febrile neutropenia of any grade, then every 3 weeks the patient is administered a dose of rubicatin that is reduced compared to the first dose.

[0578] 10. The method of clause 9, wherein the first reduced dose is 2.6 mg / m 2 .

[0579] 11. The method of clause 10, wherein if 2.6 mg / m 2 After the dose reduction, the patient experienced ≥ Grade 3 (severe) hepatotoxicity or other adverse reactions, Grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm 3 ), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm 3 ) is accompanied by an adverse reaction of bleeding or febrile neutropenia of any grade, then 21 days after said administration of said previous dose or when said patient's neutrophil count is greater than 1500 cells / mm 3 ; Platelet count greater than about 100,000 mm 3 and optionally after the hemoglobin level is greater than about 9 g / dL and the hepatotoxicity or other adverse reaction is grade 1 or less, 2.0 mg / m 2 Second reduced dose of Lubicardin.

[0580] 12. The method of clause 11, further comprising identifying the adverse reaction after administration of the second reduced dose or if the patient does not recover to at least 1500 cells / mm within 2 weeks of the planned dose 3 Absolute neutrophil count of at least 100,000 / mm 3 If the platelet count is below 0.05, the administration of Lubicardin should be discontinued.

[0581] 13. A method as described in any of the preceding clauses, wherein the lubicartin is administered as an infusion formulation prepared by diluting a reconstituted lyophilized formulation comprising 4 mg lubicartin, a buffer derived from an organic carboxylic acid (e.g., lactic acid), and a disaccharide (e.g., sucrose), the formulation having a pH of 3.5 to 4.5 upon reconstitution.

[0582] 14. A method of treating small cell lung cancer (SCLC) in a patient in need thereof, comprising:

[0583] Lupicardin infusion solution was administered by intravenous infusion at 3.2 mg / m 2 The invention relates to administering Lupicardin to the patient in a dose of 500 mg / mL, wherein the Lupicardin infusion solution administered to the patient is prepared from a lyophilized composition comprising 4 mg of Lupicardin, a buffer derived from an organic carboxylic acid, and a disaccharide, which is reconstituted to form a reconstituted solution having a pH of 3.5 to 4.5.

[0584] 15. The method of clause 14, wherein the disaccharide is sucrose and optionally wherein the composition comprises lupicardin and sucrose in a ratio of 1 mol lupicardin: 455 to 465 mol sucrose.

[0585] 16. The method of clause 14 or 15, wherein the organic carboxylic acid is lactic acid and optionally wherein the composition comprises lupicadin and lactic acid in a ratio of 1 mol lupicadin:44 to 54 mol lactic acid.

[0586] 17. The method of any one of clauses 14 to 16, wherein the pH is 3.8 to 4.5

[0587] 18. The method of any one of clauses 14 to 17, wherein the lyophilized composition is reconstituted in about 8 mL of aqueous solution to obtain the reconstituted solution.

[0588] 19. The method of clause 18, wherein the lupicardin infusion solution is prepared by diluting the reconstituted solution with an isotonic solution.

[0589] 20. The method of any one of clauses 14 to 19, wherein the lupicardin infusion solution is prepared by diluting the reconstituted solution with at least 100 mL or at least 250 mL of the isotonic solution.

[0590] 21. The method of clause 20, wherein the isotonic solution is a 0.9% sodium chloride solution or a 5% glucose solution.

[0591] 22. The method of any of the preceding clauses, wherein the lyophilized composition comprises:

[0592] 22.1 mg of lactic acid;

[0593] 5.1 mg of sodium hydroxide; and

[0594] 800mg sucrose

[0595] Or wherein the lyophilized composition comprises 800 mg of sucrose, 0.245 mmol of lactate and 0.128 mmol of sodium.

[0596] 23. The method of any of the preceding clauses, wherein the lyophilized composition is provided in a 30 mL vial.

[0597] 24. The method of any of the preceding clauses, wherein the lyophilized composition comprises impurity D at a value of no greater than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% wt / wt based on the total weight of lupicardin.

[0598] 25. The method of any of the preceding clauses, wherein the lyophilized composition does not comprise phosphate buffer.

[0599] 26. The method of any of the preceding clauses, wherein the reconstituted solution or the lubicartin infusion solution comprises impurity D at a value of no greater than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% wt / wt based on the total weight of lubicartin.

[0600] 27. The method of any one of clauses 14 to 26, further comprising administering a prophylactic dose of a corticosteroid and a serotonin antagonist effective to reduce nausea associated with administering lupicardin to the patient on and before the day of administering lupicardin to the patient.

[0601] 28. The method of clause 27, wherein the corticosteroid is dexamethasone administered intravenously at a dose of 8 mg dexamethasone or at a dose of corticosteroid equivalent to 8 mg dexamethasone administered intravenously.

[0602] 29. The method of clause 27 or 28, wherein the serotonin antagonist is ondansetron administered intravenously at a dose of 8 mg or at a dose of the serotonin antagonist equivalent to 8 mg ondansetron administered intravenously.

[0603] 30. The method of any one of clauses 27 to 29, further comprising administering one or more antiemetics within 2, 3 or 4 days after administering lupicardin to the patient.

[0604] 31. The method of clause 30, wherein the one or more antiemetics are selected from corticosteroids, serotonin antagonists, and metoclopramide.

[0605] 32. The method of clause 31, wherein the one or more antiemetics is 4 mg dexamethasone, 8 mg ondansetron or 10 mg metoclopramide or a combination thereof.

[0606] 33. A method as described in any preceding clause, further comprising providing a 3 G-CSF is administered to patients with neutrophil counts above or below the normal range and associated with infection / sepsis.

[0607] 34. The method of any preceding clause, wherein one dose of lupicardin is administered per treatment cycle and the patient undergoes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23 or 24 treatment cycles.

[0608] 35. The method of any preceding clause, wherein for patients with a CTFI interval <90 days, the overall response rate is at least 11% or at least 20%, or wherein for patients with a CTFI interval >90 days, the overall response rate is at least 30% or at least 40%.

[0609] 36. A method as described in any preceding clause, wherein for patients with a CTFI interval <90 days, the duration of response is at least 2.5 months or at least 4.5 months, or wherein for patients with a CTFI interval >90 days, the duration of response is at least 3.5 months, 5 months or 6 months.

[0610] 37. The method of any preceding clause, wherein the patient has not received platinum-containing therapy within at least 30 days, or at least 60 days, or at least 90 days prior to administration of rubikatin.

[0611] 38. The method of any preceding clause, wherein the patient ceased to respond to platinum-containing therapy prior to administration of rubicatin.

[0612] 39. A method as described in any preceding clause, wherein the patient has previously been administered immunotherapy.

[0613] 40. The method of clause 39, wherein the immunotherapy is an anti-CTLA-4 antibody, an anti-PD-1 antibody, or an anti-PD-L1 antibody.

[0614] 41. The method of clause 40, wherein the immunotherapy is atezolizumab, optionally in combination with carboplatin and etoposide, or nivolumab.

[0615] 42. The method of any one of clauses 39 to 41, wherein the patient progresses following administration of the immunotherapy.

[0616] 43. The method of any preceding clause, wherein the patient has a calculated creatinine clearance greater than 30 mL / min and an AST or ALT less than 3 x ULN or a bilirubin less than 1.5 x ULN.

[0617] 44. The method of any preceding clause, wherein rubicatin is administered to the patient as a 1 hour intravenous infusion to achieve a total plasma C within 80% to 125% of about 107 μg / L. max and AUC∞ within 80% to 125% of approximately 551 μg*h / L.

[0618] 45. A method for storing a lyophilized Lupicardin composition comprising:

[0619] storing a lyophilized composition at a temperature of 5°C ± 3°C for at least 48 months, the lyophilized composition comprising 4 mg of lupicardin; a buffer derived from an organic carboxylic acid; and a disaccharide,

[0620] wherein the lyophilized composition is formulated such that reconstitution with 8 mL of water will produce a solution having a pH of 3.5 to 4.5, and

[0621] wherein after said at least 24 months of storage, the amount of impurity D present in said composition does not exceed 0.8% wt. / wt. of the total weight of Lupicadine.

[0622] 46. ​​The method of clause 45, wherein the amount of impurity D present in the composition after storage for at least 48 months does not exceed 0.8% wt. / wt. of the total weight of Lupicadin.

[0623] 47. The method of clause 45 or 46, wherein the lyophilized composition comprises 4 mg lupicardin; 22.1 mg lactic acid; 5.1 mg sodium hydroxide; and 800 mg sucrose, or wherein the lyophilized composition comprises 800 mg sucrose, 0.245 mmol lactate, and 0.128 mmol sodium.

[0624] 48. The method of any one of clauses 45 to 47, wherein the lyophilized composition is stored in a 30 mL vial.

[0625] 49. A pharmaceutical product comprising:

[0626] A vial containing a lyophilized composition consisting of 4 mg of lupicardin; 22.1 mg of lactic acid; 5.1 mg of sodium hydroxide; and 800 mg of sucrose, or a lyophilized composition consisting of 800 mg of sucrose, 0.245 mmol of lactate, and 0.128 mmol of sodium;

[0627] A label affixed to the vial, the label including an expiration date of at least 24 months from the date of manufacture.

[0628] 50. The pharmaceutical product of Clause 49, wherein the label affixed to the vial includes an expiration date of at least 48 months from the date of manufacture.

[0629] 51. The pharmaceutical product of clause 49 or 50, wherein the vial is a 30 mL vial.

[0630] 52. The pharmaceutical product of any one of clauses 49 to 51, wherein the lyophilized composition comprises impurity D at a value of no greater than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% wt / wt of the total weight of lupicardin.

[0631] 53. The pharmaceutical product of any one of clauses 49 to 52, wherein the lyophilized composition does not comprise phosphate buffer.

[0632] 54. A method of treating a solid tumor, endometrial cancer, SCLC, soft tissue sarcoma, glioblastoma, pancreatic cancer, mesothelioma, colorectal cancer, or epithelial ovarian cancer in a patient in need thereof, the method comprising:

[0633] administering to the patient lubicatin and a topoisomerase inhibitor selected from SN-38 and irinotecan on day one of a treatment cycle;

[0634] wherein the amount of rubicatin is 1 to 2.5 mg / m 2 The dosage is administered, and

[0635] The topoisomerase inhibitor is administered in an amount equivalent to 50 to 75 mg irinotecan / m 2 dosage administration.

[0636] 55. The method of clause 54, wherein the amount of irinotecan is equivalent to 50 mg to 75 mg / m 2The dose of the topoisomerase inhibitor is administered on day 8 of the treatment cycle.

[0637] 56. The method of clause 54 or 55, wherein the treatment cycle is an 18, 19, 20, 21, 22, 23, 24 or 25 day cycle.

[0638] 57. The method of any one of clauses 54 to 56, wherein the lupicardin is administered at 2 mg / m 2 dosage administration.

[0639] 58. The method of any one of clauses 54 to 57, wherein the topoisomerase inhibitor is irinotecan and is administered at 75 mg / m 2 dosage administration.

[0640] 59. The method of any one of clauses 54 to 58, wherein the treatment cycle is 21 days.

[0641] 60. The method of any one of clauses 54 to 59, wherein the solid tumor is SCLC, endometrial carcinoma, soft tissue sarcoma, or glioblastoma.

[0642] 61. The method of any one of clauses 54 to 60, wherein G-CSF is administered to the patient to manage myelosuppressive effects of the treatment.

[0643] 62. The method of any one of clauses 54 to 61, wherein administration of said dose of irinotecan on day 8 of said treatment cycle is omitted if, following said administration on day 1, said patient experiences hematological toxicity.

[0644] 63. The method of any one of clauses 54 to 62, further comprising administering one or more antiemetics on the first day of the treatment cycle.

[0645] 64. A method as described in any of clauses 55 to 64, wherein the lubicartin is administered as an infusion formulation prepared by diluting a reconstituted lyophilized formulation of 4 mg lubicartin, 22.1 mg lactic acid or 0.245 mmol lactate, 5.1 mg sodium hydroxide or 0.128 mmol sodium and 800 mg sucrose, the formulation having a pH of 3.5 to 4.5 upon reconstitution.

[0646] 65. The method of clause 64, wherein the pH is 3.8 to 4.5.

[0647] 66. The method of any one of clauses 64 or 65, wherein the lyophilized composition is reconstituted in about 8 mL of an aqueous solution to obtain a reconstituted solution.

[0648] 67. The method of clause 66, wherein the lupicardin infusion solution is prepared by diluting the reconstituted solution with an isotonic solution.

[0649] 68. The method of any one of clauses 64 to 67, wherein the lupicardin infusion solution is prepared by diluting the reconstituted solution with at least 100 mL or at least 250 mL of the isotonic solution.

[0650] 69. The method of clause 68, wherein the isotonic solution is a 0.9% sodium chloride solution or a 5% glucose solution.

[0651] 70. The method of any one of clauses 64 to 69, wherein the lyophilized composition is provided in a 30 mL vial.

[0652] 71. The method of any one of clauses 64 to 70, wherein the lyophilized composition comprises impurity D at a value of no greater than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% wt / wt.

[0653] 72. The method of any one of clauses 64 to 71, wherein the reconstituted solution or the lupicardin infusion solution comprises impurity D at a value of no greater than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% wt / wt.

[0654] 73. A pharmaceutical composition prepared by:

[0655] An aqueous stock solution comprising lupicardin, an organic carboxylic acid, sodium hydroxide and sucrose is lyophilized to produce a lyophilized powder,

[0656] wherein the concentration of rubicatin in the aqueous stock solution is 0.5 mg / mL, wherein the ratio of rubicatin to sucrose is 1 mol rubicatin to 455 to 465 mol sucrose, and wherein the lyophilized powder is formulated such that reconstitution with 8 mL of water will produce a solution having a pH of 3.5 to 4.1; and

[0657] storing the lyophilized powder at 5°C ± 3°C for 30 to 60 months to produce the pharmaceutical composition,

[0658] wherein after storage, the amount of impurity D present in the composition does not exceed 0.8% wt. / wt. based on the total weight of Lupicadine.

[0659] 74. A method of administering a pharmaceutical composition comprising:

[0660] reconstitute the lyophilized pharmaceutical composition in a vial after storing the composition for 30 to 60 months,

[0661] The lyophilized pharmaceutical composition is prepared by lyophilizing a stock solution containing 4 mg of lupicardin, a buffer derived from an organic carboxylic acid and sucrose,

[0662] wherein the composition comprises lupicardin and a disaccharide in a ratio of 1 mol lupicardin:455 to 465 mol sucrose,

[0663] wherein the lyophilized composition is formulated such that reconstitution with 8 mL of water will produce a solution having a pH of 3.5 to 4.5; and

[0664] The reconstituted solution is administered to the patient.

[0665] 75. The method of clause 74, wherein the pharmaceutical composition comprises an amount of Lubicartin that is at least 95% of the amount of Lubicartin on the first day of storage.

[0666] 76. The method of clause 74 or 75, wherein the vial is a 30 mL vial.

[0667] 77. A method of treating SCLC in a patient in need thereof, comprising:

[0668] The patient was administered 2 to 3.2 mg / m by intravenous infusion. 2 dose of Rubicartin;

[0669] wherein an immunotherapeutic antibody for treating SCLC is administered to the patient prior to starting a treatment cycle, and

[0670] wherein the duration of response is at least 2 months, 3 months, 4 months, 5 months or 6 months, or wherein the overall response rate is at least 40%.

[0671] 78. The method of clause 77, wherein the immunotherapeutic antibody is an anti-CTLA-4 antibody, an anti-PD-1 antibody, or an anti-PD-L1 antibody.

[0672] 79. The method of clause 78, wherein the immunotherapeutic antibody is atezolizumab or nivolumab.

[0673] 80. The method of clause 79, wherein the immunotherapeutic antibody is administered to the patient simultaneously with a chemotherapeutic agent.

[0674] 81. The method of clause 80, wherein the chemotherapeutic agent is carboplatin or etoposide.

[0675] 82. The method of clause 81, wherein the immuno-oncogenic therapeutic antibody is atezolizumab and the chemotherapeutic agent is carboplatin or etoposide.

[0676] 83. The method of any one of clauses 69 to 74, wherein one dose of lupicardin is administered per treatment cycle and the treatment cycle is an 18, 19, 20, 21, 22, 23, 24 or 25 day cycle.

[0677] 84. The method of any one of clauses 77 to 83, wherein one dose of lupicardin is administered per treatment cycle and the patient undergoes at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23 or 24 treatment cycles.

[0678] 85. The method of any one of clauses 77 to 84, wherein the overall response rate is at least 40% or at least 50% or at least 60%.

[0679] 86. The method of any one of clauses 77 to 85, wherein the duration of response is at least 2 months, 3 months, 4 months, 5 months or 6 months.

[0680] 87. The method of any one of clauses 77 to 86, wherein the patient has not received the immuno-oncogenic therapeutic antibody within at least 30 days, or at least 60 days, or at least 90 days prior to administration of rubicatin.

[0681] 88. The method of any one of clauses 77 to 87, wherein the patient ceases to respond to the immuno-oncogenic therapy antibody prior to administration of rubicatin.

[0682] 89. The method of any one of clauses 77 to 87, wherein the immuno-oncogenic therapeutic antibody is not administered concurrently with rubicatin.

[0683] 90. A pharmaceutical composition comprising:

[0684] A lyophilized composition comprising 4 mg of lupicardin, a buffer derived from an organic acid and a disaccharide,

[0685] wherein the rubikatin and the disaccharide are present in a ratio of 1 mol of rubikatin to 455 to 465 mol of disaccharide,

[0686] wherein the lyophilized composition is formulated such that reconstitution with 8 mL of water will produce a solution having a pH of 3.5 to 4.5, and

[0687] The lyophilized composition further comprises degradation products resulting from the deacetylation of Lubicartin at a value of no greater than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% .wt. / wt based on the total weight of Lubicartin.

[0688] 91. The pharmaceutical composition of clause 90, wherein the lubicartin and the organic acid are present in a ratio of 1 mol lubicartin to 44 to 54 mol organic acid.

[0689] 92. A pharmaceutical composition as described in clause 90 or 91, wherein the vial is a 30 mL vial.

[0690] 93. The pharmaceutical composition of any one of clauses 90 to 92, wherein the lyophilized composition does not comprise phosphate buffer.

[0691] 94. A pharmaceutical composition as described in any of clauses 90 to 93, wherein the buffer derived from an organic acid is selected from lactate buffer, butyrate buffer, propionic acid buffer, acetate buffer, succinate buffer, citric acid buffer, ascorbic acid buffer, tartaric acid buffer, malic acid buffer, maleic acid buffer, fumaric acid buffer, glutamate buffer, aspartic acid buffer, gluconic acid buffer and α-ketoglutarate buffer.

[0692] 95. The pharmaceutical composition of any one of clauses 90 to 94, wherein the buffer derived from an organic acid is lactic acid.

[0693] 96. A pharmaceutical composition as described in any of clauses 90 to 95, wherein the composition comprises 22.1 mg lactic acid; 5.1 mg sodium hydroxide; and 800 mg sucrose, or wherein the composition comprises 800 mg of sucrose, 0.245 mmol lactate and 0.128 mmol sodium.

[0694] 97. A method for reducing the degradation of rubikatin in a lyophilized formulation comprising rubikatin, the method comprising adding a lactate buffer to a stock solution for preparing the lyophilized formulation, wherein the resulting ratio of rubikatin to lactate buffer is between 1 mol:44 mol and 1 mol:54 mol; wherein the rubikatin degradation products from deacetylation do not exceed 0.8% wt. / wt. of the total weight of rubikatin when stored at 5°C±3°C for at least 24 months, or at least 36 months, or at least 48 months, or at least 60 months.

[0695] 98. The method of clause 97, comprising adding sucrose to the stock solution from which the lyophilized formulation is prepared, wherein the resulting ratio of lupicardin to lactate buffer is between 1 mol:455 mol and 1 mol:465 mol;

[0696] 99. The method of clause 97, wherein the lyophilized formulation does not contain phosphate buffer.

[0697] 100. A method of treating small cell lung cancer (SCLC) in a patient in need thereof, comprising administering to the patient 2 to 3.2 mg / m by intravenous infusion every 3 weeks 2 A dose of rubicatin, wherein the rubicatin is provided as a lyophilized formulation comprising rubicatin, lactic acid and sucrose, wherein the ratio of rubicatin: lactic acid: sucrose is between 1 mol:46 mol:455 mol and 1 mol:50 mol:465 mol, wherein the formulation is stable at 5°C±3°C for at least 24 months, or at least 36 months, or at least 48 months, or at least 60 months, such that rubicatin degradation products from deacetylation do not exceed 0.8% wt. / wt. of the total weight of rubicatin.

[0698] 101. The method of clause 100, wherein the topoisomerase inhibitor is administered at a dose equivalent to 75 mg irinotecan / m 2 Lubicatin was administered at a dose of 2.0 mg / m 2 dosage administration.

[0699] 102. A packaged lyophilized composition comprising:

[0700] 4 mg of rubikatin, a buffer derived from an organic acid, and a disaccharide packaged in a vial.

[0701] wherein dissolving the lyophilized composition in about 8 mL of water provides a lupicadin solution having a pH of about 3.5 to about 4.1, and

[0702] wherein the lyophilized composition comprises less than about 0.3% of impurity D (w / w, based on rubikatin) when the composition is packaged, and wherein after storage at about 5°C for about 24 months, about 36 months, or about 48 months, the composition comprises no more than about 0.8% of impurity D (w / w, based on rubikatin).

[0703] 103. The composition of clause 102, wherein the composition comprises substantially the same amount of impurity D (w / w, based on rubikatin) when the composition is packaged and after the composition is stored at about 5°C for about 24 months, about 36 months, or about 48 months.

[0704] 104. The composition of any of clauses 102-103, wherein the buffer is a salt of an organic anion selected from the group consisting of acetate, succinate, citrate and lactate.

[0705] 105. The composition of clause 104, wherein the salt is lactate.

[0706] 106. The composition of any of clauses 102-105, wherein the disaccharide is selected from the group consisting of sucrose, trehalose, lactose, and combinations of two or all three thereof.

[0707] 107. The composition of Clause 106, wherein the disaccharide is sucrose.

[0708] 108. The composition of clause 107, wherein the w / w ratio of lupicardin to sucrose is about 1:200.

[0709] 109. A composition as described in any of clauses 102-108, wherein the composition comprises: 4 mg lupicadine, 22.1 mg lactic acid, 5.1 mg sodium hydroxide and 800 mg sucrose, or wherein the lyophilized composition comprises 800 mg of sucrose, 0.245 mmol lactate and 0.128 mmol sodium.

[0710] 110. The composition of any of clauses 102-109, wherein the dissolving in about 8 mL of water provides a Lupicadin solution having a pH of about 4.0.

[0711] 111. A packaged freeze-dried composition comprising:

[0712] 4 mg of rubikatin, a buffer derived from an organic acid, and a disaccharide packaged in a vial.

[0713] wherein dissolving the lyophilized composition in about 8 mL of water provides a lupicadin solution having a pH of about 3.8 to about 4.1, and

[0714] wherein the lyophilized composition comprises less than about 0.3% of impurity D (w / w, based on Lubicardin) when the composition is packaged, and wherein after the packaged composition is stored at about 25° C. and about 60% relative humidity for up to about 1, 2, 3, 6, 9 or 12 months, the composition comprises substantially the same amount of impurity D (w / w, based on Lubicardin).

[0715] 112. The composition of clause 111, wherein the composition comprises: 4 mg lupicadine, 22.1 mg lactic acid, 5.1 mg sodium hydroxide and 800 mg sucrose, or wherein the lyophilized composition comprises 800 mg sucrose, 0.245 mmol lactate and 0.128 mmol sodium.

[0716] 113. The composition of clause 111 or clause 112, wherein dissolution in about 8 mL of water provides a solution of Lupicadin having a pH of about 4.0.

[0717] 114. The composition of any one of clauses 102-113, wherein the composition is prepared by a method comprising:

[0718] (a) providing a solution of lupicardin and an organic acid;

[0719] (b) providing a solution of a base, an organic acid and a disaccharide;

[0720] (c) combining the solutions of step (a) and step (b);

[0721] (d) adjusting the pH of the solution of step (c) to about 3.8 to about 4.1; and

[0722] (e) lyophilizing the solution of step (d) to provide the lyophilized composition.

[0723] 115. The composition of clause 114, wherein the organic acid is selected from the group consisting of citric acid, succinic acid, lactic acid, and acetic acid.

[0724] 116. The composition of clause 114, wherein the organic acid is lactic acid.

[0725] 117. The composition of any of clauses 114-116 wherein the base is sodium hydroxide.

[0726] 118. The composition of any of clauses 114-117, wherein the disaccharide is selected from the group consisting of sucrose, trehalose, lactose, and combinations of two or all three thereof.

[0727] 119. The composition of any one of clauses 14-117, wherein the organic acid is lactic acid, the base is sodium hydroxide, and the disaccharide is sucrose.

[0728] 120. A method of treating small cell lung cancer (SCLC) in a patient in need thereof, comprising:

[0729] 1) dissolving a packaged lyophilized composition comprising 4 mg of Lupicardin, a buffer derived from an organic acid, and a disaccharide in about 8 mL of water to provide a Lupicardin solution having a pH of about 3.5 to about 4.1, and

[0730] 2) About 2 to 3.2 mg / m2 by intravenous infusion every 3 weeks to patients whose SCLC has progressed after prior platinum-containing therapy 2 Ruby Cardin, and

[0731] wherein upon packaging, the lyophilized composition comprises less than about 0.3% of impurity D (w / w, based on Lubicardin), and wherein after storage at about 5° C. for about 24 months, the composition comprises less than about 0.8% of impurity D (w / w, based on Lubicardin).

[0732] 121. The method of clause 120, wherein the administering comprises:

[0733] 1) dissolving a packaged lyophilized composition comprising 4 mg of Lupicardin, a buffer derived from an organic acid, and a disaccharide in about 8 mL of water to provide a Lupicardin solution having a pH of about 3.8 to about 4.1, and

[0734] 2) administering the rubicatin to the patient in need thereof,

[0735] wherein the lyophilized composition comprises less than about 0.3% of impurity D (w / w, based on rubikatin) when the composition is packaged, and wherein after storage at about 5°C for about 24 months, the composition comprises less than about 0.8% of impurity D (w / w, based on rubikatin).

[0736] 122. The method of clause 120 or 121, wherein prior to administration, the lyophilized composition is reconstituted in about 8 mL of an aqueous solution to obtain a reconstituted lupicardin solution.

[0737] 123. The method of clause 122, wherein prior to administration, the reconstituted lubicartin solution is stored at room temperature or at 5°C ± 3°C for up to 24 hours after reconstitution, wherein after storage, the reconstituted lubicartin solution comprises no more than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% wt / wt lubicartin impurity D.

[0738] 124. The method of clause 122 or 123, wherein the lupicardin infusion solution is prepared by diluting the reconstituted solution with an isotonic solution.

[0739] 125. The method of clause 124, wherein the lupicardin infusion solution is prepared by diluting the reconstituted solution with at least 100 mL or at least 250 mL of the isotonic solution.

[0740] 126. The method of clause 124 or 125, wherein the isotonic solution is a 0.9% sodium chloride solution or a 5% glucose solution.

[0741] 127. The method of any one of clauses 120 to 126, wherein the infusion lubicartin solution is stored at room temperature or at 5°C ± 3°C for up to 24 hours after reconstitution of the lyophilized lubicartin formulation, wherein after storage, the reconstituted lubicartin solution contains no more than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% wt / wt of impurity D based on the total weight of lubicartin.

[0742] 128. Use of rubicatin in the manufacture of a medicament for use in a therapy for treating small cell lung cancer (SCLC) in a patient in need thereof, wherein the medicament is administered by intravenous infusion at a dose of 2 to 3.2 mg / m 2 A dose of a corticosteroid and a serotonin antagonist effective to reduce nausea associated with administration of lumikatin to the patient is administered to the patient in combination with a prophylactic dose, wherein the prophylactic dose is administered on the day and prior to administration of lumikatin to the patient.

[0743] 129. The use of clause 128, wherein the corticosteroid is dexamethasone formulated for intravenous administration at a dose of 8 mg dexamethasone or at a dose of corticosteroid equivalent to 8 mg dexamethasone administered intravenously.

[0744] 130. The use of clause 128 or 129, wherein the serotonin antagonist is ondansetron formulated for intravenous administration at a dose of 8 mg ondansetron or at a dose of the serotonin antagonist equivalent to 8 mg ondansetron administered intravenously.

[0745] 131. The use of any one of clauses 128 to 130, wherein the medicament is administered in combination with one or more antiemetics administered within 2, 3 or 4 days after administration of lupicardin to the patient.

[0746] 132. The use of clause 131, wherein the one or more antiemetics administered after administration of lupicardin are selected from corticosteroids, serotonin antagonists and metoclopramide.

[0747] 133. The use of clause 132, wherein the one or more antiemetics is 4 mg dexamethasone, 8 mg ondansetron or 10 mg metoclopramide or a combination thereof.

[0748] 134. The use of any one of clauses 121 to 126, wherein the patient is not treated with doxorubicin in combination with the rubicatin.

[0749] 135. The use of any one of clauses 128 to 134, wherein the patient has progressed following prior platinum-containing therapy or prior immunotherapy.

[0750] 136. Use of rubicatin in the manufacture of a medicament for use in a therapy for treating small cell lung cancer (SCLC) in a patient in need thereof, wherein the medicament is administered by intravenous infusion at 3.2 mg / m in a first treatment cycle. 2 A first dose of 100 mg / kg is administered to the patient, and the same dose is administered in subsequent treatments unless an adverse reaction is identified in the patient,

[0751] The adverse reaction is selected from the group consisting of: grade 3 (severe) non-hematological toxicity, grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm 3 ), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm 3 ) with bleeding requiring transfusion, grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ) or any grade of neutropenia (neutrophil count <LLN);

[0752] After the adverse reaction is identified and the patient's neutrophil count is greater than 1500 cells / mm 3 ; Platelet count greater than about 100,000 mm 3 ; and after the hemoglobin level is greater than about 9 g / dL:

[0753] (i) If the identified adverse reaction consists of Grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ), then in said subsequent treatment cycle a dose of G-CSF is administered in combination with a dose of lupicardin equivalent to said first dose; or

[0754] (ii) if the identified adverse reaction is not isolated Grade 4 neutropenia, administering to the patient a dose of rubicatin that is reduced compared to the first dose,

[0755] The two doses of Lubicartin were administered at least 21 days apart.

[0756] 137. The use of clause 136, wherein after the first occurrence of said adverse reaction that is not isolated Grade 4 neutropenia, the first dose reduction is 80% to 85% of the first dose, or wherein after the first occurrence of said adverse reaction that is not isolated Grade 4 neutropenia, the first dose reduction is 2.6 mg / m 2 .

[0757] 138. The use of clause 137, wherein after a second occurrence of said adverse reaction that is not isolated Grade 4 neutropenia, the second reduced dose is 60-65% of the first dose, or wherein after a second occurrence of said adverse reaction that is not isolated Grade 4 neutropenia, the second reduced dose is 2.0 mg / m 2 , wherein said second reduced dose is administered to said patient.

[0758] 139. The use of clause 138, wherein administration of lupicatin is discontinued following identification of the adverse reaction following administration of the second reduced dose.

[0759] 140. The use as described in any of the preceding clauses, wherein the medicament is administered as an infusion formulation prepared by diluting a reconstituted lyophilized formulation of 4 mg lupicardin, 22.1 mg lactic acid or 0.245 mmol lactate, 5.1 mg sodium hydroxide or 0.128 mmol sodium and 800 mg sucrose, the formulation having a pH of 3.5 to 4.5 upon reconstitution.

[0760] 141. Use of rubicatin in the manufacture of a medicament for use in the treatment of small cell lung cancer (SCLC) in a patient in need thereof, wherein the medicament is administered by intravenous infusion of a rubicatin infusion solution at a dose of 3.2 mg / m 2 A dose of 500 mg / mL is administered to the patient, wherein the lupicardin infusion solution administered to the patient is prepared from a lyophilized composition comprising 4 mg of lupicardin, a buffer derived from an organic carboxylic acid, and a disaccharide, which is reconstituted to form a reconstituted solution with a pH of 3.5 to 4.5.

[0761] 142. The use of clause 141, wherein the disaccharide is sucrose and optionally wherein the composition comprises lupicardin and sucrose in a ratio of 1 mol lupicardin: 455 to 465 mol sucrose.

[0762] 143. The use of clause 141 or 142, wherein the organic carboxylic acid is lactic acid and optionally wherein the composition comprises lupicadin and lactic acid in a ratio of 1 mol lupicadin:44 to 54 mol lactic acid.

[0763] 144. The use of any one of clauses 141 to 143, wherein the pH is 3.8 to 4.5

[0764] 145. The use of any one of clauses 141 to 144, wherein the lyophilized composition is reconstituted in about 8 mL of aqueous solution to obtain the reconstituted solution.

[0765] 146. The use according to clause 145, wherein the lupicardin infusion solution is prepared by diluting the reconstituted solution with an isotonic solution.

[0766] 147. The use of any one of clauses 141 to 146, wherein the lupicardin infusion solution is prepared by diluting the reconstituted solution with at least 100 mL or at least 250 mL of the isotonic solution.

[0767] 148. The use according to clause 146, wherein the isotonic solution is a 0.9% sodium chloride solution or a 5% glucose solution.

[0768] 149. The use of any one of clauses 141 to 148, wherein the lyophilized composition comprises:

[0769] 22.1 mg of lactic acid;

[0770] 5.1 mg of sodium hydroxide; and

[0771] 800mg sucrose

[0772] Or wherein the lyophilized composition comprises 800 mg of sucrose, 0.245 mmol of lactate and 0.128 mmol of sodium.

[0773] 150. The use of any one of clauses 141 to 149, wherein the lyophilized composition is provided in a 30 mL vial.

[0774] 151. The use of any one of clauses 141 to 150, wherein the lyophilized composition comprises impurity D at a value of no greater than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% wt / wt based on the total weight of lupicardin.

[0775] 152. The use of any one of clauses 141 to 151 wherein the lyophilized composition does not comprise phosphate buffer.

[0776] 153. The use of any one of clauses 141 to 152, wherein the reconstituted solution or the lubicartin infusion solution comprises impurity D at a value of no greater than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% wt / wt based on the total weight of lubicartin.

[0777] 154. The use of any one of clauses 141 to 153, which is administered in combination with a prophylactic dose of a corticosteroid and a serotonin antagonist effective to reduce nausea associated with administration of lupicardin to the patient, wherein the prophylactic dose is administered on the day of and prior to administration of lupicardin to the patient.

[0778] 155. The use of clause 154, wherein the corticosteroid is dexamethasone formulated for intravenous administration at a dose of 8 mg dexamethasone or at a dose of a corticosteroid equivalent to 8 mg dexamethasone administered intravenously.

[0779] 156. The use of clause 154 or 155, wherein the serotonin antagonist is ondansetron formulated for intravenous administration at a dose of 8 mg ondansetron or at a dose of the serotonin antagonist equivalent to 8 mg ondansetron administered intravenously.

[0780] 157. The use of any one of clauses 154 to 156, wherein the medicament is administered in combination with one or more antiemetics administered within 2, 3 or 4 days after administration of lupicardin to the patient.

[0781] 158. The use of clause 157, wherein the one or more antiemetics are selected from corticosteroids, serotonin antagonists and metoclopramide.

[0782] 159. The use of clause 158, wherein the one or more antiemetics is 4 mg dexamethasone, 8 mg ondansetron or 10 mg metoclopramide or a combination thereof.

[0783] 160. The use of any preceding clause, wherein the drug is combined with G-CSF to identify a patient with less than 500 / mm 3 or any value below the normal range and associated with infection / sepsis.

[0784] 161. The use of any preceding clause, wherein one dose of lupicardin is administered per treatment cycle and the patient undergoes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23 or 24 treatment cycles.

[0785] 162. The use of any preceding clause, wherein for patients with a CTFI interval <90 days, the overall response rate is at least 11% or at least 20%, or wherein for patients with a CTFI interval >90 days, the overall response rate is at least 30% or at least 40%.

[0786] 163. The use of any preceding clause, wherein for patients with a CTFI interval <90 days, the duration of response is at least 2.5 months or at least 4.5 months, or wherein for patients with a CTFI interval >90 days, the duration of response is at least 3.5 months, 5 months or 6 months.

[0787] 164. The use of any preceding clause, wherein the patient has not received platinum-containing therapy within at least 30 days, or at least 60 days, or at least 90 days prior to administration of rubikatin.

[0788] 165. The use of any preceding clause, wherein the patient ceased to respond to platinum-containing therapy prior to administration of rubicatin.

[0789] 166. The use of any preceding clause, wherein the patient has previously been administered immunotherapy.

[0790] 167. The use according to clause 166, wherein the immunotherapy is an anti-CTLA-4 antibody, an anti-PD-1 antibody or an anti-PD-L1 antibody

[0791] 168. The use of clause 167, wherein the immunotherapy is atezolizumab or nivolumab.

[0792] 169. The use of any one of clauses 166 to 168, wherein the patient progresses following administration of the immunotherapy.

[0793] 170. The use of any preceding clause, wherein the patient has a calculated creatinine clearance greater than 30 mL / min and an AST or ALT less than 3 x ULN or a bilirubin less than 1.5 x ULN.

[0794] 171. The use of any preceding clause, wherein rubicatin is administered to the patient as a 1 hour intravenous infusion to achieve a total plasma C within 80% to 125% of about 107 μg / L. max and AUC∞ within 80% to 125% of approximately 551 μg*h / L.

[0795] 172. Use of rubicatin in the manufacture of a medicament for use in the treatment of endometrial cancer, SCLC, soft tissue sarcoma, glioblastoma, pancreatic cancer, mesothelioma, colorectal cancer or epithelial ovarian cancer in a patient in need thereof, wherein the medicament is administered by intravenous infusion on the first day of a treatment cycle at a dose of 1 to 2.5 mg / m 2 The patient is administered a dose of 50 to 75 mg irinotecan / m 2 dosage administration.

[0796] 173. The use of clause 172, wherein on day 1 of the treatment cycle, the lubicartine is administered intravenously at 2.0 mg / m 2 The irinotecan was administered at a dose of 75 mg / m 2 dosage administration.

[0797] 174. The use of clause 172 or 173, wherein 75 mg / m is administered on day 8 of the treatment cycle. 2 of subsequent doses of irinotecan.

[0798] 175. The use of any one of clauses 172 to 174, wherein the treatment cycle is 21 days.

[0799] 176. The use of any one of clauses 172 to 175, wherein the medicament is administered in combination with G-CSF during the treatment cycle.

[0800] 177. The use of any one of clauses 172 to 176, wherein if the patient experiences hematological toxicity following the dose on day 1, a subsequent dose of irinotecan is not administered to the patient during the treatment cycle.

[0801] 178. The use of any one of clauses 172 to 177, further comprising administering one or more antiemetics on the first day of the treatment cycle.

[0802] 179. The use of any one of clauses 172 to 178, wherein the patient is treating endometrial cancer, SCLC, soft tissue sarcoma or glioblastoma.

[0803] 180. Use of a lyophilized pharmaceutical composition for administering a pharmaceutical composition to a patient in need thereof, wherein the composition is reconstituted in a vial and administered to the patient after storage for 30 to 60 months,

[0804] The lyophilized pharmaceutical composition is prepared by lyophilizing a stock solution containing 4 mg of lupicardin, a buffer derived from an organic carboxylic acid and sucrose,

[0805] wherein the composition comprises lupicardin and a disaccharide in a ratio of 1 mol lupicardin: 455 to 465 mol sucrose,

[0806] wherein the lyophilized composition is formulated such that reconstitution with 8 mL of water will result in a solution having a pH of 3.5 to 4.5.

[0807] 181. The use of clause 180, wherein the pharmaceutical composition comprises an amount of Lubicartin that is at least 95% of the amount of Lubicartin on the first day of storage.

[0808] 182. The use of clause 180 or 181, wherein the vial is a 30 mL vial.

[0809] 183. Use of rubikatin in the manufacture of a medicament for treating SCLC in a patient in need thereof,

[0810] Lupicardin is administered by intravenous infusion at a dose of 2 to 3.2 mg / m 2 administering to the patient a dose of;

[0811] wherein an immunotherapeutic antibody for treating SCLC is administered to the patient prior to starting a treatment cycle, and

[0812] wherein the duration of response is at least 2 months, 3 months, 4 months, 5 months or 6 months, or wherein the overall response rate is at least 40%.

[0813] 184. The use of clause 183, wherein the immunotherapeutic antibody is an anti-CTLA-4 antibody, an anti-PD-1 antibody or an anti-PD-L1 antibody.

[0814] 185. The use of clause 184, wherein the immunotherapeutic antibody is atezolizumab or nivolumab.

[0815] 186. The use of clause 185, wherein the immunotherapeutic antibody is administered to the patient simultaneously with a chemotherapeutic agent.

[0816] 187. The use of clause 186, wherein the chemotherapeutic agent is carboplatin or etoposide.

[0817] 188. The use of clause 187, wherein the immuno-oncogenic therapeutic antibody is atezolizumab and the chemotherapeutic agent is carboplatin or etoposide.

[0818] 189. The use of any one of clauses 183 to 188, wherein one dose of lupicardin is administered per treatment cycle and the treatment cycle is an 18, 19, 20, 21, 22, 23, 24 or 25 day cycle.

[0819] 190. The use of any one of clauses 183 to 189, wherein one dose of lupicardin is administered per treatment cycle and the patient undergoes at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23 or 24 treatment cycles.

[0820] 191. The use of any one of clauses 183 to 190, wherein the patient is administered 5 doses of Lubicartin over a 17 week period or at least 6 doses of Lubicartin over a 20 week period or at least 7 doses of Lubicartin over a 22 week period.

[0821] 192. The use of any one of clauses 183 to 191, wherein the overall response rate is at least 40% or at least 50% or at least 60%.

[0822] 193. The use of any one of clauses 183 to 192, wherein the duration of response is at least 2 months, 3 months, 4 months, 5 months or 6 months.

[0823] 194. The use of any one of clauses 183 to 193, wherein the patient has not received the immuno-oncogenic therapeutic antibody within at least 30 days, or at least 60 days, or at least 90 days prior to administration of rubicatin.

[0824] 195. The use of any one of clauses 183 to 194, wherein the patient ceases to respond to the immuno-oncogenic therapy antibody prior to administration of rubicatin.

[0825] 196. The use of any one of clauses 183 to 195, wherein the immuno-oncogenic therapeutic antibody is not administered simultaneously with rubicatin.

[0826] 197. Use of rubicatin in the manufacture of a medicament for treating small cell lung cancer (SCLC) in a patient in need thereof, wherein the rubicatin is administered to the patient by intravenous infusion at a dose of 2 to 3.2 mg / m2 every 3 weeks, wherein the medicament is provided as a lyophilized formulation comprising rubicatin, lactic acid and sucrose, wherein the ratio of rubicatin: lactic acid: sucrose is between 1 mol:46 mol:455 mol and 1 mol:50 mol:465 mol, wherein the formulation is stable at 5°C±3°C for at least 24 months, or at least 36 months, or at least 48 months, or at least 60 months, such that rubicatin degradation products from deacetylation do not exceed 0.8% wt. / wt. of the total weight of rubicatin.

[0827] 198. The use according to clause 197, wherein the drug is administered at a dose equivalent to 75 mg irinotecan / m 2 The topoisomerase inhibitor was used in combination with rubicatin at a dose of 2.0 mg / m 2 dosage administration.

[0828] 199. Use of rubikatin for the manufacture of a medicament for treating small cell lung cancer (SCLC) in a patient in need thereof, wherein the medicament is a packaged lyophilized composition comprising 4 mg of rubikatin, a buffer derived from an organic carboxylic acid, and a disaccharide, and dissolved in about 8 mL of water to provide a rubikatin solution having a pH of about 3.5 to about 4.1,

[0829] About 2 to 3.2 mg / m2 is administered by intravenous infusion every 3 weeks to patients whose SCLC has progressed after prior platinum-containing therapy. 2 Ruby Cardin, and

[0830] wherein the lyophilized composition comprises less than about 0.3% of impurity D (w / w, based on rubikatin) when the composition is packaged, and wherein after storage at about 5°C for about 24 months or about 36 months, the composition comprises less than about 0.8% of impurity D (w / w, based on rubikatin).

[0831] 200. The use of any one of clauses 128-199, wherein the medicament is a packaged lyophilized composition comprising 4 mg of lupicardin, a buffer derived from an organic carboxylic acid, and a disaccharide, and dissolved in about 8 mL of water to provide a lupicardin solution having a pH of about 3.8 to about 4.1 for administration to the patient in need thereof,

[0832] wherein the lyophilized composition comprises less than about 0.3% of impurity D (w / w, based on rubikatin) when the composition is packaged, and wherein after storage at about 5°C for about 24 months or about 36 months, the composition comprises less than about 0.8% of impurity D (w / w, based on rubikatin).

[0833] 201. The use of any of the preceding clauses, wherein prior to administration, the lyophilized composition is reconstituted in about 8 mL of an aqueous solution to obtain a reconstituted lupicardin solution.

[0834] 202. The use according to clause 201, wherein the reconstituted lubicartin solution is stored at room temperature or at 5°C ± 3°C for up to 24 hours after reconstitution prior to administration, wherein after storage, the reconstituted lubicartin solution contains no more than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% wt / wt of impurity D based on the total weight of lubicartin.

[0835] 203. The use of clause 201 or 202, wherein the lupicardin infusion solution is prepared by diluting the reconstituted solution with an isotonic solution.

[0836] 204. The use of clause 203, wherein the lupicardin infusion solution is prepared by diluting the reconstituted solution with at least 100 mL or at least 250 mL of the isotonic solution.

[0837] 205. The use of clause 203 or 204, wherein the isotonic solution is a 0.9% sodium chloride solution or a 5% glucose solution.

[0838] 206. The use of any one of clauses 203 to 205, wherein the infusion rubikatin solution is stored at room temperature or at 5°C±3°C for up to 24 hours after reconstitution of the lyophilized rubikatin formulation, wherein after storage, the reconstituted rubikatin solution contains no more than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% wt / wt of impurity D based on the total weight of rubikatin.

[0839] 207. A composition for treating small cell lung cancer (SCLC) in a patient in need thereof, comprising:

[0840] (1) administering a prophylactic dose of a corticosteroid and a serotonin antagonist effective to reduce nausea associated with administration of lupicardin to said patient on and before the day of administration of lupicardin to said patient; and

[0841] (2) Administer 2 to 3.2 mg / m 2 Dose of Rubicartin.

[0842] 208. The composition of clause 207, wherein the corticosteroid is dexamethasone administered intravenously at a dose of 8 mg dexamethasone or at a dose of corticosteroid equivalent to 8 mg dexamethasone administered intravenously.

[0843] 209. The composition of clause 207 or 208, wherein the serotonin antagonist is ondansetron administered intravenously at a dose of 8 mg or at a dose of the serotonin antagonist equivalent to 8 mg ondansetron administered intravenously.

[0844] 210. The composition of any one of clauses 207 to 209, further comprising administering one or more antiemetics within 2, 3 or 4 days after administering lupicardin to the patient.

[0845] 211. The composition of clause 210, wherein the one or more antiemetics administered after administration of lupicardin are selected from corticosteroids, serotonin antagonists, and metoclopramide.

[0846] 212. The composition of clause 211, wherein the one or more antiemetics is 4 mg dexamethasone, 8 mg ondansetron or 10 mg metoclopramide or a combination thereof.

[0847] 213. The composition of any of clauses 207-212, wherein the patient has progressed following prior platinum-containing therapy or prior immunotherapy.

[0848] 214. A composition for treating small cell lung cancer (SCLC) in a patient in need thereof, comprising:

[0849] (1) Administer 3.2 mg / m 2 first dose of Lubicardin; and

[0850] (2) Identify adverse reactions in the patient, wherein the adverse reactions are selected from the group consisting of: ≥ Grade 3 (severe) non-hematological toxicity, Grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm 3 ), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm 3 ) with bleeding requiring transfusion, grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ) or any grade of neutropenia (neutrophil count <LLN);

[0851] (3) After the adverse reaction is identified and the patient's neutrophil count is greater than 1500 cells / mm 3 ; Platelet count greater than about 100,000 mm 3 ; and after the hemoglobin level is greater than about 9 g / dL:

[0852] (i) If the identified adverse reaction consists of Grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ), administering to the patient a dose of G-CSF and a dose of lupicardin equivalent to the first dose; or

[0853] (ii) if the identified adverse reaction is more than Grade 4 neutropenia, administering to the patient a dose of rubicatin that is reduced compared to the first dose,

[0854] The two doses of Lubicartin were administered at least 21 days apart.

[0855] 215. The composition of clause 214, wherein after the first occurrence of said adverse reaction that is more than Grade 4 neutropenia, the first reduced dose is 80% to 85% of the first dose, or wherein after the first occurrence of said adverse reaction that is more than Grade 4 neutropenia, the first reduced dose is 2.6 mg / m 2 .

[0856] 216. The composition of clause 215, wherein after a second occurrence of said adverse reaction that is more than Grade 4 neutropenia, the second reduced dose is 60-65% of the first dose, or wherein after a second occurrence of said adverse reaction that is more than Grade 4 neutropenia, the second reduced dose is 2.0 mg / m 2 , wherein said second reduced dose is administered to said patient.

[0857] 217. The composition of clause 216, further comprising discontinuing administration of lupicatin following identification of the adverse reaction following administration of the second reduced dose.

[0858] 218. A composition as described in any of the preceding clauses, wherein the lubicartin is administered as an infusion formulation prepared by diluting a reconstituted lyophilized formulation of 4 mg lubicartin, 22.1 mg lactic acid, 5.1 mg sodium hydroxide and 800 mg sucrose, the formulation having a pH of 3.5 to 4.5 upon reconstitution.

[0859] 219. A composition for treating small cell lung cancer (SCLC) in a patient in need thereof, comprising:

[0860] Lupicardin infusion solution was administered by intravenous infusion at 3.2 mg / m 2 The invention relates to administering Lupicardin to the patient in a dose of 500 mg / mL, wherein the Lupicardin infusion solution administered to the patient is prepared from a lyophilized composition comprising 4 mg of Lupicardin, a buffer derived from an organic carboxylic acid, and a disaccharide, which is reconstituted to form a reconstituted solution having a pH of 3.5 to 4.5.

[0861] 220. The composition of clause 219, wherein the disaccharide is sucrose and optionally wherein the composition comprises rubicartin and sucrose in a ratio of 1 mol rubicartin: 455 to 465 mol sucrose.

[0862] 221. The composition of clause 219 or 220, wherein the organic carboxylic acid is lactic acid and optionally wherein the composition comprises lupicadine and lactic acid in a ratio of 1 mol lupicadine:44 to 54 mol lactic acid.

[0863] 222. A composition as described in any one of clauses 219 to 221, wherein the pH is 3.8 to 4.5

[0864] 223. The composition of any one of clauses 219 to 222, wherein the lyophilized composition is reconstituted in about 8 mL of aqueous solution to obtain the reconstituted solution.

[0865] 224. The composition of clause 223, wherein the lupicardin infusion solution is prepared by diluting the reconstituted solution with an isotonic solution.

[0866] 225. The composition of any one of clauses 219 to 224, wherein the lupicardin infusion solution is prepared by diluting the reconstituted solution with at least 100 mL or at least 250 mL of the isotonic solution.

[0867] 226. The composition of clause 225, wherein the isotonic solution is a 0.9% sodium chloride solution or a 5% glucose solution.

[0868] 227. The composition of any one of clauses 219 to 226, wherein the lyophilized composition comprises:

[0869] 22.1 mg of lactic acid;

[0870] 5.1 mg of sodium hydroxide; and

[0871] 800mg of sucrose.

[0872] 228. The composition of any one of clauses 219 to 227, wherein the lyophilized composition is provided in a 30 mL vial.

[0873] 229. The composition of any one of clauses 219 to 228, wherein the lyophilized composition comprises impurity D at a value of no greater than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% wt / wt based on the total weight of lupicardin.

[0874] 230. The composition of any one of clauses 219 to 229, wherein the lyophilized composition does not comprise phosphate buffer.

[0875] 231. A composition as described in any of clauses 219 to 231, wherein the reconstituted solution or the lubicartin infusion solution comprises impurity D at a value of no greater than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% wt / wt based on the total weight of lubicartin.

[0876] 232. The composition of any one of clauses 219 to 231, further comprising administering a prophylactic dose of a corticosteroid and a serotonin antagonist effective to reduce nausea associated with administering Lupicardin to the patient on and before the day of administering Lupicardin to the patient.

[0877] 233. The composition of clause 232, wherein the corticosteroid is dexamethasone administered intravenously at a dose of 8 mg dexamethasone or at a dose of corticosteroid equivalent to 8 mg dexamethasone administered intravenously.

[0878] 234. The composition of clause 232 or 233, wherein the serotonin antagonist is ondansetron administered intravenously at a dose of 8 mg or at a dose of the serotonin antagonist equivalent to 8 mg ondansetron administered intravenously.

[0879] 235. The composition of any one of clauses 232 to 234, further comprising administering one or more antiemetics within 2, 3 or 4 days after administering lupicardin to the patient.

[0880] 236. The composition of clause 235, wherein the one or more antiemetics are selected from corticosteroids, serotonin antagonists, and metoclopramide.

[0881] 237. The composition of clause 236, wherein the one or more antiemetics is 4 mg dexamethasone, 8 mg ondansetron or 10 mg metoclopramide or a combination thereof.

[0882] 238. A composition as described in any of the preceding clauses, further comprising a 3 G-CSF is administered to patients with neutrophil counts above or below the normal range and associated with infection / sepsis.

[0883] 239. The composition of any preceding clause, wherein one dose of lupicardin is administered per treatment cycle and the patient undergoes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23 or 24 treatment cycles.

[0884] 240. A composition as described in any of the preceding clauses, wherein for patients with a CTFI interval <90 days, the overall response rate is at least 11% or at least 20%, or wherein for patients with a CTFI interval >90 days, the overall response rate is at least 30% or at least 40%.

[0885] 241. A composition as described in any of the preceding clauses, wherein for patients with a CTFI interval <90 days, the duration of response is at least 2.5 months or at least 4.5 months, or wherein for patients with a CTFI interval >90 days, the duration of response is at least 3.5 months, 5 months or 6 months.

[0886] 242. The composition of any preceding clause, wherein the patient has not received platinum-containing therapy within at least 30 days, or at least 60 days, or at least 90 days prior to administration of lupicardin.

[0887] 243. The composition of any preceding clause, wherein the patient ceased to respond to platinum-containing therapy prior to administration of rubicatin.

[0888] 244. A composition as described in any preceding clause, wherein the patient has previously been administered immunotherapy.

[0889] 245. The composition of clause 244, wherein the immunotherapy is an anti-CTLA-4 antibody, an anti-PD-1 antibody, or an anti-PD-L1 antibody

[0890] 246. The composition of clause 245, wherein the immunotherapy is atezolizumab or nivolumab.

[0891] 247. The composition of any one of clauses 244 to 246, wherein the patient progresses following administration of the immunotherapy.

[0892] 248. The composition of any preceding clause, wherein the patient has a calculated creatinine clearance greater than 30 mL / min and an AST or ALT less than 3 x ULN or a bilirubin less than 1.5 x ULN.

[0893] 249. A composition as described in any preceding clause, wherein rubicatin is administered to the patient as a 1 hour intravenous infusion to achieve a total plasma C within 80% to 125% of about 107 μg / L. max and AUC∞ within 80% to 125% of approximately 551 μg*h / L.

[0894] 250. A method for treating a solid tumor, endometrial cancer, SCLC, soft tissue sarcoma, glioblastoma, pancreatic cancer, mesothelioma, colorectal cancer, or epithelial ovarian cancer in a patient in need thereof, the treatment comprising:

[0895] administering to the patient lubicatin and a topoisomerase inhibitor selected from SN-38 and irinotecan on day one of a treatment cycle;

[0896] wherein the amount of rubicatin is 1 to 2.5 mg / m 2 The dosage is administered, and

[0897] The topoisomerase inhibitor is administered in an amount equivalent to 50 to 75 mg irinotecan / m 2 dosage administration.

[0898] 251. The composition of clause 250, wherein on day 1 of the treatment cycle, the lupicardin is administered intravenously at 2.0 mg / m 2 The irinotecan was administered at a dose of 75 mg / m 2 dosage administration.

[0899] 252. A composition as described in clause 250 or 251, wherein 75 mg / m is administered on day 8 of the treatment cycle. 2 of subsequent doses of irinotecan.

[0900] 253. The composition of any one of clauses 250 to 252, wherein the treatment cycle is 21 days.

[0901] 254. The composition of any one of clauses 250 to 254, wherein the drug is administered in combination with G-CSF during the treatment cycle.

[0902] 255. The composition of any one of clauses 250 to 254, wherein if the patient experiences hematological toxicity following the dose on day 1, a subsequent dose of irinotecan is not administered to the patient during the treatment cycle.

[0903] 256. The composition of any one of clauses 250 to 255, further comprising administering one or more antiemetics on the first day of the treatment cycle.

[0904] 257. The composition of any one of clauses 250 to 256, wherein the patient is treated for endometrial cancer, SCLC, soft tissue sarcoma or glioblastoma.

[0905] 258. A composition for treating SCLC in a patient in need thereof, comprising:

[0906] The patient was administered 2 to 3.2 mg / m by intravenous infusion. 2 dose of Rubicartin;

[0907] wherein an immunotherapeutic antibody for treating SCLC is administered to the patient prior to starting a treatment cycle, and

[0908] wherein the duration of response is at least 2 months, 3 months, 4 months, 5 months or 6 months, or wherein the overall response rate is at least 40%.

[0909] 259. The composition of clause 258, wherein the immunotherapeutic antibody is an anti-CTLA-4 antibody, an anti-PD-1 antibody, or an anti-PD-L1 antibody.

[0910] 260. The composition of clause 259, wherein the immunotherapeutic antibody is atezolizumab or nivolumab.

[0911] 261. The composition of clause 260, wherein the immunotherapeutic antibody is administered to the patient simultaneously with a chemotherapeutic agent.

[0912] 262. The composition of clause 261, wherein the chemotherapeutic agent is carboplatin or etoposide.

[0913] 263. The composition of clause 262, wherein the immuno-oncogenic therapeutic antibody is atezolizumab and the chemotherapeutic agent is carboplatin or etoposide.

[0914] 264. The composition of any one of clauses 258 to 263, wherein one dose of lupicardin is administered per treatment cycle and the treatment cycle is an 18, 19, 20, 21, 22, 23, 24 or 25 day cycle.

[0915] 265. The composition of any one of clauses 258 to 264, wherein one dose of lupicatin is administered per treatment cycle and the patient undergoes at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23 or 24 treatment cycles.

[0916] 266. The composition of any one of clauses 258 to 264, wherein the overall response rate is at least 40% or at least 50% or at least 60%.

[0917] 267. The composition of any one of clauses 258 to 264, wherein the duration of response is at least 2 months, 3 months, 4 months, 5 months or 6 months.

[0918] 268. The composition of any one of clauses 258 to 264, wherein the patient has not received the immuno-oncogenic therapeutic antibody within at least 30 days, or at least 60 days, or at least 90 days prior to administration of rubicatin.

[0919] 269. The composition of any one of clauses 258 to 264, wherein the patient ceased to respond to the immuno-oncogenic therapy antibody prior to administration of rubicatin.

[0920] 270. The composition of any one of clauses 258 to 269, wherein the immuno-oncogenic therapeutic antibody is not administered concurrently with rubicatin.

[0921] 271. A composition for treating small cell lung cancer (SCLC) in a patient in need thereof, comprising administering to the patient a dose of 2 to 3.2 mg / m2 of rubikatin by intravenous infusion every 3 weeks, wherein the rubikatin is provided as a lyophilized formulation comprising rubikatin, a buffer derived from lactic acid, and sucrose, wherein the ratio of rubikatin: lactic acid: sucrose is between 1 mol:46 mol:455 mol and 1 mol:50 mol:465 mol, wherein the formulation is stable at 5°C±3°C for at least 24 months, or at least 36 months, or at least 48 months, or at least 60 months, such that rubikatin degradation products from deacetylation do not exceed 0.8% wt. / wt. of the total weight of rubikatin.

[0922] 272. A composition for treating small cell lung cancer (SCLC) in a patient in need thereof, comprising:

[0923] 1) dissolving a packaged lyophilized composition comprising 4 mg of Lupicardin, a buffer derived from an organic acid, and a disaccharide in about 8 mL of water to provide a Lupicardin solution having a pH of about 3.5 to about 4.1, and

[0924] 2) About 2 to 3.2 mg / m2 by intravenous infusion every 3 weeks to patients whose SCLC has progressed after prior platinum-containing therapy 2 Ruby Cardin, and

[0925] wherein the lyophilized composition comprises less than about 0.3% of impurity D (w / w, based on rubikatin) when the composition is packaged, and wherein after storage at about 5°C for about 24 months, the composition comprises less than about 0.8% of impurity D (w / w, based on rubikatin).

[0926] 273. The method, composition or use of any one of clauses 1-45, 54-72, 74-89, 100-101 and 120-272, 93-94 and 113-120, wherein the patient is an adult patient.

[0927] 274. The method, composition or use of any one of clauses 1-45, 54-72, 74-89, 100-101 and 120-273, wherein the cancer is metastatic SCLC.

[0928] 275. The method, composition or use of any one of clauses 1-45, 54-72, 74-89, 100-101 and 120-274, wherein the cancer is metastatic SCLC with disease progression following platinum-based chemotherapy.

[0929] 276. A method of reducing adverse events associated with administration of rubicatin for treating cancer in a patient in need thereof, the method comprising:

[0930] The patient was administered Lupicardin at a dose of 3.2 mg / m2 by intravenous infusion;

[0931] determining whether the patient experiences an adverse event selected from the group consisting of neutropenia, thrombocytopenia, and hepatotoxicity; and

[0932] If the patient experiences neutropenia, thrombocytopenia, or hepatotoxicity, the dose is modified.

[0933] Wherein when there is no dose modification (ie, normal administration schedule), the 3.2 mg / m2 dose of lupicardin is administered every 21 days.

[0934] 277. The method of clause 276, wherein prior to said administering, said patient has an absolute neutrophil count (ANC) of at least 1500 cells / mm 3 , and a platelet count of at least 100,000 / mm 3 .

[0935] 278. The method of any of clauses 276-277, wherein the dose is modified by delaying administration of the lupicardin compared to the normal administration schedule.

[0936] 279. The method of any one of clauses 276 to 278, wherein the dosage is modified by reducing the amount of lupicadin administered compared to the normal administration schedule.

[0937] 280. The method of clause 279, wherein the dose modification comprises administering 2.6 mg / m every 21 days. 2 Dose of Rubicartin.

[0938] 281. The method of clause 279, wherein the dose modification comprises administering 2.0 mg / m every 21 days. 2 Dose of Rubicartin.

[0939] 282. The method of any of clauses 276-277, wherein when the patient experiences Grade 4 neutropenia or febrile neutropenia of any grade; the dose is modified by withholding rubicatin treatment until the patient's neutropenia is ≤ Grade 1, and when the patient's neutropenia is ≤ Grade 1, 2.6 mg / m2 is administered every 21 days. 2 Dosage of Rubiconazole.

[0940] 283. The method of any one of clauses 276-277, wherein when the patient experiences isolated grade 4 neutropenia neutropenia (neutrophil count less than 500 cells / mm 3 ); modify the dose by withholding rubicatin treatment until the patient's neutropenia is ≤ Grade 1, and when the patient's neutropenia is ≤ Grade 1, administer 3.2 mg / m every 21 days 2 doses of rubikatin and G-CSF prophylaxis.

[0941] 284. The method of any one of clauses 276-277, wherein when the patient experiences grade 3 thrombocytopenia with bleeding or grade 4 thrombocytopenia; the dose is modified by withholding rubicatin treatment until the patient's platelet count is at least 100,000 / mm 3, and when the patient's platelet count is at least 100,000 / mm 3 2.6 mg / m2 every 21 days 2 Dose of Rubicartin.

[0942] 285. The method of any of clauses 276-277, wherein when the patient experiences grade 2 hepatotoxicity, the dose is modified by withholding rubicatin treatment until the patient's hepatotoxicity is ≤ grade 1, and when the hepatotoxicity is ≤ grade 1, 3.2 mg / m2 is administered every 21 days. 2 Dose of Rubicartin.

[0943] 286. The method of any of clauses 276-277, wherein when the patient experiences ≥ Grade 3 hepatotoxicity, the dose is modified by withholding rubicatin treatment until the patient's hepatotoxicity is ≤ Grade 1, and when the hepatotoxicity is ≤ Grade 1, 2.6 mg / m2 is administered every 21 days. 2 Dose of Rubicartin.

[0944] 287. The method of any of clauses 282-286, further comprising:

[0945] determining whether the patient experiences an adverse event selected from the group consisting of neutropenia, thrombocytopenia, and hepatotoxicity at the modified dose; and

[0946] The dose was further modified if the patient experienced neutropenia, thrombocytopenia, or hepatotoxicity.

[0947] 288. The method of clause 287, wherein when the patient experiences Grade 4 neutropenia or febrile neutropenia of any grade at the modified dose; the dose is further modified by withholding rubicatin treatment until the patient's neutropenia is ≤ Grade 1, and when the patient's neutropenia is ≤ Grade 1, 2.0 mg / m2 is administered every 21 days. 2 Dose of Rubicartin.

[0948] 289. The method of clause 287, wherein when the patient experiences grade 3 thrombocytopenia with bleeding or grade 4 thrombocytopenia at the modified dose; the dose is further modified by suspending rubicatin treatment until the patient's platelet count is at least 100,000 / mm 3 , and when the patient's platelet count is at least 100,000 / mm 3 2.0 mg / m2 every 21 days 2 Dose of Rubicartin.

[0949] 290. The method of clause 287, wherein when the patient experiences grade 2 hepatotoxicity at the modified dose, the dose is further modified by withholding rubicatin treatment until the patient's hepatotoxicity is ≤ grade 1, and when the hepatotoxicity is ≤ grade 1, 3.2 mg / m2 is administered every 21 days. 2 Dose of Rubicartin.

[0950] 291. The method of clause 287, wherein when the patient experiences ≥ Grade 3 hepatotoxicity at the modified dose, the dose is further modified by withholding lupicardin treatment until the patient's hepatotoxicity is ≤ Grade 1, and when the hepatotoxicity is ≤ Grade 1, 2.0 mg / m2 is administered every 21 days. 2 Dose of Rubicartin.

[0951] 292. The method of any one of clauses 277-291, wherein the administration is permanently discontinued when the suspension of lubicartin treatment is greater than two weeks.

[0952] 292a. The method of any one of clauses 282, 283 and 288, wherein the administration is permanently discontinued when the suspending of rubicatin treatment to achieve ≤ Grade 1 neutropenia exceeds two weeks.

[0953] 292b. The method of any one of clauses 284 and 289, wherein when the suspending rubicatin treatment to achieve at least 100000 / mm 3 If the platelet count exceeds 2.5 for more than two weeks, the administration is permanently discontinued.

[0954] 292c. The method of any one of clauses 285, 286, 290 and 291, wherein the administration is permanently discontinued when the suspending of lupicardin treatment to achieve ≤ Grade 1 hepatotoxicity exceeds two weeks.

[0955] 293. The method of any one of clauses 277-291, wherein if the patient cannot tolerate 2 mg / m 2 If the dose is too low, the administration is permanently discontinued.

[0956] 294. The method of any one of clauses 277-293, wherein the cancer is metastatic SCLC with disease progression following platinum-based chemotherapy.

[0957] 295. A method of safely administering rubicatin for treating cancer in a patient in need thereof, the method comprising:

[0958] determining whether the patient is taking a CYP3A inhibitor; and

[0959] When the patient is taking a moderate or strong CYP3A inhibitor, warn of the potential for drug / drug interactions due to the combination of the CYP3A inhibitor and lupicatin; and

[0960] When co-administration of a moderate CYP3A inhibitor and lupicardin cannot be avoided, administer a modified dose of lupicardin compared to the normal dosing schedule.

[0961] 296. The method of clause 295, wherein the warning is to avoid co-administration of the strong or moderate CYP3A inhibitor and lupicardin.

[0962] 297. The method of clause 295, wherein the patient is co-administered a moderate CYP3A inhibitor and 2.6 mg / m 2 Dose of Rubicartin.

[0963] 298. The method of clause 295, wherein the patient is co-administered with a moderate CYP3A inhibitor and 2.0 mg / m 2 Dose of Rubicartin.

[0964] 299. A lyophilized composition comprising:

[0965] 4 mg of rubikatin, a buffer and a disaccharide derived from an organic acid, and

[0966] wherein the lyophilized composition comprises less than about 0.8% impurity D (w / w, based on rubikatin) when the composition is stored at about 25°C and about 60% relative humidity for up to about 1, 2, 3, 6, 9 or 12 months.

[0967] 300. The lyophilized composition of clause 299, wherein the lyophilized composition comprises less than about 0.5% impurity D (w / w, based on rubikatin) when the composition is stored at about 25°C and about 60% relative humidity for up to about 1, 2, 3, 6, 9 or 12 months.

[0968] 301. The lyophilized composition of clause 299, wherein the lyophilized composition comprises less than about 0.3% impurity D (w / w, based on rubikatin) when the composition is stored at about 25°C and about 60% relative humidity for up to about 1, 2, 3, 6, 9 or 12 months.

[0969] 302. The lyophilized composition of clause 299, wherein the lyophilized composition comprises less than about 0.1% impurity D (w / w, based on rubikatin) when the composition is stored at about 25°C and about 60% relative humidity for up to about 1, 2, 3, 6, 9 or 12 months.

[0970] 303. The lyophilized composition of any of clauses 299-302, wherein the organic acid is selected from the group consisting of citric acid, succinic acid, lactic acid, and acetic acid.

[0971] 304. The lyophilized composition of clause 303, wherein the organic acid is lactic acid.

[0972] 305. The lyophilized composition of any one of clauses 299-304, wherein the disaccharide is selected from the group consisting of sucrose, trehalose, lactose, and combinations of two or all three thereof.

[0973] 306. The lyophilized composition of any one of clauses 299-305, wherein the organic acid is lactic acid and the disaccharide is sucrose.

[0974] 307. The lyophilized composition of any of clauses 299-306, wherein the composition comprises: 4 mg lupicadine, 22.1 mg lactic acid, 5.1 mg sodium hydroxide and 800 mg sucrose, or wherein the lyophilized composition comprises 800 mg sucrose, 0.245 mmol lactate and 0.128 mmol sodium.

[0975] 308. The lyophilized composition of any one of clauses 299-307, wherein dissolving the lyophilized composition in about 8 mL of water provides a rubicatin solution having a pH of about 3.8 to about 4.1

[0976] 309. The lyophilized composition of any of clauses 299-307, wherein dissolution in about 8 mL of water provides a rubikatin solution having a pH of about 4.0.

[0977] 310. The lyophilized composition of any of clauses 299-307, wherein dissolution in about 8 mL of water provides a solution of Lupicardin comprising 0.47-0.5 mg / mL and having a pH of about 3.5-4.5.

[0978] 311. The lyophilized composition of any of clauses 299-310, wherein the lyophilized composition is packaged in a vial.

[0979] 311a. The lyophilized composition of any of clauses 299-311, wherein the lyophilized composition is packaged in a 30 mL vial.

[0980] 312. A Rubikatin of Formula (I) Form B:

[0981]

[0982] It exhibits an X-ray powder diffraction pattern including four or more peaks at 2-θ angles selected from the group consisting of 6.2±0.2°, 7.6±0.2°, 9.0±0.2°, 10.9±0.2°, 14.9±0.2°, and 15.3±0.2°.

[0983] 313. Rubikatin as described in clause 312, wherein the X-ray powder diffraction pattern comprises five or more peaks at 2-θ angles selected from the group consisting of: 6.2±0.2°, 7.6±0.2°, 9.0±0.2°, 10.9±0.2°, 14.9±0.2° and 15.3±0.2°.

[0984] 314. Rubikatin as described in clause 312, wherein the X-ray powder diffraction pattern includes peaks at the following 2-θ angles: 6.2±0.2°, 7.6±0.2°, 9.0±0.2°, 10.9±0.2°, 14.9±0.2° and 15.3±0.2°.

[0985] 315. Rubikatin as described in any of clauses 312 to 314, further comprising peaks at the following 2-theta angles: 12.4±0.2°, 19.2±0.2°, and 26.5±0.2°.

[0986] 316. Rubikatin as described in any of clauses 312 to 315, further comprising peaks at the following 2-theta angles: 18.4±0.2°, 20.7±0.2°, and 24.9±0.2°.

[0987] 317. Rubikatin as described in clause 312, further comprising the following peaks and relative intensities:

[0988] Angle [2-θ] Relative strength [%] 6.2±0.2° 79±6 7.6±0.2° 100±3 9.0±0.2° 63±3 10.9±0.2° 100±3 14.9±0.2° 76±3 15.3±0.2° 75±3

[0989] 318. Rubikatin as described in clause 312, further comprising the following peaks and relative intensities:

[0990]

[0991]

[0992] 319. Rubikatin as described in clause 312, further comprising the following peaks and relative intensities:

[0993] Angle [2-θ] Relative strength [%] Angle [2-θ] Relative strength [%] 6.2±0.2° 79±6 15.3±0.2° 75±3 7.6±0.2° 100±3 18.4±0.2° 29±3 9.0±0.2° 63±3 19.2±0.2° 34±3 10.9±0.2° 100±3 20.7±0.2° 32±3 12.4±0.2° 40±3 24.9±0.2° 26±3 14.9±0.2° 76±3 26.5±0.2° 33±3

[0994] 320. A Rubicartin as described in any one of clauses 312 to 319, which exhibits Figure 2a An X-ray powder diffraction pattern substantially the same as any of the X-ray powder diffraction patterns shown in or 2b.

[0995] 321. Rubicartin as described in any of clauses 312 to 320, characterized by comprising wavelengths (cm2) of 2928, 1755, 1626, 1485, 1456, 1370, 1197, 1150, 1088, 1003, 959, 916 and 587 -1 ) at the IR spectrum of the peak.

[0996] 322. Rubikatin as described in any of clauses 312 to 321, further characterized by TG-FTIR degradation above 150°C; and / or characterized by a TG-FTIR mass change relative to 150°C due to water loss; and / or characterized by a TG-FTIR mass change relative to 150°C due to a water loss of less than about 5%, less than about 4% or less than about 3%; and / or characterized by a TG-FTIR indicating a water loss of preferably about 2-3% water, more preferably 2.6% water.

[0997] 323. Lupicadin as described in any one of clauses 312 to 322, further characterized by a DSC wherein degradation starts above 130°C.

[0998] 324. Rubikatin as described in any of clauses 312 to 323, further characterized by an average charge density of no more than about 30 nC / g, no more than about 20 nC / g, no more than about 10 nC / g, no more than about 6 nC / g, no more than about 5 nC / g, about 5±2 nC / g, about 4±2 nC / g, about 4-5 nC / g, about 5 nC / g or about 4 nC / g.

[0999] 325. Rubikatin as described in any of clauses 312 to 324, further characterized by a charge density dispersion of less than 4.8 nC / g, between about 0.7 nC / g and less than 4.8 nC / g, or 2.4±2 nC / g.

[1000] 326. Rubikatin as described in any of clauses 312 to 325, characterized by a water content higher than 1.6% w / w or 1.7-5% w / w.

[1001] 327. Lupicadin as described in any of clauses 312 to 326, further characterized by no more than 1%, 0.5%, 0.1%, or substantially no detected residual solvent.

[1002] 328. A partially crystallized Rubicartine.

[1003] 329. The partially crystallized Rubikatin of clause 328, wherein the partially crystallized Rubikatin comprises Form B Rubikatin of any one of clauses 312 to 327.

[1004] 330. Partially crystallized Rubikatin as described in clause 328 or 329, comprising at least a detectable amount of crystalline Rubikatin, up to 1% crystalline Rubikatin, up to 5% crystalline Rubikatin, up to 10% crystalline Rubikatin, up to 20% crystalline Rubikatin, up to 30% crystalline Rubikatin, up to 40% crystalline Rubikatin, up to 50% crystalline Rubikatin, up to 60% crystalline Rubikatin, up to 70% crystalline Rubikatin, up to 80% crystalline Rubikatin, up to 90% crystalline Rubikatin, up to 95% crystalline Rubikatin, up to 98% crystalline Rubikatin or substantially pure crystalline Rubikatin.

[1005] 331. Partially crystallized rubikatin as described in any of clauses 328 to 330, comprising at least a detectable amount of Form B, up to 1% w / w Form B, up to 5% w / w Form B, up to 10% w / w Form B, up to 20% w / w Form B, up to 30% w / w Form B, up to 40% w / w Form B, up to 50% w / w Form B, up to 60% w / w Form B, up to 70% w / w Form B, up to 80% w / w Form B, up to 90% w / w Form B, up to 95% w / w Form B, up to 98% w / w Form B or substantially pure Form B.

[1006] 332. Partially crystallized Rubikatin as described in any of clauses 328 to 331, comprising at least a detectable amount of amorphous Rubikatin, up to 1% w / w amorphous Rubikatin, up to 5% w / w amorphous Rubikatin, up to 10% w / w amorphous Rubikatin, up to 20% w / w amorphous Rubikatin, up to 30% w / w amorphous Rubikatin, up to 40% w / w amorphous Rubikatin, up to 50% w / w amorphous Rubikatin, up to 60% w / w amorphous Rubikatin, up to 70% w / w amorphous Rubikatin, up to 80% w / w amorphous Rubikatin, up to 90% w / w amorphous Rubikatin, up to 95% w / w amorphous Rubikatin or up to 98% w / w amorphous Rubikatin.

[1007] 333. A pharmaceutical composition or pharmaceutical intermediate comprising the partially crystallized lupicadine of any one of clauses 328 to 332.

[1008] 334. A pharmaceutical composition prepared by a process comprising partially crystallized lupicadine as described in any one of clauses 328 to 332.

[1009] 335. A composition as described in claim 333 or claim 334, wherein the composition has a total water content of no more than 3%; and / or no more than 1%, 0.5%, 0.1% or substantially no detected residual solvents; and / or no more than 1.9%, 1.8%, 1.7%, 1.6%, 1.5%, 1.4% or 1.3% total impurities; and / or no more than 0.8% impurity D; and / or no more than 0.3% of any unspecified impurities; and / or no more than 2.0% total related substances and no more than 0.7% of any unspecified substances (maximum).

[1010] 336. The pharmaceutical composition of any one of clauses 333 to 335, wherein the pharmaceutical composition is a lyophilized composition.

[1011] 337. A method for preparing Form B of Rubikatin as described in any one of clauses 312 to 327, comprising the steps of:

[1012] a) preparing an acidic aqueous solution comprising lupicardin or a protonated form thereof; and

[1013] b) alkalizing the resulting acidic aqueous solution with a base or a buffer to precipitate the B-form of rubikatin.

[1014] 338. The method of clause 337, wherein the acidic aqueous solution comprising Lupicadin is prepared by dissolving Lupicadin in any form in acidic water.

[1015] 339. A method as described in clause 337, wherein the acid water is an aqueous HCl solution, preferably 0.1M.

[1016] 340. The method of any one of clauses 337 to 339, wherein the resulting acidic aqueous solution is basified with a buffer.

[1017] 341. A method as described in clause 340, wherein the buffer is NH4Cl / NH4OH.

[1018] 342. A method as described in any of clauses 337 to 341, further comprising a washing step between steps a) and b), wherein the acidic aqueous solution is washed one or more times with a pharmaceutically acceptable water-immiscible polar solvent and one or more times with a pharmaceutically acceptable water-immiscible non-polar solvent, preferably a C5-C7 alkane.

[1019] 343. A method as described in clause 342, wherein the acidic aqueous solution is washed one or more times with dichloromethane and one or more times with n-pentane.

[1020] 344. The method of any one of clauses 337 to 343, wherein the Rubikatin Form B is collected by filtration.

[1021] 345. The method of any one of clauses 337 to 344, wherein the Rubikatin Form B is dried under vacuum.

[1022] 346. The method of any one of clauses 337 to 345, wherein the Rubikatin Form B is converted to a different physical form.

[1023] 347. A method as described in clause 346, wherein the different physical form is amorphous.

[1024] 348. A pharmaceutical composition comprising lupicardin as described in any one of clauses 312 to 327 and a pharmaceutically acceptable carrier.

[1025] 349. A pharmaceutical composition comprising Lupicardin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is manufactured by Lupicardin as described in any one of clauses 312 to 327.

[1026] 350. The pharmaceutical composition of clause 348 or 349, wherein the pharmaceutical composition comprises lupicadine and a disaccharide.

[1027] 351. A method for making a Rubikatin composition, the method employing Rubikatin as described in any one of clauses 312 to 327 or partially crystallized Rubikatin as described in any one of clauses 328 to 332; preferably as a starting material.

[1028] 352. The method of clause 351, wherein the method comprises pre-dissolving the lupicadin in an organic acid.

[1029] 353. A method as described in clause 352, wherein the organic acid has a pH of less than 4, preferably less than 3.5, more preferably less than 3 or about 3.

[1030] 354. A method as described in clause 352 or 353, wherein the organic acid has a molar concentration of about 0.1M to 0.5M, preferably about 0.2M to 0.4M, more preferably about 0.3M or 0.31M.

[1031] 355. The method of any one of clauses 352 to 354, wherein the organic acid has a molar concentration of about 0.1M to 0.5M, preferably about 0.2M to 0.4M, more preferably about 0.3M or 0.31M.

[1032] 356. The method of any one of clauses 352 to 354, wherein the pre-dissolution step is at least 30 minutes, at least 60 minutes or at least 90 minutes, between 30-90 minutes, between 60-90 minutes, between 60-70 minutes or about 60 minutes.

[1033] 357. The method of any one of clauses 352 to 356, wherein the solution is diluted with water for injection (WFI) to form a target concentration; wherein the target concentration is 8.3 mg / mL, optionally in 0.1 M organic acid.

[1034] 358. The method of any one of clauses 352 to 357, wherein the organic acid is a carboxylic acid, such as succinic acid, citric acid, acetic acid or lactic acid, preferably lactic acid.

[1035] 359. The method of any one of clauses 351 to 358, wherein a solution comprising an organic buffer and a bulking agent (eg, a disaccharide) is prepared to form a buffered solution.

[1036] 360. The method of clause 359, wherein the buffer solution has a pH of about 5.6 or less, preferably about 4 to about 5.6 or about 4.2 to about 5.6.

[1037] 361. A method as described in clause 359 or 360, wherein the buffer is derived from an organic acid, preferably an organic carboxylic acid, such as an organic carboxylic acid buffer, such as lactate buffer, butyrate buffer, propionic acid buffer, acetate buffer, succinate buffer, citric acid buffer, ascorbic acid buffer, tartaric acid buffer, malic acid buffer, maleic acid buffer, fumaric acid buffer, glutamic acid buffer, aspartic acid buffer, gluconic acid buffer and α-ketoglutarate buffer.

[1038] 362. The method of any one of clauses 359 to 361 wherein the bulking agent is a disaccharide, preferably sucrose.

[1039] 363. The method of any one of clauses 352 to 362, wherein the dissolved Lupicadin solution of any one of clauses 352 to 358 is mixed with a buffer solution of any one of clauses 359 to 362 to form a final bulk solution.

[1040] 364. A method as described in clause 363, wherein the final bulk solution is adjusted with WFI to achieve a final target weight.

[1041] 365. The method of any one of clauses 352 to 364, wherein the final target composition comprises 0.5 mg / mL Lupicadin in 0.03 M sodium lactate buffer pH=4+10% (w / v) sucrose.

[1042] 366. The method of any one of clauses 352 to 365, wherein the bulk solution of any one of clauses 363 to 365 is subjected to column sterilization filtration prior to filling into vials.

[1043] 367. The method of any one of clauses 351 to 366, wherein the composition is subjected to freeze drying to form a lyophilized formulation.

[1044] 368. The method of clause 367, wherein the lyophilized composition is labeled for use.

[1045] 369. The method of clause 367 or 368, wherein the lyophilized composition is reconstituted for use.

[1046] 370. The method of clause 369, wherein the composition is reconstituted with 8 mL of water to produce a solution having a pH of 3.5 to 4.5 and a concentration of 0.5 mg / ml of lupicardin.

[1047] 371. A method as described in clause 369 or 370, wherein the reconstituted solution is optionally diluted with 0.9% sodium chloride solution or 5% glucose solution to form an infusion solution; further optionally, wherein the reconstituted solution is diluted with at least 100 mL or at least 250 mL to prepare a lupicardin infusion solution.

[1048] 372. A Lupicardin infusion solution prepared according to the method of any one of clauses 351 to 371.

[1049] 373. A reconstituted solution prepared according to the method of any one of clauses 351 to 370.

[1050] 374. A lyophilized composition prepared according to the method of any one of clauses 351 to 368.

[1051] 375. A bulk composition prepared according to the method of any one of clauses 351 to 366.

[1052] 376. Lubicartin as described in any one of clauses 312 to 327 or partially crystallized Lubicartin as described in any one of clauses 328 to 332 for use as a medicament.

[1053] 377. Lubicartin as described in any one of clauses 312 to 327 or partially crystallized Lubicartin as described in any one of clauses 328 to 332 for use in the preparation of a medicament.

[1054] 378. Lubicartin as described in any one of clauses 312 to 327 or partially crystallized Lubicartin as described in any one of clauses 328 to 332 for use in the manufacture of a medicament for treating cancer.

[1055] 379. A method of treating an individual affected by cancer comprising administering to said affected individual a therapeutically effective amount of Lubicartin as described in any one of clauses 312 to 327 or partially crystallized Lubicartin as described in any one of clauses 328 to 332.

[1056] 380. A method of treating an individual affected by cancer comprising administering to said affected individual a therapeutically effective amount of a Rubikatin composition made by administering Rubikatin as described in any one of clauses 312 to 327 or partially crystallized Rubikatin as described in any one of clauses 328 to 332.

[1057] 381. The composition, method, use or method of any one of clauses 1 to 380, wherein a reference to reconstituting 4 mg lupicadine in 8 mL to a concentration of 0.5 mg / mL is a reference to a calculated concentration of 0.47 mg / mL in 8.55 mL.

[1058] 382. Rubikatin substantially as hereinbefore described with reference to the Examples, excluding the Comparative Examples.

[1059] 383. A Lupicadine composition substantially as hereinbefore described with reference to the Examples, excluding the Comparative Examples.

[1060] 384. Rubikatin for use in the treatment of small cell lung cancer (SCLC), the treatment comprising:

[1061] (1) administering a prophylactic dose of a corticosteroid and a serotonin antagonist effective to reduce nausea associated with administration of lupicardin to the patient on and before the day lupicardin is administered to the patient; and

[1062] (2) Administer 2 to 3.2 mg / m 2 dose of Rubicartin;

[1063] wherein the corticosteroid is dexamethasone administered intravenously at a dose of 8 mg dexamethasone or at a dose of corticosteroid equivalent to 8 mg dexamethasone administered intravenously.

[1064] 385. Rubikatin for treating small cell lung cancer (SCLC), including metastatic SCLC, the treatment comprising:

[1065] (1) If the patient has at least 1500 cells / mm 3 Absolute neutrophil count of at least 100,000 / mm3 If the platelet count is below 50%, the patient is given 3.2 mg / m by intravenous infusion. 2 first dose of Lubicardin; and

[1066] (2) identifying adverse reactions in the patient after the administration, wherein the adverse reactions are grade 2 hepatotoxicity or other adverse reactions, grade 3 (severe) hepatotoxicity or other adverse reactions, grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm 3 ), grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm 3 ) with bleeding, grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ), or any grade of febrile neutropenia (neutrophil count <LLN);

[1067] (3) After the adverse reaction is identified and 21 days after the first dose or when the patient's neutrophil count is greater than 1500 cells / mm 3 ; Platelet count greater than about 100,000 mm 3 and optionally after the hemoglobin level is greater than about 9 g / dL and the hepatotoxicity or other adverse reaction is Grade 1 or less:

[1068] (i) If the adverse reaction identified consists of isolated Grade 4 neutropenia (neutrophil count less than 500 cells / mm 3 ), then administering to the patient a dose of Lupicardin equivalent to the first dose and G-CSF prevention every three weeks;

[1069] (ii) if the identified adverse reaction consists of Grade 2 hepatotoxicity or other adverse reaction, administering to said patient a dose of rubicatin equivalent to said first dose every three weeks; or

[1070] (iii) if the identified adverse reaction is ≥ Grade 3 (severe) hepatotoxicity or other adverse reaction, Grade 4 thrombocytopenia (platelet count less than 25,000 cells / mm3), Grade 3 thrombocytopenia (platelet count less than 50,000 cells / mm3) with bleeding, or febrile neutropenia of any grade, then every 3 weeks, the patient is administered a dose of rubicatin that is reduced compared to the first dose.

[1071] 386. A method for storing a freeze-dried Rubikatin composition, comprising:

[1072] storing a lyophilized composition at a temperature of 5°C ± 3°C for at least 48 months, the lyophilized composition comprising 4 mg of lupicardin; a buffer derived from an organic carboxylic acid; and a disaccharide,

[1073] wherein the lyophilized composition is formulated such that reconstitution with 8 mL of water will produce a solution having a pH of 3.5 to 4.5, and

[1074] wherein the amount of impurity D present in the composition after storage for at least 24 months does not exceed 0.8% wt. / wt. based on the total weight of Lupicadine.

[1075] 387. Lubicardin and a topoisomerase inhibitor selected from SN-38 and irinotecan; for treating solid tumors, endometrial cancer, SCLC, soft tissue sarcoma, glioblastoma, pancreatic cancer, mesothelioma, colorectal cancer, or epithelial ovarian cancer in a patient in need thereof; the treatment comprising:

[1076] administering to the patient lubicatin and a topoisomerase inhibitor selected from SN-38 and irinotecan on day one of a treatment cycle;

[1077] wherein the amount of rubicatin is 1 to 2.5 mg / m 2 The dosage is administered, and

[1078] The topoisomerase inhibitor is administered in an amount equivalent to 50 to 75 mg irinotecan / m 2 dosage administration.

[1079] 388. The use according to clause 387, wherein the amount of irinotecan is equivalent to 50 mg to 75 mg / m 2 The dose of the topoisomerase inhibitor is administered on day 8 of the treatment cycle.

[1080] 389. The use according to clause 387 or clause 388, wherein the treatment cycle is an 18, 19, 20, 21, 22, 23, 24 or 25 day cycle.

[1081] 390. The use according to any one of clauses 387 to 389, wherein the rubicatin is administered at 2 mg / m 2 dosage administration.

[1082] 391. The use according to any one of clauses 387 to 390, wherein the topoisomerase inhibitor is irinotecan and is administered at 75 mg / m 2 dosage administration.

[1083] 392. The use according to any one of clauses 387 to 391, wherein the treatment cycle is 21 days.

[1084] 393. The use according to any one of claims 387 to 392, wherein the solid tumor is SCLC, endometrial carcinoma, soft tissue sarcoma or glioblastoma.

[1085] 394. The use of any one of clauses 387 to 393, wherein G-CSF is administered to the patient to manage the myelosuppressive effects of the treatment.

[1086] 395. The use according to any one of ...

Claims

1. A lyophilized pharmaceutical composition, wherein the composition comprises lubicartin, a disaccharide as a bulking agent, and a buffer derived from an organic carboxylic acid; and wherein the composition comprises no more than 0.8% wt / wt of deacetylated lubicartin based on the total weight of lubicartin in the composition.

2. The lyophilized pharmaceutical composition according to claim 1, wherein the organic carboxylic acid is lactic acid.

3. The lyophilized pharmaceutical composition according to claim 1 or 2, wherein the disaccharide is sucrose.

4. The lyophilized pharmaceutical composition according to any one of claims 1 to 3, wherein the buffer is a sodium lactate buffer.

5. The lyophilized pharmaceutical composition according to any one of claims 1 to 4, wherein the buffer is a sodium lactate buffer, and the disaccharide is sucrose.

6. The lyophilized pharmaceutical composition according to any one of claims 1 to 5, wherein the composition comprises 4 mg of lupicadine, the buffer is sodium lactate buffer, and the disaccharide is sucrose.

7. The lyophilized pharmaceutical composition according to any one of claims 1 to 6, wherein the composition comprises 4 mg lupicardin; 22 mg lactic acid; 5 mg sodium hydroxide; and 800 mg sucrose.

8. The lyophilized pharmaceutical composition according to any one of claims 1 to 7, wherein the composition consists essentially of: 4mg rubicin; 22.1mg lactic acid; 5.1 mg sodium hydroxide; and 800mg sucrose.

9. The lyophilized pharmaceutical composition according to any one of claims 1 to 8, wherein the lyophilized powder is formulated such that reconstitution with 8 mL of water will result in a solution with a pH of 3.5 to 4.

1.

10. The lyophilized pharmaceutical composition according to any one of claims 1 to 9, wherein the lyophilized powder is formulated such that reconstitution with 8 mL of water will result in a solution with a pH of 3.8 to 4.

1. 11 . The lyophilized pharmaceutical composition according to any one of claims 1 to 10 , wherein the molar ratio of the buffer to rubikatin is 44 to 54:

1.

12. The lyophilized pharmaceutical composition according to claim 11, wherein the molar ratio of the buffer to rubikatin is 46 to 52:1, 48 to 52:1, 48 to 51:1, 48 to 50:1 or 48:

1.

13. The lyophilized pharmaceutical composition according to any one of claims 1 to 12, wherein the lyophilized composition is formulated such that reconstitution with 8 mL of water will produce a solution with a molar concentration of 0.03 M.

14. The lyophilized pharmaceutical composition according to any one of claims 1 to 13, wherein after storage at 5°C ± 3°C for 24 months, the composition will contain no more than 0.8% wt / wt of deacetylated lubicartin based on the total weight of lubicartin in the composition.

15. The lyophilized pharmaceutical composition according to any one of claims 1 to 13, wherein after storage at 25°C, 60% relative humidity for 12 months, the composition will contain no more than 0.8% wt / wt of deacetylated lubicartin based on the total weight of lubicartin in the composition.

16. The lyophilized pharmaceutical composition according to any one of claims 1 to 15, wherein the amount of deacetylated lupicadin in the composition remains unchanged after storage at 5°C ± 3°C for 24 months.

17. The lyophilized pharmaceutical composition according to any one of claims 1 to 15, wherein the amount of deacetylated rubicatin in the composition remains unchanged after storage at 25°C, 60% relative humidity for 12 months.

18. The lyophilized pharmaceutical composition according to any one of claims 1 to 17, wherein the composition comprises or will comprise no more than 0.7%, 0.6%, 0.5%, 0.4% or 0.3% wt / wt of deacetylated lubicartin based on the total weight of lubicartin in the composition.

19. A pharmaceutical composition prepared by: An aqueous stock solution comprising lupicardin, an organic carboxylic acid, sodium hydroxide and sucrose is lyophilized to produce a lyophilized powder, wherein the concentration of rubicatin in the aqueous stock solution is 0.5 mg / mL, wherein the ratio of rubicatin to sucrose is 1 mol rubicatin to 455 to 465 mol sucrose, and wherein the lyophilized powder is formulated such that reconstitution with 8 mL of water will produce a solution having a pH of 3.5 to 4.1; and storing the lyophilized powder at 5°C ± 3°C for 30 to 60 months to produce the pharmaceutical composition, wherein after storage, the amount of deacetylated lubicartin present in the composition does not exceed 0.8% wt / wt based on the total weight of lubicartin.

20. A pharmaceutical composition comprising: A lyophilized composition comprising 4 mg of lupicardin, a buffer derived from an organic acid and a disaccharide, wherein the rubikatin and the disaccharide are present in a ratio of 1 mol of rubikatin to 455 to 465 mol of disaccharide, wherein the lyophilized composition is formulated such that reconstitution with 8 mL of water will produce a solution having a pH of 3.5 to 4.5, and The lyophilized composition further comprises no more than 0.8%, 0.7%, 0.6%, 0.5% or 0.4% wt / wt of degradation products resulting from deacetylation of Lubicartin based on the total weight of Lubicartin.

21. A packaged freeze-dried composition comprising: 4 mg of rubikatin, a buffer derived from an organic acid, and a disaccharide packaged in a vial. wherein dissolving the lyophilized composition in about 8 mL of water provides a lupicadine solution having a pH of 3.5 to 4.1, and wherein the lyophilized composition comprises less than 0.3% wt / wt of deacetylated rubicatin based on the total weight of rubicatin when the composition is packaged, and wherein after storage at 5°C for about 24 months, about 36 months, or about 48 months, the composition comprises no more than 0.8% w / w of deacetylated rubicatin based on the total weight of rubicatin.

22. A packaged freeze-dried composition comprising: 4 mg of rubikatin, a buffer derived from an organic acid, and a disaccharide packaged in a vial. wherein dissolving the lyophilized composition in about 8 mL of water provides a lupicadin solution having a pH of 3.8 to 4.1, and wherein the lyophilized composition comprises less than 0.3% wt / wt of deacetylated rubicatin based on the total weight of rubicatin when the composition is packaged, and wherein after the packaged composition is stored at 25°C and 60% relative humidity for up to 1, 2, 3, 6, 9 or 12 months, the composition comprises the same amount of deacetylated rubicatin based on the total weight of rubicatin.

23. A composition according to claim 21 or claim 22, wherein the composition is prepared by a method comprising: (a) providing a solution of lupicardin and an organic acid; (b) providing a solution of a base, an organic acid and a disaccharide; (c) combining the solutions of step (a) and step (b); (d) adjusting the pH of the solution of step (c) to 3.8 to 4.1; and (e) lyophilizing the solution of step (d) to provide the lyophilized composition.

24. A method for preparing a lyophilized pharmaceutical composition, comprising: (a) dissolving lupicadin in an aqueous solution having a pH of less than 4.0 to provide a first solution; (b) mixing the first solution with a second solution comprising an organic acid buffer and a swelling agent, and adjusting the pH to provide a third solution having a pH of 3.5 to 4.5; as well as (c) lyophilizing the third solution to provide a lyophilized pharmaceutical lupicardin composition, wherein the lyophilized composition comprises no more than 0.8% w / w of deacetylated rubikatin based on the total weight of rubikatin in the composition.

25. The method of claim 24, wherein the first solution comprises an organic acid selected from the group consisting of butyric acid, lactic acid, propionic acid, acetic acid, succinic acid, citric acid, ascorbic acid, tartaric acid, malic acid, maleic acid, fumaric acid, glutamic acid, aspartic acid, gluconic acid, and alpha-ketoglutaric acid.

26. The method of claim 24 or 25, wherein the first solution comprises lactic acid.

27. The method of any one of claims 24 to 26, wherein the bulking agent is a disaccharide.

28. A method according to any one of claims 24 to 27, wherein the bulking agent is sucrose.

29. The method of any one of claims 24 to 28, wherein the organic acid buffer is sodium lactate.

30. The method of any one of claims 24 to 29, wherein the organic acid buffer is sodium lactate and the bulking agent is sucrose.

31. The method of any one of claims 24 to 30, wherein the second solution consists essentially of water, an organic acid buffer, and a swelling agent.

32. A method according to any one of claims 24 to 31, wherein step (b) comprises adjusting the pH of the solution with sodium hydroxide.

33. The method of any one of claims 24 to 32, wherein the pH of the aqueous solution is less than 3.5, less than 3, or 3.

34. The method of any one of claims 24 to 33, wherein the first solution comprises an organic acid at a molar concentration of 0.1 M to 0.5 M, 0.2 M to 0.4 M, 0.3 M or 0.31 M.

35. The method of any one of claims 24 to 34, wherein the lyophilized powder is formulated such that reconstitution with 8 mL of water will produce a solution with a pH of 3.5 to 4.1 or 3.8 to 4.

1.

36. The method of any one of claims 24 to 35, wherein the molar ratio of buffer to rubikatin is 46 to 52:1, 48 to 52:1, 48 to 51 :1, 48 to 50:1 or 48:

1.

37. The method of any one of claims 24 to 36, wherein the lyophilized composition is formulated such that reconstitution with 8 mL of water will produce a solution with a molar concentration of 0.03M.

38. The method of any one of claims 28 to 37, wherein after storage for 24 months at 5°C ± 3°C, the composition will contain no more than 0.8% w / w of deacetylated rubicatin based on the total weight of rubicatin in the composition; and / or wherein after storage for 12 months at 25°C, 60% relative humidity, the composition will contain no more than 0.8% w / w of deacetylated rubicatin based on the total weight of rubicatin in the composition.

39. The method according to any one of claims 28 to 38, wherein the amount of deacetylated rubicatin in the composition remains unchanged after storage at 5°C ± 3°C for 24 months; and / or wherein the amount of deacetylated rubicatin in the composition remains unchanged after storage at 25°C, 60% relative humidity for 12 months.

40. The method of any one of claims 28 to 39, wherein the composition comprises or will comprise no more than 0.7%, 0.6%, 0.5%, 0.4% or 0.3% wt / wt of deacetylated lubicartin based on the total weight of lubicartin in the composition.

41. A lyophilized pharmaceutical composition prepared by a method comprising the following steps: (a) dissolving lupicadin in an aqueous solution having a pH of less than 4.0 to provide a first solution; (b) mixing the first solution with a second solution comprising an organic acid buffer and a swelling agent, and adjusting the pH to provide a third solution having a pH of 3.5 to 4.5; as well as (c) lyophilizing the third solution to provide a lyophilized pharmaceutical composition of lupicardin, wherein the lyophilized pharmaceutical composition comprises no more than 0.8% w / w of deacetylated lubicartin based on the total weight of lubicartin in the composition.

42. The lyophilized pharmaceutical composition of claim 41, wherein the first solution comprises an organic acid selected from the group consisting of butyric acid, lactic acid, propionic acid, acetic acid, succinic acid, citric acid, ascorbic acid, tartaric acid, malic acid, maleic acid, fumaric acid, glutamic acid, aspartic acid, gluconic acid, and alpha-ketoglutaric acid.

43. The lyophilized pharmaceutical composition of claim 41 or 42, wherein the first solution comprises lactic acid.

44. The lyophilized pharmaceutical composition according to any one of claims 41 to 43, wherein the bulking agent is a disaccharide.

45. The lyophilized pharmaceutical composition of any one of claims 41 to 44, wherein the bulking agent is sucrose.

46. ​​The lyophilized pharmaceutical composition according to any one of claims 41 to 45, wherein the organic acid buffer is sodium lactate.

47. The lyophilized pharmaceutical composition of any one of claims 41 to 46, wherein the organic acid buffer is sodium lactate and the bulking agent is sucrose.

48. The lyophilized pharmaceutical composition of any one of claims 41 to 47, wherein the second solution consists essentially of water, an organic acid buffer, and a bulking agent.

49. The lyophilized pharmaceutical composition according to any one of claims 41 to 48, wherein step (b) comprises adjusting the pH of the solution with sodium hydroxide.

50. The lyophilized pharmaceutical composition according to any one of claims 41 to 49, wherein the pH of the aqueous solution is less than 3.5, less than 3 or 3.

51. The lyophilized pharmaceutical composition of any one of claims 41 to 50, wherein the first solution comprises an organic acid at a molar concentration of 0.1 M to 0.5 M, 0.2 M to 0.4 M, 0.3 M or 0.31 M.

52. The lyophilized pharmaceutical composition of any one of claims 41 to 51, wherein the lyophilized powder is formulated such that reconstitution with 8 mL of water will produce a solution with a pH of 3.5 to 4.1 or 3.8 to 4.

1.

53. The lyophilized pharmaceutical composition according to any one of claims 41 to 52, wherein the molar ratio of buffer to rubikatin is 46 to 52:1, 48 to 52:1, 48 to 51 :1, 48 to 50:1 or 48:

1.

54. The lyophilized pharmaceutical composition of any one of claims 41 to 53, wherein the lyophilized composition is formulated such that reconstitution with 8 mL of water will produce a solution with a molar concentration of 0.03 M.

55. The lyophilized pharmaceutical composition according to any one of claims 41 to 54, wherein after storage at 5°C ± 3°C for 24 months, the composition will contain no more than 0.8% w / w of deacetylated rubicatin based on the total weight of rubicatin in the composition; and / or wherein after storage at 25°C, 60% relative humidity for 12 months, the composition will contain no more than 0.8% w / w of deacetylated rubicatin based on the total weight of rubicatin in the composition.

56. The lyophilized pharmaceutical composition according to any one of claims 41 to 55, wherein the amount of deacetylated rubicatin in the composition remains unchanged after storage at 5°C ± 3°C for 24 months; and / or wherein the amount of deacetylated rubicatin in the composition remains unchanged after storage at 25°C, 60% relative humidity for 12 months.

57. The lyophilized pharmaceutical composition of any one of claims 41 to 56, wherein the composition comprises or will comprise no more than 0.7%, 0.6%, 0.5%, 0.4% or 0.3% wt / wt of deacetylated lubicartin based on the total weight of lubicartin in the composition.

Citation Information

Cited By

  • Reubitedin pharmaceutical composition as well as preparation method and application thereof

    CN122351177A